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“As the anecdotes coalesce into data, there’s another layer, too, a sense of paradigms 
shifting. Immunotherapy marks an entirely different way of treating cancer—by targeting 
the immune system, not the tumor itself. Oncologists, a grounded-in-reality bunch, say a 
corner has been turned and we won’t be going back.” 
With these words, the editors of Science elected cancer immunotherapy in 2013 as the 
scientific breakthrough of the year1. To say, however, that this breakthrough occurred in 
one year, or even several years, would not do justice to the decades of efforts that have led 
to our current understanding of the fundamentals of the immune system and its complex 
interaction with cancer. 
The development of cancer immunotherapy as it stands today can roughly be divided 
into three distinct stages. The first stage, between 1900 and 1990, was one of discovery and 
compilation of knowledge, as the notion germinated that, somehow, the immune system 
may protect us against the development of cancer or even mediate spontaneous tumor 
regression in already afflicted individuals2-4. Seminal work in the ‘50s and ‘60s supported this 
idea by demonstrating immune-mediated tumor rejection in mouse models5,6, and it was 
around this time that histocompatibility antigens in mice were discovered7. However, it was 
not until the late ‘80s when the first non-viral tumor antigen that was recognized by T cells, 
again in mice, was described8. The second stage of cancer immunotherapy development 
runs from 1990 until 2010, and is characterized by increasing efforts to understand tumor 
specific immune responses in humans and attempts to translate this knowledge into clinical 
interventions. In the early ‘90s, the first human tumor antigen recognized by T cells was 
identified9; a collection that was rapidly expanded in the following years by the SEREX 
approach10. In that same period, administration of high-dose interleukin-2 (IL-2) showed 
a moderate survival benefit in metastatic melanoma and renal cell carcinoma patients, 
and was approved in 1992 as the first form of immunotherapy for patients with cancer11,12. 
The discovery and subsequent characterization of T-cell checkpoint molecules, such as 
cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and programmed cell death protein 
1 (PD-1) and its ligand PD-L1, sparked renewed enthusiasm for the potential of cancer 
immunotherapy13-17. Work from Steven Rosenberg and colleagues in the late ‘90s and 2000s 
showed that immunotherapy could also be implemented as a direct treatment approach. 
The adoptive cell transfer (ACT) of autologous tumor infiltrating lymphocytes (TIL) or T-cell 
receptor (TCR) gene-modified lymphocytes that had been cultured and expanded ex vivo 
showed profound clinical effects in some metastatic melanoma patients18,19. Importantly, 
cytotoxic T cells appeared to form an important component of this anti-tumor immune 
response20, explaining much of the focus on this cell type in this thesis. However, the effects 
of these therapies on overall survival in the metastatic setting were only limited, or restricted 








































12  |  Chapter 1
most recent stage of development, as treatment with a fully human monoclonal antibody 
targeting CTLA-4 was found to significantly prolong survival of patients with metastatic 
melanoma, leading to FDA and EMA approval in the following year21,22. In 2014 and 2015, 
reports came out that showed even more impressive clinical results when therapeutically 
targeting the PD-1/PD-L1 axis alone or in combination with anti-CTLA-423-25. Importantly, 
these and other studies showed that clinical efficacy was not limited to melanoma, 
traditionally considered the most immunogenic of malignancies, but could likewise be 
observed in more common cancer types such as lung and colorectal cancer26-28. Similarly, 
ACT approaches are now reaching beyond melanoma, as TIL and TCR gene therapy have 
demonstrated clinical effectiveness in patients with human papilloma virus (HPV)-induced 
cervical cancer and synovial cell sarcoma, respectively29,30, and CAR-modified T cells show 
strong clinical activity in B-cell malignancies31,32. 
Another important aspect of this third stage of cancer immunotherapy development 
is the availability of high-throughput next-generation sequencing (NGS) technologies33-35, 
which has allowed immunologists to systematically study the composition of the tumor 
micro-environment, as well as the consequences of DNA damage and their interaction 
with the T-cell based immune system. A growing body of evidence now suggests that T-cell 
specific immunity is often directed against peptide antigens that result from tumor-specific 
mutations36-38. Importantly, immune responses targeting these so-called neo-antigens, that 
are highly patient-specific, can be influenced by therapy thereby providing an incentive to 
further develop personalized immunotherapies for human cancer39-42.
In summary, cancer immunotherapy has taken up its place in oncological practice and it is 
likely there to stay. Although the field has come from far, much is still to learn as oncologists 
observe that not all patients with the same disease type respond to cancer immunotherapy, 
Furthermore, in some cancer types, no clinical benefit is observed at all, despite the 
presence of an abundant local immune infiltrate, indicating that our understanding of cancer 
– immune interaction is still incomplete. The overall goal of this thesis is to help address 
these matters in three ways. First, we have retrospectively analyzed a cohort of melanoma 
patients treated with ipilimumab, an anti-CTLA-4 antibody, for markers of responsiveness 
and review the literature to explore the limitations and curative potential of treatment 
strategies currently used in the clinic or under development. Second, we have developed 
several technology platforms that allow us to characterize and compare different types of 
T-cell responses that are directed against tumor-specific antigens in patient tumor material. 
Third, we aim to increase our understanding of the potential of cancer immunotherapy in 
ovarian and colorectal cancer, by analysis of the tumor-reactive compartment within these 
diseases. 
In Chapter 2, we discuss the efficacy of an anti-CTLA4 blocking antibody, ipilimumab, in 








































Scope of the thesis  |  13
1
program (EAP). We find that overall survival and response rates are similar to what was 
observed in the initial phase III trials that led to FDA and EMA approval of ipilimumab21,22. 
Moreover, we describe the identification of a serological biomarker that correlates with 
survival and confirm these findings in an independent validation cohort. In Chapter 3, we 
extend our analysis of the ipilimumab EAP to a small cohort of metastatic uveal melanoma 
patients in which we describe that 1 out of 22 patients responded to the therapy. 
Following the clinical development of anti-CTLA-4, a second immune checkpoint molecule 
that has received much attention recently is PD-1. Anti-PD-1 therapy has significantly 
extended overall survival in phase III trials for metastatic melanoma. Despite the fact that 
clinical responses were also observed in several other cancer types, in particular those with 
a high mutational burden40,43, disease regression was only observed in a single patient with 
colorectal cancer44. A follow-up study demonstrated that anti-PD-1 therapy mainly benefitted 
patients with mismatch-repair deficient tumors, while being largely ineffective in mismatch-
repair proficient colorectal tumors, again suggesting an important role for the expression of 
neo-antigens in cancer immunotherapy27. In Chapter 4, we discuss the findings of this phase 
II clinical trial and highlight the need to further extend anti-PD-1 therapy to other mismatch 
repair-deficient tumors independent of the underlying tumor type.
Although some patients clearly benefit from cancer immunotherapy, as we observed in 
the previous chapters, a good deal of patients does not respond or only does so temporarily. 
In Chapter 5, we review the potential mechanisms of resistance to cancer immunotherapy. 
Intrinsic or naturally acquired resistance is likely to play a role in patients that show no 
response to the treatment, whereas we can assume that therapy-induced resistance occurs 
in patients that initially respond but fail to do so in a durable manner. We dissect resistance 
to cancer immunotherapy by enumerating three discrete steps in the anti-tumor immune 
response: induction of the T-cell response, trafficking of T cells to the tumor, and cytolotyic 
activity at the intended effector site. This chapter is complementary to an earlier published 
review from Chen and Mellman in which they divide the cancer immunity cycle into seven 
distinct components45. At the heart of this cycle sits the antigen that is being recognized by 
the immune system, as its presence is first required to stimulate T cells in the lymph node and 
later serves as the target for tumor cell destruction. In Chapter 6, we review which antigens 
are the most suitable tumor rejection antigens and discuss why the focus on patient-specific 
neo-antigens is warranted in some, but should not be pursued in all cancer types.
We continue on the topic of antigen-directed cancer immunotherapy in Chapter 7, in 
which we describe the development of a highly flexible technology platform that allows 
us to purify antigen-specific T cells from T-cell cultures. This strategy can for instance be 
used to steer immune-reactivity of clinical-grade TIL infusion products towards desired 
target antigens and thus enhance their anti-tumor efficacy. We demonstrate that even low 








































14  |  Chapter 1
activity is enhanced in in vitro assays. Using the flexibility of the platform described in the 
previous chapter, we were able to purify neo-antigen specific T cells from a melanoma 
TIL culture, and in Chapter 8 we demonstrate superior tumor control of this enriched TIL 
product over a non-enriched TIL product in a preclinical setting. Furthermore, we show that 
tumor control is best obtained by T cells directed against mutated antigens rather than non-
mutated antigens. 
Data from preceding chapters indicate that the isolation and reconstruction of T-cell 
receptor (TCR) gene sequences with tumor-reactive potential is of great value to the field. 
Many of these technologies exist but these often rely on elaborate screening platforms to 
determine antigen-specificity or can only assess single-chain CDR3 sequences without being 
able to assess functionality46. In Chapter 9, we develop a novel RNA-based PCR technology 
that allows the unbiased identification of TCRα/β sequences at single cell resolution. 
Importantly, this technology bypasses the need for in vitro culture systems and thus allows 
us to assess the degree of naturally induced tumor-specific immunity in an unbiased manner 
for virtually every solid tumor.
We successfully applied this method to a small set of colorectal and ovarian cancer 
tissue (in which the presence of CD8+ T cells has been linked to increased survival47-50) and – 
for a small fraction of the evaluated TCRs – could demonstrate reactivity against autologous 
tumor cells upon reconstruction of the full-length TCR α/β heterodimer. These data are 
consistent with the possibility that many of the tumor-resident T cells may not be tumor-
reactive in these diseases, a topic that deserves further attention. 
As the presence of CD8+ T cells in ovarian cancer is linked to improved survival we 
hypothesized that such patients might be responsive to TIL treatment as was previously 
shown for melanoma. In Chapter 10, we demonstrate in vitro anti-tumor activity against 
autologous tumor cells in the majority of established ovarian cancer TIL cultures. These 
findings have led to the initiation of a phase I/II clinical trial for metastatic ovarian cancer at 
the Netherlands Cancer Institute.
Finally, in Chapter 11, the future prospects of cancer immunotherapy are discussed in 
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ABSTRACT
Ipilimumab, a CTLA-4 blocking antibody, has improved overall survival in metastatic 
melanoma in phase III trials. However, about 80% of patients fail to respond and no 
predictive markers for benefit from therapy have been identified. We analysed a ‘real world’ 
population of patients treated with ipilimumab to identify markers for treatment benefit. 
Patients with advanced cutaneous melanoma were treated in the Netherlands and the 
United Kingdom with ipilimumab at 3mg/kg. Baseline characteristics and peripheral blood 
parameters were assessed and patients were monitored for the occurrence of adverse 
events and outcomes.
A total of 166 patients were treated in the Netherlands. Best overall response and 
disease control rates were 17% and 35%, respectively. Median follow-up was 17.9 months, 
with a median progression-free survival of 2.9 months. Median overall survival was 7.5 
months, and overall survival at 1 year was 37.8% and at 2 years 22.9%. In a multivariate 
model, baseline serum lactate dehydrogenase (LDH) was demonstrated to be the strongest 
predictive factor for overall survival. These findings were validated in an independent cohort 
of 64 patients from the UK. 
In both the NL and UK cohorts, long-term benefit of ipilimumab treatment was unlikely 
for patients with baseline serum LDH greater than twice the upper limit of normal. In the 
absence of prospective data, clinicians treating melanoma may wish to consider the data 
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INTRODUCTION
Ipilimumab is a fully human monoclonal IgG1 antibody that blocks the immune-checkpoint 
molecule cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) thereby reversing its 
immunosuppressive effect on T cells, although its exact mechanism of action is still under 
investigation1.
Ipilimumab was approved for the treatment of advanced melanoma by the Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) in 2011, on the basis 
of increased overall survival (OS) in two phase III studies2,3. Treatment with ipilimumab at 
3mg/kg as a second and subsequent line of therapy resulted in a median OS of 10.1 months 
compared to 6.4 months in the vaccine control arm together with a 1-year survival of 45.6% 
versus 25.3%, respectively in one of the studies2. Best overall response rate (BORR) was 11%. 
Subgroup analysis for OS revealed that the hazard ratio for ipilimumab in comparison to 
the control arm was only significant in patients with normal serum lactate dehydrogenase 
(LDH) levels2. Raised serum LDH is known to be a poor prognostic factor in a number of 
cancers including melanoma for reasons that remain unknown. This is reflected in the 
2009 AJCC staging system for melanoma, which subdivides metastatic disease into: M1a, 
skin, lymph node or subcutaneous metastases only; M1b, lung metastases only; and M1c, 
visceral metastases or metastases at any site with a raised LDH4.
Ipilimumab is currently under evaluation in several phase II trials for other malignancies 
including renal cell carcinoma, non-small cell lung cancer and metastatic castration-
refractory prostate carcinoma5-8. While potentially effective, ipilimumab can be toxic as a 
consequence of reduction in peripheral tolerance to self-antigens, which is reflected in the 
induction of immune-related Adverse Events (irAEs) such as colitis, dermatitis, hepatitis and 
hypophysitis2,3.
Several clinical parameters, such as high absolute lymphocyte count (ALC) after two 
courses of ipilimumab, a rise of ALC over baseline and the occurrence of grade 3 or 4 irAEs 
have been suggested to correlate with OS and response to therapy9-15. A major drawback of 
these potential markers is that they become evident only during the course of treatment, 
thereby making them unsuitable for upfront patient selection. The aim of this study 
was, therefore, to identify baseline patient characteristics for response to ipilimumab, to 
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PATIENTS AND METHODS
Patient inclusion and treatment plan
Patients with advanced melanoma and progression on systemic therapy were treated in 
expanded access programs in the Netherlands (NL EAP) (NCT00495066) and in the United 
Kingdom after licensing. Consequently, the NL cohort included patients exclusively treated 
within the EAP, whereas the UK cohort comprised of both EAP and post-licensing patients. A 
modified World Health Organization (mWHO) performance status of 0, 1, or 2 was required. 
An mWHO performance status of 0 indicates that the patient has no restrictions in carrying 
out pre disease activities; a mWHO performance status of 1 indicates that the patient has 
restrictions in more strenuous activities but is completely ambulatory and is able to carry 
out work of a light nature; a mWHO performance status of 2 indicates that the patient is 
in bed for less than 50% during the day but is still ambulatory and capable of all self care. 
Treatment protocols were approved according to local regulations and ethical committees. 
Data acquisition and subsequent analyses mentioned hereafter apply to the NL cohort 
unless stated otherwise. Data from the UK cohort were obtained to validate findings on 
baseline LDH and survival probability. All patients received four cycles of 3mg/kg ipilimumab 
every three weeks, unless severe side effects or rapid disease progression occurred. M-stage 
was defined according to site of metastasis in combination with elevated LDH levels, as 
described previously4.
Safety measures
Patients underwent clinical evaluation prior to each ipilimumab infusion. Immune-related 
Adverse Events (irAEs) were scored using the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.02 and patients received standard of care accordingly. A list of 
irAEs was pre-specified in the protocol and a serious adverse event was determined as grade 
3 or 4. Haematological and serum parameters were determined at baseline, every three 
weeks during treatment, and three-monthly during follow-up. These included ALC, S100, 
erythrocyte sedimentation rate (ESR), LDH, liver, kidney and endocrine function. Upper 
limits of normal (ULN) were normalised for the reference range at each participating centre.
Response evaluation and follow-up
Radiologic evaluation (CT or PET/CT scanning) was performed at baseline and week 12 
(i.e. three weeks after the fourth infusion) if patients had undergone all four cycles of 
ipilimumab. Responses were scored according to RECIST 1.1 criteria as well as immune-
related Response Criteria (irRC), the latter to determine BORR18. Responses were confirmed 
at least four weeks later and during follow-up every three months thereafter or when 
disease progression was clinically suspected. Survival status from patients that withdrew 
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Statistical analysis
Data were analysed using SPSS statistical software version 20.0 and R statistical software 
version 2.15.0. Univariate analysis for clinical and laboratory parameters was performed 
with respect to OS and progression-free survival (PFS). Survival curves of categorical 
variables were drawn using the Kaplan-Meier technique and compared by the log-rank 
test. Continuous variables in association with survival outcomes were explored by means of 
martingale residuals. LDH and S100 were log-transformed. Multivariate models of patient 
and tumour characteristics in association with PFS and OS were based on Cox-proportional 
hazards regression analyses. PFS was defined as time from start of ipilimumab to the onset 
of progression or death. Patients without progression and still alive at time of analysis 
were censored. OS was defined as time from start of ipilimumab to death of any cause. 
Patients still alive at analysis were censored. OS analyses were identical for both cohorts. 
The association of parameters measured at six weeks with either PFS or OS were analysed 
by means of a landmark method (ignoring time and events before six weeks) or as time-




166 patients received ipilimumab between April 2010 and December 2011 within the 
Netherlands expanded access program (NL EAP). As of August 2012, 28% of patients were 
still alive. The median follow-up of the cohort was 17.9 months; clinical characteristics 
are listed in Table 1. Median patient age at the time of study inclusion was 55 years and 
58% were male. Modified WHO performance status 0, 1, and 2 was scored in 59, 36, and 
5% of patients respectively; 83% of the patients had stage M1c disease. Baseline levels of 
LDH were elevated between the ULN and 2x ULN in 28% of patients and >2x ULN in 16% 
of patients. From the UK cohort 64 patients were analysed. The median follow-up of this 
cohort was 19.0 months and patient characteristics were similar as shown in Table 1. In this 
cohort, 39% of patients had baseline levels of LDH elevated between ULN and 2x ULN, while 
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Table 1. Patient characteristics. WHO World Health Organization. NA not available. LDH lactate 
dehydrogenase. ULN upper limit of normal.
Variable NL (N=166) UK (N=64)
Age
Median (range) 55 (22-88) 58 (18-84)
Sex
female 69 (42%) 27 (42%) 
male 97 (58%) 37 (58%)
WHO status 
WHO 0 98 (59%) 21 (33%) 
WHO 1 60 (36%) 37 (58%) 
WHO 2 8 (5%) 6 (9%)
Breslow 
<1mm 10 (6%) 5 (8%)
1-2mm 23 (14%) 14 (22%) 
2-4mm 50 (30%) 14 (22%)
>4mm 24 (14%) 7 (11%) 
NA 59 (36%) 24 (38%)
M stage
M1a 8 (5%) NA
M1b 20 (12%) NA
M1c 138 (83%) NA
Site metastasis 
single 31 (19%) 5 (8%)
multiple 135 (81%) 59 (92%)
Cycles of ipilimumab 
1 7 (10%) 17 (27%) 
2 19 (11%) 11 (17%)
3 22 (13%) 11 (17%) 
4 114 (66%) 25 (39%)
Responders 17 (11%) 7 (11%) 
Non-responders 149 (89%) 57 (89%)
Immune-related adverse events (grade III/IV)
Responders 3/17 (18%) 3/7 (43%) 
Non-responders 25/149 (17%) 2/57 (4%)
Baseline LDH 
≤ 1x ULN 87 (52%) 24 (38%)
1-2x ULN 46 (28%) 25 (39%) 
> 2x ULN 27 (16%) 15 (23%) 
NA 6 (4%) 0 (0%)
Prior and post ipilimumab treatment modalities
All patients in the NL cohort had received prior systemic treatment of which 80% received 
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than one prior treatment including DTIC (Supplementary Table 1). Most patients (75%) 
did not receive any other treatment after ipilimumab therapy. Post-ipilimumab treatment 
modalities comprised BRAF-inhibitors (13%) or reinduction therapy with ipilimumab (3%). 
One out of five patients experienced disease stabilisation upon reinduction with ipilimumab.
Toxicities
The frequencies of irAEs in the NL cohort are listed in Supplementary Table 2. We observed 
serious (grade 3 or 4) adverse events in 28/166 (16%) of the patients. The majority 
(75%) comprised dermatitis, hypophysitis and colitis, of which only the latter two led to 
discontinuation of treatment with ipilimumab in 8% of patients. There was one treatment-
related death (1%) due to severe colitis resulting in bowel perforation. Grade 1 and 2 
immune-related toxicity events mainly comprised dermatitis for which topical intervention 
was sufficient. 
Response to therapy
The clinical responses in the NL cohort measured using RECIST or irRC (including BORR) 
are listed in Supplementary Table 3. Response rates at 12 weeks were 10% by RECIST and 
11% by irRC, indicating no initial difference between the two response evaluation methods. 
However, when looking at the BORR, which takes into account the late development of 
anti-tumour immune effects, we observed an increase in the RR to 17%. The median time to 
achieve BORR was 3.7 months (range 2.5 – 18.6), which is beyond the standard time point 
for response evaluation at week 12 and underscores the relevance of a week-16 response 
re-evaluation. Four patients eventually became complete responders after initially being 
scored as SD or PR and one patient was scored with progressive disease (PD) at 12 weeks but 
eventually became a complete responder 18 months after treatment initiation. A substantial 
number of patients (27%) were not evaluable (NE) for response due to rapid deterioration 
and death (39/166) before week 12 or serious adverse events (5/166) resulting in withdrawal 
from ipilimumab treatment. There was no correlation between the occurrences of grade 3 
and 4 irAEs and response to therapy (P = 0.62).
Survival analysis and biomarker assessment
Data on all patients was available for survival analysis. The median progression free survival 
(PFS) in the NL cohort was 2.9 months (95% CI: 2.8 – 3.2, Fig. 1A). Median OS of the patients 
in the NL cohort was 7.5 months (95% CI: 6.1 – 10.5, Fig. 1B). The 1-year survival was 37.8% 
(95% CI: 31.1 – 46.0) and 2-year survival 22.9% (95% CI: 16.4 – 32.1).  The median OS in the 
UK cohort was 4.1 months (95% CI: 3.6 – 5.1, Fig. 1C). The 1-year survival was 15.6% (95% 
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Figure 1. Kaplan-Meier curves for progression free survival and overall survival
of NL and UK cohort. (a) Progression free survival curve for the NL cohort and overall survival curves 








































Ipilimumab in metastatic cutaneous melanoma  |  27
2
Univariate analysis of the NL cohort for patient and disease characteristics such as 
gender, age, Breslow thickness and location of primary tumour, as well as prior treatment 
revealed no significant association with OS. Both mWHO performance score 0 and disease 
stage M1a/b, univariately correlated with a favourable outcome for OS (P = 0.001 and P 
= 0.04, respectively). Baseline ALC and week 6 ALC measurements showed a significant 
difference for survival when stratifying high versus low (P = 0.01 and P = 0.001, Fig. 2A 
and B, respectively). When assessing the slope in ALC as identified by Martingale residuals, 
we found that patients with greater than or equal to 1.35 fold higher value compared to 
baseline after two cycles of treatment, determined six weeks after the start of therapy, had 
a significantly better OS than patients with a lower increase (P = 0.02, Fig. 2C). Low baseline 
levels of respectively LDH, S100 and ESR, were also significantly associated with improved 
OS (all P <0.0001, Fig. 2D-F). 
When patient characteristics (M-stage and mWHO performance status), baseline LDH, 
S100, ESR, and ALC were examined in a multivariate model, only ESR and LDH remained 
as significant independent negative prognostic factors (P < 0.01). Using this approach we 
identified a subset of patients with a significantly better OS. The majority of patients with low 
OS were identified when separating the cohort by elevated baseline levels of LDH (median 
OS 14.7 months for LDH normal versus 3.7 months for LDH >ULN; P < 0.001), with some 
further discrimination after stratification by baseline ESR (Supplementary Fig. 1). Of note, 
only 17/44 patients not evaluable for response were available for baseline ESR assessment 
while 40/44 were available for baseline LDH assessment. Within the poor prognosis group 
(elevated LDH above ULN) a small number of patients, including four with a partial response 
and one complete response (5/73), survived beyond the first year. The response rate in 
this subgroup was 9% compared to 23% in the ≤1x ULN group, indicating some potential 
predictive value of this marker. When stratifying by 2x ULN of baseline LDH values, only one 
patient survived beyond 12 months in the LDH-high group who had a partial response and 
was censored at 12.9 months follow-up. In total, only two partial responses occurred in this 
subgroup whereas all other responding patients occurred in the LDH-low group. Median 
OS was 2.9 months versus 10.0 months in the LDH greater than twice ULN versus less than 
twice ULN group, respectively  (P < 0.001, Fig. 3). 
To investigate the broader value of these findings, we analysed an independent cohort 
of 64 patients treated in the UK at two academic centres. Only baseline LDH values were 
assessed in this cohort and, unlike in the Dutch cohort, stratification on 1x ULN baseline LDH 
did not significantly influence OS. However, a significant difference in survival was observed 
when stratifying patients on their 2x ULN baseline LDH values (Fig. 3). Median OS in the LDH-
high group was 3.2 months compared to 5.0 months in the LDH-low group (P = 0.004). Only 
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Figure 2. Kaplan-Meier curves for overall survival stratified by blood parameters. (a) Overall survival 
is shown when stratifying for blood values of baseline absolute lymphocyte count (ALC), (b) ALC at 
week 6, (c) slope of ALC after two infusions, (d) baseline lactate dehydrogenase (LDH), (e) S100 and 
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Figure 3. Patient selection based on baseline LDH for NL and UK cohort. Upper part of panel A 
shows the stratification of patients based on their upper limit of normal (ULN) baseline values of 
serum lactate dehydrogenase (LDH) in the NL cohort. For six patients baseline LDH values were not 
available and these were excluded from further analyses. Lower part shows patients grouped by their 
response to therapy and the occurrence of toxicities. A statistically significant difference in overall 
survival (OS) was observed when stratifying by 1x ULN baseline LDH. However, seven patients with a 
clinical response upon ipilimumab treatment would have been missed when implementing this cut-
off. Only two patients with a clinical response remained in the LDH-high subgroup when stratifying by 
2x ULN of baseline LDH. Toxicities in the high and low LDH subgroups were similar. Panel B shows the 
stratification by baseline LDH values of patients from the UK cohort. At a cut-off of 1x ULN of baseline 
LDH there is no significant influence on OS. Stratification by 2x ULN baseline LDH does significantly 
increase OS and no patients in the LDH-high subgroup survive beyond the first year after treatment 
initiation. Percentages may not add up to 100 due to rounding. HR hazard ratio. CR complete response. 
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Overall, 1- and 2-year survival rates of the combined NL and UK cohorts in the LDH-low 
group (≤2x ULN; N=182) were 51.2% and 34.6%, respectively, whereas they were 4.8% and 
0% in the LDH-high group (>2x ULN; N=42) (Supplementary Table 4). We found that 66% of 
patients in the LDH-low group received all four cycles, whereas in the LDH-high group only 
24% of patients completed the full treatment (data not shown).
DISCUSSION AND CONCLUSIONS
The aim of our analysis was to identify, from a ‘real world’ melanoma patient cohort, 
parameters used in routine clinical practice that may identify patients most likely to benefit 
from ipilimumab therapy prior to the start of treatment. We found that a high ESR and in 
particular a high LDH at baseline are statistically significant independent prognostic factors. 
The use of LDH alone at the cut-off at 2x ULN, as a negative prognosticator, was confirmed 
in an external cohort of patients. Patient characteristics such as M-stage and performance 
status did not have an independent significant effect on overall survival. 
While ESR was also identified as an independent prognostic factor, only a small subgroup 
of twelve patients would additionally be excluded when implementing this cut-off, three of 
which had a partial response upon ipilimumab treatment. Therefore, we chose to focus on 
the more clinically relevant stratification based on baseline LDH alone. However, it cannot 
be excluded based on these data, that the combination of low LDH / low ESR is of superior 
value to low LDH alone. Also, ESR data were not available for the UK cohort to confirm these 
findings. A planned meta-analysis on all EAP treated patients in Europe should give more 
insight into the prognostic value of an inflammatory marker such as ESR combined with LDH. 
The data presented here indicate that patients with elevated LDH, for the NL cohort at 
1x ULN and for both cohorts at 2x ULN, are unlikely to benefit from ipilimumab therapy. 
High disease load and cell turnover, resulting in high serum levels of LDH, may negatively 
influence the potency of an immune response at the tumor site. Rapidly growing tumors 
are often poorly vascularized, resulting in anaerobic glycolysis as an alternative energy 
source, which in turn is mediated by activity of LDH that converts pyruvate into lactate19,20. 
This switch of tumor cells to a glycolytic phenotype, which can even occur under normoxic 
conditions, gives rise to lactate accumulation and a subsequent decrease in extracellular pH, 
negatively affecting the function of lymphocytes present in the tumor microenvironment21,22. 
Alternatively, elevated LDH may simply form a measure of disease state and thereby be 
correlated with likelihood of response.  
We observed that the median OS in the >2x ULN group (hereafter referred to as LDH-
high) was significantly lower than in the ≤2x ULN group (hereafter referred to as LDH-low): 
2.9 months versus 10.0 months in the NL cohort and 3.2 months versus 5.0 months in the UK 
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a non-elevated LDH was associated with an increased OS2,3. This fact, and the observation 
that in two other ipilimumab EAPs with smaller patient numbers, reported by Wilgenhof 
et al. and Delyon et al., elevated LDH showed a negative association with survival further 
supports our findings13,14. Overall survival in our cohorts was lower than what was reported 
in the phase III studies. This is not surprising because the inclusion criteria were less strict 
for the expanded access programmes than for the phase III studies. Furthermore, patients in 
the UK cohort benefited less from therapy than those in the NL cohort, potentially because 
fewer patients had a performance status of 0: 33% versus 59%, respectively. 
The 1- and 2-year survival rates of 51.2% and 34.6% for the LDH-low patients of the 
combined NL and UK cohort indicate that the survival rates are comparable to the phase III 
study cohorts2,3. In the LDH-high group, however, we found 1- and 2-year survival rates of 4.8% 
and 0%, respectively, indicating no long-term benefit at all; except for one patient censored 
at 12.9 months. Taken together, our data show that treatment benefit from ipilimumab is 
almost exclusively concentrated in the LDH-low group. Patients in the high-LDH group, which 
is 19% of patients from both cohorts combined, that carry the BRAF V600E mutation might 
benefit more from targeted therapies such as BRAF- and MEK-inhibitors that are capable of 
inducing rapid anti-tumour responses. Recent data from an open label multicentre safety 
study of vemurafenib showed that patients with elevated LDH at baseline were on therapy 
for a median duration 4.1 months, which is longer than the median OS for the ipilimumab 
patients with elevated LDH here23. The efficacy of sequential treatment with BRAF inhibitors 
and ipilimumab should be evaluated in a randomized trial. Sequencing targeted therapies 
with ipilimumab might be especially helpful to patients with more aggressive disease where 
the delayed tumour responses generally observed with immunotherapies take too long for 
the patient to benefit18,23-26.
Our analysis clearly has a number of limitations of which the most obvious is its 
retrospective nature and consequent possibility of bias. A strength of our dataset however is 
that it involves a ‘real world’ population as opposed to the more selected group of patients 
that enter phase III registration trials. Furthermore, the observation of a similarly strong 
predictive value of elevated LDH in two independent cohorts lends further credibility to 
our observations. Ideally, our data would stimulate a prospective analysis of the value of 
elevated LDH as a patient selection criterion. However, in view of the rapidly changing 
landscape in melanoma immunotherapy, with the likely registration of agents targeting 
programmed cell death 1 (PD1) and programmed cell death ligand 1 (PDL1)27-29 we consider 
such prospective studies unlikely to happen.  Without such data, we feel that is important to 
carry out similar analyses on other large cohorts of ipilimumab-treated melanoma patients 
treated in routine clinical practice.  
In November 2013, the EMA approved ipilimumab as a first-line therapy in metastatic 
melanoma at a 3mg/kg dosing schedule30. This registration will extend the availability of 
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of limited and mostly failing therapies, treating oncologists are now faced with the difficulty 
of having to decide patient eligibility at both earlier and later stages of the disease. This 
will consequently have an effect on the number of responding patients as well as overall 
survival. Related to this, the expected administration of ipilimumab to patients at earlier 
disease stages, due to its recent approval as a first-line treatment, warrants continued 
assessment of the prognostic value of the markers proposed here.
In conclusion, our results show efficacy of ipilimumab comparable to that reported in the 
phase III studies. Furthermore, we propose that elevated levels of baseline LDH at a 2x ULN 
cut-off may help physicians to select patients before treatment initiation. Serum LDH has 
been established for some time as a negative prognostic factor in advanced melanoma16,17. 
From our data, in the absence of a control arm, we are unable to determine whether LDH 
forms either a predictive or a prognostic marker for benefit from ipilimumab. However, we 
would assert that in routine clinical practice the difference is not relevant, and that using 
serum LDH to stratify patients for ipilimumab treatment should simply be considered 
pragmatic. 
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DTIC  133 80%
BRAF inhibitor 5 3%
DTIC and BRAF inhibitor 3 2%
DC/DNA/peptide vaccination 3 2%
Other chemotherapy 2 1%
Other systemic therapy 1 1%
Other several lines 18 11%
After Treatment
BRAF inhibitor 18 11%
MEK inhibitor 6 4%
Ipilimumab 2 1%
TIL 2 1%
BRAF inhibitor and ipilimumab 2 1%
BRAF inhibitor and TIL 2 1%
Ipilimumab and TIL 2 1%
DC/DNA/peptide vaccination 1 1%
Other chemotherapy 3 2%













































Grade 0 134 81%
Grade 1 10 6%
Grade 2 7 4%
Grade 3 10 6%
Grade 4 4 2%
Grade 5 1 1%
Dermatitis
Grade 0 134 81%
Grade 1 21 13%
Grade 2 7 4%
Grade 3 4 2%
Hypophysitis
Grade 0 161 97%
Grade 2 2 1%
Grade 3 3 2%
Hepatitis
Grade 0 158 95%
Grade 1 2 1%
Grade 2 5 3%
Grade 3 1 1%
Uveitis
Grade 0 164 99%
Grade 2 2 1%
Other toxicity 
Grade 0 138 83%
Grade 1 15 9%
Grade 2 7 4%
Grade 3 4 2%
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Supplementary Table 3.
PD SD PR CR NE Total
Total 79 (48%) 26 (16%) 15 (95%) 2 (1%) 44 (27%) 166
irRC
PD 66 (40%) 66 (40%)
SD 12 (7%) 26 (16%) 38 (23%)
PR 1 (1%) 15 (95%) 16 (10%)
CR 2 (1%) 2 (1%)
NE 44 (27%) 44 (27%)
BORR
PD 64 (39%) 64 (39%)
SD 12 (7%) 18 (11%) 30 (18%)
PR 2 (1%) 6 (4%) 13 (8%) 21 (13%)
CR 1 (1%) 2 (1%) 2 (1%) 2 (1%) 7 (4%)
NE 44 (27%) 44 (27%)
Supplementary Table 4.
Survival (%) LDH normal LDH >1X ULN LDH >2X ULN
1 year NL 58.4% 13.7% 7.4%
2 year NL 38.3% 0% 0%
1 year UK 25.0% 10.0% 0%
2 year UK 20.8% 10.0% 0%
1 year NL + UK 51.2% 12.4% 4.8%
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INTRODUCTION
Uveal melanoma arises from melanocytes that reside in the iris, ciliary body or choroid 
of the eye. Local treatment can be divided into ‘radical’ enucleation and ‘conservative’ 
treatment. About 50% of patients develop metastasized disease and in up to 95% of these 
cases  the liver is affected, due to the absence of lymphoid structures in the uvea. Once 
metastasized to the liver, surgical resection may be beneficial for small lesions, but less than 
9% of patients fall into this category1. 
The blockade of cytotoxic T lymphocyte-associated antigen-4 (CTLA4) by ipilimumab has 
become standard for pretreated patients with cutaneous melanoma based on a randomized 
phase III study2. This drug significantly improved the overall survival resulting in 20-25% of 
the patients still being alive after more than two years. 
Due to its distinct biological and clinical nature (fast progression) uveal melanoma 
patients are often excluded from melanoma studies. Uveal melanoma patients have been 
allowed to be included in ipilimumab expanded access programs, in which some clinical 
activity has been described3-6. 
In our study, 22 pretreated metastatic uveal melanoma patients were treated 
homogenously with 3mg/kg ipilimumab in the named patient program (NPP) by the Dutch 
immunotherapy working group (WIN-O) in The Netherlands. We describe here the toxicity 




Patients were treated by the Dutch immunotherapy working group (WIN-O) in a NPP of 
ipilimumab (NCT00495066) in which uveal melanoma patients were allowed to be included. 
Patients had to have unresectable, metastatic uveal melanoma (with or without brain 
metastases) and were required to have received at least one prior treatment regimen for 
metastatic disease. They had to be at least 16 years of age with a WHO performance status of 
0, 1, or 2. A 28-day interval since the last treatment was required before inclusion. Evaluable 
patients that had given their written informed consent underwent radiologic evaluation of 
their tumor burden at baseline and at twelve weeks after their first ipilimumab course. The 
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Treatment
Ipilimumab was administered at 3 mg/kg in week 1, 4, 7 and 10. Prior to every infusion, 
hemoglobin, leucocytes and differentiation, platelets, liver function, renal function, thyroid 
and adrenal function were assessed for safety reasons and monitoring of toxicity. Immune-
related adverse evants (IrAEs) were scored using Common Terminology Criteria for Adverse 
Events (CTCAE) version 3.0. 
Response and survival evaluation
At baseline and after four courses of ipilimumab at week 12, a computed tomography (CT) 
scan was made to evaluate the tumor response. We used the following radiological scoring 
systems; Immune-related response criteria (irRC) and RECIST version 1.1. The response rates 
were termed as partial remission (PR) and complete remission (CR). BOR was also assessed 
using irRC to capture delayed anti-tumor responses often observed with immunotherapy. 
Clinical benefit was defined as the response proportion of patients plus SD lasting longer 
than 24 weeks. Estimates of OS and PFS were obtained using the Kaplan-Meier method.
Data-analysis
Data were retrospectively collected from all Dutch centers organized in the Dutch 
immunotherapy working group (WIN-O) participating in the Dutch expanded access program 
and having treated uveal melanoma patients (see also co-authors affiliations). Patients’ data 
were retrospectively collected into a predefined SPSS database by each center individually. 
Descriptive statistics were performed using SPSS statistical software (version 17.0 for 
Windows, SPSS, Chicago). The final data were graphed and analyzed using GraphPad Prism 
Version 5.0.
RESULTS
Twenty-two metastatic uveal melanoma patients were treated in an NPP, which was open in 
The Netherlands from May 2010 until August 2011. The patient characteristics of this cohort 
are described in Supplementary Table 1. Median follow-up was 177 days (6.3 months). 
Twelve patients (55%) completed the four infusions of ipilimumab. Of the remaining ten 
patients, nine had to discontinue treatment because of clinical deterioration due to disease 
progression (two of them died) and one because of severe adverse events (Fig. 1).
In Table 1 the response to treatment is described. Of the 22 patients who received at 
least one ipilimumab infusion, 13 patients showed progressive disease (PD) and one patient 
had a PR. There was no SD or CR achieved according to RECIST 1.1. Eight patients were not 
evaluable (NE). Following irRC there were twelve patients with PD, one with SD, one with 
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Figure 1. OS and PFS of uveal melanoma patients treated with ipilimumab 3mg/kg. All uveal 
melanoma patients treated in the Dutch expanded access program were evaluated retrospectively 
for (a) OS and (b) PFS. All 22 patients were included for PFS analysis, and the patients not evaluable at 
week 12 were defined to be progressive at the date of clinical deterioration. (c) The detailed follow up 
of the patients during treatment is shown.
Table 1. Response to treatment
RECIST after 12 weeks         Clinical benefit (based on BOR)
Progressive disease 13 (59.1%) PD/NE 20 (90.9%)
Stable disease  0 (0%) SD >24w/PR/CR 2 (9.1%)
Partial response 1 (4.5%)
Complete response 0 (0%) Response rate (based on BOR)
Not evaluable 8 (36.4%) SD/PD/NE 21 (95.5%)
CR/PR 1 (4.5%)
IRRC after 12 weeks
Progressive disease 12 (54.5%)
Stable disease  1 (4.5%)
Partial response 1 (4.5%)
Complete response 0 (0%)
Not evaluable 8* (36.4%)
Best overall response
Progressive disease 12 (54.5%)
Stable disease  1 (4.5%)
Partial response 1 (4.5%)
Complete response 0 (0%)
Not evaluable 8* (36.4%)
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At the time of manuscript preparation one patient (4.5%) was still alive with ongoing SD 
(+16 months). The patient observing a PR was eligible for ipilimumab re-induction due to 
disease progression 7 months after ipilimumab initiation. Unfortunately, the re-induction 
did not result in a renewed response. The OS and PFS curves of our 22 patients are depicted 
in Fig. 1. The Kaplan-Meier analyses show a median PFS of 2.9 months. The median OS 
was 5.2 months with a 1-year survival of 27%. As shown in Supplementary Table 2 most 
adverse events were immune-related. Here, we only describe the grade 3 irAEs, as grade 
1 or 2 was not considered clinically relevant. Grade 3 colitis was seen in two patients. One 
patient developed grade 3 hepatitis. All patients received corticosteroid treatment (1mg/kg 
predisolon) after which irAEs quickly resolved.
DISCUSSION 
In our study, 22 M1c uveal melanoma patients were treated by the Dutch immunotherapy 
working group (WIN-O) in an ipilimumab NPP in The Netherlands. Only twelve patients 
(55%) completed the treatment course consisting of four infusions of ipilimumab at the 
dose of 3mg/kg. Within the cohort of the 22 patients, only one patient had a PR according 
to RECIST and another patient had SD according to irRC. 
In another recently published study performed by Danielli et al., nine out of thirteen 
patients (69%) completed the course of four infusions and two patients showed SD that 
remained until week 36 4. Median OS was 36 weeks (9 months), in contrast to 21 weeks (5.2 
months) in our cohort. 
Three other, so far unpublished, retrospective analyses have evaluated the efficacy of 
ipilimumab in uveal melanoma patients. A single center analysis of twenty uveal melanoma 
patients treated at the Memorial Sloan-Kettering Cancer Center observed within a group of 
20 patients that received a median of four infusions of ipilimumab (20%) two PRs (one at 
week 12 and one at week 24) and seven SD. This resulted in a median survival of 8.6 months 
(95% CI, 3.5-NR), with two ongoing PRs (3+ yrs and 24+ wks)3. The other expanded access 
programs, the Italian and the US, observed a 1-year OS rate of 32% and 34%, respectively, 
which were comparable to the 1-year OS rate observed in our study (27%)5,6.     
Furthermore, initial phase 1 studies indicated a correlation between the presence of 
grade 3-4 irAEs and response7, that was not confirmed in the phase 3 studies2,8. Similarly, no 
such correlation was found in our analysis. 
In conclusion, our retrospective analysis from the Dutch expanded access program 
indicate limited clinical activity of ipilimumab in pretreated patients with metastatic uveal 
melanoma at a dose of 3mg/kg. Currently, two single-arm phase II clinical trials are testing 
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and NCT01034787). In addition a phase Ib/II study exploring the combination of ipilimumab 
with radiofrequency ablation (RFA) in uveal melanoma patients has been started recently 
at the Netherlands Cancer Institute (NKI-AVL), Amsterdam (www.trialregister.nl Identifier: 
NTR3488). Intensive patient characterization and biomarker research in these studies will 
hopefully be able to identify predictive factors for response and survival to targeted therapy 
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Supplementary Table 1. Patient characteristics (N=22)
Gender of the patient                Treatment before ipi
Male 10 (45%) DTIC 19 (86.4%)
Female 12 (55%) Other chemo 1 (4.5%)
Other several 2 (91.%)
Age
Median 54 (37-73) Number of ipi courses
1 course 3 (13.6%)
Mstage 2 courses 3 (13.6%)
M1a 0 (0%) 3 courses 4 (18.2%)
M1b 0 (0%) 4 courses 12 (54.5%)
M1c 0 (100%)
Median follow-up




Supplementary Table 2. Immune-related adverse events (irAEs)
Colitis Hepatitis
Grade 0 20 (90.9%) Grade 0 20 (90.9%)
Grade 1 0 (0%) Grade 1 0 (0%)
Grade 2 0 (0%) Grade 2 1 (4.5%)
Grade 3 2 (9.1%) Grade 3 1 (4.5%)
Dermatitis Uveitis
Grade 0 15 (86.2%) Grade 0 21 (95.5)
Grade 1 5 (22.7%) Grade 1 0 (0%)
Grade 2 2 (9.1%) Grade 2 1 (4.5%)
Grade 3 0 (0%) Grade 3 0 (0%)
Hypophysitis Other
Grade 0 22 (100%) Grade 0 14 (63.6%)
Grade 1 0 (0%) Grade 1 3 (13.6%)
Grade 2 0 (0%) Grade 2 2 (9.1%)








































Chapter 4  
Mismatch repair-deficient cancers are 
targets for anti-PD-1 therapy
Sander Kelderman1, Ton N. Schumacher1, Pia Kvistborg1
1The Netherlands Cancer Institute NKI-AVL, Amsterdam, The Netherlands 








































50  |  Chapter 4
ABSTRACT
Immune checkpoint-blocking therapies have yielded positive clinical data in a series of 
human malignancies. Recent work from Le and colleagues strongly supports the use of 
these therapies for mismatch repair-deficient tumors, independent of underlying tumor 
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PREVIEW
Over the past few years, therapies that interfere with T cell checkpoints and, in particular, 
the PD-1/PD-L1 axis, have reached center stage in oncology. Clinical trials with anti-PD-1 
and anti-PD-L1 antibodies have now shown objective responses in a series of human 
malignancies, including non-small cell lung cancer (NSCLC), bladder cancer, renal cell 
carcinoma, and Hodgkin’s lymphoma1. In non-melanoma tumors, clinical development of 
anti- PD-1 therapy is most advanced for NSCLC, with recent approval by FDA as second-line 
therapy. A proposed explanation for the activity of T cell checkpoint blockade in tumors such 
as melanoma and NSCLC has been the boosting of T cell reactivity against ‘‘neo-antigens’’, T 
cell epitopes that are newly formed as a consequence of tumor-specific mutations2. In line 
with this, T cell checkpoint blockade has been shown to enhance neo-antigen-specific T cell 
responses in both diseases3,4.
Contrary to the data in a number of other tumor types, clinical testing of anti-PD-1 has 
thus far not shown encouraging results in colorectal cancer (CRC). In two trials, a total of 33 
CRC patients were treated with anti-PD-1 therapy and only 1 patient (3%) experienced an 
objective response, which was, however, a complete response1. Interestingly, the tumor of 
this patient displayed a hyper-mutated phenotype, a characteristic of approximately 4% of 
metastasized colorectal cancers. 
Based on these data, Le and colleagues hypothesized that patients with mismatch 
repair-defects might be particularly responsive to checkpoint targeting. They now provide 
compelling data in favor of this hypothesis in a recent publication in the New England 
Journal of Medicine5. In a phase II study that evaluated the activity of PD-1 blockade in 41 
patients, 3 cohorts of patients were included: 11 patients with mismatch repair-deficient 
CRC, 21 patients with mismatch repair-proficient CRC, and 9 patients with mismatch repair-
deficient cancers other than CRC. DNA mismatch- repair deficiency results in large numbers 
of mutations, particularly in regions of repetitive DNA sequences, a phenomenon known as 
microsatellite instability (MSI). Mismatch-repair deficiency can arise as a consequence of 
inheritance of an inactive allele of one of the mismatch repair genes, with subsequent loss 
of the remaining wild-type copy, a genetic disorder known as Lynch syndrome. Alternatively, 
sporadic inactivation of mismatch-repair genes may occur, and, in this trial, patients with 
both types of mismatch- repair deficiency were included. Strikingly, 40% (4 out of 10) 
of mismatch repair-deficient CRC patients and 71% (5 of 7 patients) of mismatch repair- 
deficient non-CRC patients experienced an objective clinical response, whereas none of the 
patients with mismatch repair-proficient tumors responded (0 of 18). Furthermore, CRC 
patients with mismatch-repair deficiency had a significantly longer progression free survival 
(p < 0.001) as well as overall survival (p = 0.03). An unexpected observation in this study is 
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deficient tumors not linked to Lynch syndrome (3 out of 11 versus 6 out of 6 responders). 
Before speculating about possible biological explanations, it will be important to further 
address this issue in future studies. 
Consistent with a large body of literature on genomic alterations in mismatch repair-
deficient and -proficient tumors, the authors demonstrated a profound difference in 
mutational load between the two. On average, 1,782 somatic mutations were identified in 
mismatch repair-deficient tumors (n = 9) (by far surpassing the mutational load in melanoma 
and NSCLC), whereas, on average, only 73 somatic mutations were observed in mismatch 
repair-proficient tumor (n = 6). A prior analysis of patients treated with anti-PD-1 has shown 
that patients with NSCLC with a high mutational load have a significantly higher likelihood of 
clinical benefit than patients with less mutated tumors3. A similar, albeit weaker, correlation 
was seen for melanoma patients treated with anti-CTLA-4 therapy6. Thus, the data from Le 
and coworkers add to the increasing body of evidence that, in at least some malignancies, 
high mutational load can increase the likelihood of clinical response to immune check- 
point-blocking therapies. 
The most straightforward explanation for the heightened activity of anti-PD-1 therapy 
in mismatch repair-deficient tumors is the increased probability of a strong neo-antigen-
driven T cell response (model A in Fig. 1). Nevertheless, as also pointed out by the authors, 
other potential mechanisms should not be excluded. First, DNA repair-deficient tumors 
could potentially be characterized by changes in signaling transduction pathways that lead 
to a more inflamed tumor micro-environment, for instance, through altered cytokine or 
chemokine expression (model B). Alternatively, the high level of DNA damage in mismatch 
repair-deficient tumors may potentially cause cellular stress that could, for instance, be 
sensed by innate immune cells (model C). Nevertheless, Occam’s razor would tell us that, in 
the absence of additional evidence for such models, mismatch repair-deficient tumors may 
simply look more ‘‘foreign’’ because of the high number of neo-antigens they carry. 
A remarkable aspect of mismatch repair-deficient CRC is the frequent loss of MHC 
class I expression (in up to 60% of MSI CRC tumors7). How can this be reconciled with the 
current clinical data? First, clinical activity may primarily be seen in the subset of MHC class 
I proficient tumors, in which case straightforward MHC class I immunohistochemistry could 
be used as a potential biomarker. Alternatively, it is worth considering that PD-1 therapy 
may also work in the absence of tumor-expressed MHC class I. First, antigen-presenting 
cells within the tumor microenvironment may cross-present MHC class I-restricted tumor 
antigens to tumor infiltrating CD8+ T cells in situ, facilitating an immune response that can 
target the tumor microenvironment. Data from mouse models support the potential role of 
such a mechanism in tumor regression. In addition or alter- natively, anti-PD-1 therapy may 















































Figure 1. Potential mechanisms of action of anti-PD-1 therapy in mismatched repair-deficient 
tumors. (a) MMR deficiency results in a more diverse neo-antigen repertoire, increasing the chances 
of a tumor-specific T cell response. (b) MMR deficiency is associated with the activation of signaling 
pathways, which leads to a more inflammatory tumor micro-environment. (c) MMR deficiency leads 
to cellular stress, which, for instance, promotes T or NK cell accumulation or tumor recognition. 
Indirect support for the latter model is provided by the observation that CD4+ TIL in MSI 
tumors express higher levels of PD-1 than CD4+ T cells in MSS (microsatellite stable) tumors8 
and by the observation that CD4+ TIL in melanoma—a tumor type with a lower mutational 
load—frequently recognize mutated antigens9. Furthermore, work from Kreiter et al. has 
shown that MHC class II-restricted T cell responses can play an important role in tumor 
control in a pre-clinical colorectal cancer model10. 
The data from Le and colleagues strongly suggest that immune check- point blockade 
can form an attractive therapy for mismatch repair-deficient tumors independent of the 
underlying tumor type. The fraction of mismatch repair-deficient tumors for metastasized 
cancers is unfortunately not very high: for instance, roughly 4% of CRC, up to 11% of ovarian 
carcinomas, and 18% of endometrial cancers. In future studies, it will be important to 
under- stand if it is feasible to extend cancer immunotherapy to colorectal tumors with less 
profound DNA damage, for instance through combination check- point blockade. From a 
more mechanistic point of view, it will be of interest to understand whether clinical efficacy 
within the mismatch repair-deficient patient group is primarily restricted to MHC class I 
expressing tumors, or whether anti-PD-1 therapy can also work in the absence of tumor-
expressed MHC class I. 
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ABSTRACT
A number of immunotherapies, in particular immune checkpoint targeting antibodies and 
adoptive T-cell therapies, are starting to transform the treatment of advanced cancers. The 
likelihood to respond to these immunotherapies differs strongly across tumor types, with 
response rates for checkpoint targeting being the highest in advanced melanoma, renal 
cell cancer and non-small cell lung cancer. However, also non-responsiveness is observed, 
indicating the presence of intrinsic resistance or naturally acquired resistance. In addition, 
a subgroup of patients that do initially respond to immunotherapy will later recur, thereby 
also pointing towards a role of therapy-induced acquired resistance.
Here, we review our current understanding of both intrinsic and acquired resistance 
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INTRODUCTION
For many tumor types, including melanoma, renal cell cancer, colon cancer, ovarian cancer, 
and some subtypes of breast cancer, the presence of lymphocytic infiltrates within the 
tumor is highly correlated with improved outcome1-8. These infiltrates mostly consist of 
CD4+ and CD8+ T cells, and especially for melanoma it has been well established that part 
of these T cells recognize tumor-associated antigens9,10. The fact that these cells can have 
direct tumoricidal potential is well illustrated by the clinical effects of adoptive transfer of 
ex vivo expanded tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients. In 
several small clinical trials, response rates varying from 40% to 70% have been observed in 
highly selected metastatic melanoma patients11,12. In a more recent intent-to-treat analysis 
in a TIL trial for melanoma, a response rate of 30% has been reported13. Within these 
studies, the absolute numbers of CD8+ T cells infused is strongly correlated with response to 
treatment, suggesting an important role for MHC class I restricted, cytotoxic T-lymphocyte 
(CTL) mediated tumor killing13,14. Direct evidence in support of such a role has been obtained 
through the administration of TIL products enriched for CD8+ T cells, which showed a 
response rate comparable to that seen with unselected TIL products15. In addition to tumor-
reactive CD8+ T cells, it is clear that TIL products can also contain CD4+ T-cell populations that 
are tumor-reactive, and there is evidence for an anti-tumoral effect of such tumor-reactive 
CD4+ populations in melanoma and cholangiocarcinoma16,17.
A second, much more widely used, group of immunotherapeutic strategies that target 
the same cellular compartment focuses on the administration of antibodies that bind to 
immune checkpoint molecules, thereby (re)activating an endogenous tumor-specific T-cell 
immune response. Administration of ipilimumab, an antibody that binds the inhibitory 
receptor cytotoxic T-lymphocyte antigen 4 (CTLA4) on T cells, has shown a four month 
increase in median overall survival in phase III trials, leading to FDA and EMA approval18,19. 
An analysis of a large cohort of melanoma patients treated following this registration shows 
a long-term survival in 20-25% of treated metastatic melanoma patients20, a number that 
compares favorably to the 8-10% seen previously in patients treated with chemotherapy. 
More recently, objective response rates up to 50% have been reported in phase I/II trials 
testing antibodies that target another checkpoint molecule, programmed cell death protein 
1 (PD-1) or its ligand (PD-L1). Importantly, clinical responses upon PD-1 – PD-L1 targeting 
have been observed in malignancies other than melanoma, such as renal cell carcinoma 
(RCC) and non-small cell lung cancer (NSCLC)21-23. 
These encouraging clinical results have rightfully put immunotherapy at the forefront 
of oncological practice. Nevertheless, it is important to note that a substantial number of 
patients still derive no or only limited benefit for reasons largely unknown, sometimes at 
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immunotherapeutic treatment modalities, but also across tumor types strongly suggests 
a role for immune resistance. Further evidence for such resistance comes from patients 
treated with immunotherapy who experience an initial decrease in overall tumor burden 
but eventually succumb to disease recurrence. In the following sections we describe the 
relevance of different classes of immunotherapy resistance in oncology and contrast 
this with therapy resistance seen with targeted therapies. Furthermore, we describe the 
strategies that may be taken to obtain a better understanding of immunotherapy resistance, 
and how this knowledge can be used clinically.
Requirements for an optimal anti-tumor T-cell response
To understand at which levels resistance to T cell-based cancer immunotherapy may occur, 
it is important to first describe the key elements that are required for a successful T-cell 
response that leads to cancer regression. To do so, we subdivide this process into three 
discrete steps (Fig. 1).
S. Kelderman et al. Figure 1
3. Ability to kill the tumor2. Ability to infiltrate the
tumor-microenvironment
1. Ability to induce an antigen-
specific T cell response
Figure 1. Key elements for an effective anti-tumor T-cell response. The development of an effective 
anti-tumor T-cell response follows three distinct steps: 1.) Priming and activation of naïve antigen-
specific T cells; 2.) Migration and infiltration of activated T cells through the vasculature and tumor-
surrounding stroma; 3.) Recognition of cognate peptide in the context of MHC and release of cytoloytic 
granules to mediate tumor cell killing. 
First, T cells need to be properly activated by professional antigen-presenting cells (APCs) 
in peripheral lymphoid organs. For this to occur, two things are required: A). Dendritic cells 
(DCs) need to display tumor antigens (derived from apoptotic or necrotic tumor cells) in 
the context of MHC class I or II for which an antigen-specific T-cell repertoire is present. B). 
These DCs need to have received maturation signals that instruct the development of an 
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Second, following priming in peripheral lymphoid organs, the activated T cells need to 
home to the tumor, extravasate through the endothelium and infiltrate via the surrounding 
stromal tissue into the tumor before they can bind to their target. This both requires certain 
phenotypic characteristics, such as expression of chemokine receptors, on the T cells and 
the expression of cell adhesion molecules/ chemokines by the vascular endothelium for cells 
to pass the endothelial barrier and invade the tumor24. T cells that have been inefficiently 
activated, because of lack of costimulatory molecule expression on APCs, or as a result of 
ineffective priming, can become anergic. By the same token, also when T-cell priming is 
efficient, but the tumor lacks the inflammatory signals to attract these cells, the tumor-
specific immune response will be of little value.
Third, the T-cell receptors on the infiltrating T cells need to contact peptide MHC 
complexes on the tumor cell surface, in the case of CD8+ cells, to release lytic granules in the 
immune synapse thereby mediating tumor destruction. Furthermore, the environment that 
the T cells encounter needs to permit such cytolytic activity. Negative feedback loops that 
regulate T-cell activity at effector sites are abundant and are essential to prevent run-away 
immune responses, but can also inhibit T-cell mediated tumor regression.
Having described the requirements for an optimal anti-tumor immune response, we can 
now make a subdivision of cancer immune resistance into three distinct classes (Fig. 2A) that 
are further detailed below.
Intrinsic resistance
First, there are non-responding patients that lack anti-tumor immune activity and that also 
fail to elicit a T-cell response that has substantial tumoricidal potential upon immunotherapy, 
indicating intrinsic resistance. This form of resistance can be the result of a failing antitumor 
immune response either locally or systemically. A first class of systemic immune failure is 
observed in patients that are unable to elicit a potent immune response to a large variety 
of truly foreign antigens, such as viruses. This is for example observed in severely immune-
compromised HIV patients or transplantation patients who carry an increased risk of virally 
induced neoplasias25. Also elderly people may lose the capacity to mount a sufficiently 
strong systemic immune response upon foreign antigen exposure, possibly caused by a 
decrease in the diversity of the total T-cell pool26-28. This effect is demonstrated in elderly 
patients who suffer from the reactivation of silent viruses, such as VZV that causes shingles, 
or infection with Merkel cell polyomavirus that can cause Merkel cell carcinoma29. Although 
speculative, it is conceivable that such patient subgroups are less capable of mounting an 
anti-tumor immune response that is efficient enough to eradicate cancer cells. A second 
class of systemic intrinsic resistance is formed by tumors that express few antigens that 
can be seen as foreign by the immune system. Tumor antigens can be subdivided in distinct 
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many of the antigens that are (over-) expressed by tumors are also expressed on healthy 
tissues. For at least some of these ‘self antigens’, the avidity of the available T-cell repertoire 
will be low because of T-cell tolerance30. As a second class of antigens, human tumors can 
express epitopes that are truly foreign to the immune system, either derived from viral 
proteins or from mutant epitopes formed as a consequence of mutations. Recent evidence 
suggests that recognition of such neo-antigens may be of particular importance for tumor 
control31-35. Consequently, non-viral tumors with a low mutational load, such as pediatric 
and many of the liquid tumors, may be more likely to evade immune detection than tumors 
with a high mutational load, such as melanoma or smoking-related non-small cell lung 
cancer (NSCLC)36,37. 
Local intrinsic immune resistance may manifest itself in several ways. First, in some patients 
tumors may completely lack lymphocytic infiltrates. Assuming that in at least some of these 
patients, a systemic tumor-specific T-cell response was induced (data are presently lacking 
on this), this would signify the presence of a non-inflammatory tumor micro-environment 
that hampers infiltration of immune cells that would otherwise be able to recognize the 
tumor38,39. 
Assuming that tumor-specific T cells are properly activated and capable of homing to the 
tumor, the tumor microenvironment can pose the last barrier for T cells to exert their effector 
functions thereby giving rise to intrinsic resistance. It has been described that expression of 
PD-L1, which is the main ligand for the T-cell inhibitory molecule PD-1, can be induced upon 
loss of the tumor-suppressor gene PTEN and activation of the PI3K pathway in glioblastoma 
cell lines40 (Fig. 2B). 
Figure 2. Categories of immune resistance. (a) Several categories of immune resistance can be 
distinguished in either treatment-naïve or treatment experienced cancer patients. In the first group, 
tumor-infiltrating immune cells are either absent or scanty indicating indicative of intrinsic resistance 
or naturally acquired resistance. These patients are unlikely to respond to immune modulatory 
treatments. In the second group of patients, the degree of immune infiltration is sufficient to establish 
tumor regression upon immunotherapy initiation. However, due to several potentially overlapping 
mechanisms the tumor becomes resistant to this immune pressure and therapy-induced resistance 
ensues. (b) Mechanisms of intrinsic and naturally acquired resistance are exemplified by PD-L1 
expression and subsequent effector function inhibition of antigen-specific T cells. Upper panel shows 
tumor cells that constitutively express PD-L1 as a result of genetic alterations related to the oncogenic 
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Additionally, the secretion of inhibitory molecules such as TGF-β, IL-10 and IDO can have a 
direct negative effect on T-cell function in the microenvironment41-44, but also indirectly via 
the recruitment of tolerogenic immature DCs, myeloid derived-suppressor cells (MDSCs) or 
(inducible) regulatory CD4+ T cells45-48. It is important to point out though that the presence 
of a T-cell infiltrate within a progressing tumor does not necessarily imply local inhibition of 
T-cell function as the mechanism of intrinsic resistance. Specifically, for most cancer types 
where T-cell infiltration is apparent we do not presently know to what extent this T-cell 
infiltrate consists of tumor-specific T cells or of bystander cells, and only in the former case, 
local inhibition needs to be considered as a barrier to immune control.
Intrinsic resistance is not unique to immunotherapy but can also be observed in patients 
treated with targeted therapies. A well-described example of this is the different sensitivities 
of tumors that carry the BRAF V600E mutations to drugs such as vemurafenib that bind 
the mutant BRAF protein. Specifically, whereas the majority of melanoma patients with a 
BRAF V600E mutation show a rapid (albeit often transient, see below) tumor regression 
upon treatment with BRAF inhibitors, patients with BRAF V600E colorectal cancer are 
unresponsive to these drugs. Recent work demonstrates that this intrinsic resistance is due to 
EGFR expression in the BRAF mutant colorectal tumors, and that sensitivity can be imposed 
by concomitant EGFR inhibition49,50. While obtained in an entirely different therapeutic field, 
these data illustrate that intrinsic resistance can occur as a coincidental side effect of the 
oncogenic process, and can be overcome upon a better understanding of this process.  
Naturally acquired resistance
Naturally acquired resistance is special in that it is unique to immunotherapy. This form of 
resistance is defined as a reduced sensitivity that is not induced by cancer immunotherapy 
but that develops as a consequence of naturally occurring immune pressure. In this group 
of patients, there will generally be signs of an ongoing immune response in peripheral blood 
or tumor tissue, but they will fail to derive benefit from immune modulatory treatment. 
In the case of naturally acquired resistance, there is presently little evidence for altered 
T-cell activation or homing. Rather, this form of resistance may mostly manifest itself as 
mechanisms that interfere with T-cell activity within the tumor micro-environment. Multiple 
inhibitory feedback mechanisms can play a role here, including the expression of a variety 
of (potentially overlapping) checkpoint molecules that dampen the immune response, such 
as LAG-3, TIM-3 and BTLA51. As an example, when tumor-infiltrating effector T cells start to 
produce IFN- γ upon binding of cognate antigen, this will induce PD-L1 expression on the 
tumor cell surface, which serves to limit further T-cell effector function by engaging the 
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In addition, a naturally occurring immune response may select for tumor cell 
subpopulations with loss of MHC class I expression, or other defects in the antigen processing 
machinery, thereby cloaking the tumor cell from the immune system52-54. A similar immune 
evasive effect may be achieved through selection of tumor subclones present within 
heterogeneous tumors lacking one or multiple antigens that are subject to strong Darwinian 
selection, a process called immune-editing55-57. Strong evidence for immune editing has been 
obtained in mouse model systems. However, other murine studies suggest that antigen loss 
may be less of an issue in cases in which the release of IFN-γ and TNF-α by CTLs leads to 
the destruction of tumor stroma 58. Human data on this topic are at present lacking but may 
conceivably be obtained with the recently developed abilities to describe T-cell responses 
against (mutant) antigens within individual patients. 
Therapy-induced resistance
A third class of resistance is observed when patients that initially respond to immunotherapy 
relapse, which we define as therapy-induced resistance. This type of resistance is well 
known in patients treated with classical cytotoxic agents or with targeted agents, such as 
BRAF inhibitors59. Natural resistance upon treatment with such targeted therapies, where 
virtually all patients eventually relapse, can be due to selection of resistant tumor clones 
already present at low numbers at the start of treatment, or of newly mutated resistant 
clones. This stands in stark contrast with immunotherapy-treated patients where durable 
complete responses are often already observed after a single-modality treatment. Although 
immunotherapy-induced clinical responses can last up to years, a subgroup of patients 
experiences only temporary disease regression20,60,61. The general mechanisms of therapy-
induced resistance will be very similar to those mentioned previously in the setting of 
naturally acquired resistance: When a properly activated T-cell pool with homing capacity is 
present, an equilibrium between effector T cells and the tumor is reached locally, which at 
some point in time tips the balance in favor of renewed tumor growth. 
Strategies to study resistance mechanisms
To increase our understanding of immunotherapy resistance, we suggest to analyze this 
process on the basis of the three different nodes that are involved in an effective anti-tumor 
immune response. 
First, a diverse T-cell pool is required that can respond to a wide variety of tumor-
associated antigens. The currently used immunotherapeutic strategies that exploit the 
activity of the endogenous T-cell compartment appear predominantly effective in tumors 
with median to high mutational loads, consistent with a role of neo-antigen recognition 
in tumor control. While the occurrence of neo-antigen reactive T cells appears to be a 
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is still lacking. Longitudinal immune monitoring of neo-antigen specific T cells in a setting 
of cancer immunotherapy, using polychromatic flow cytometry or mass cytometry62 should 
be of value here. In a similar manner, assessment of immune competence (i.e. the ability to 
elicit a polyfunctional T-cell response) on a per patient basis could help guide eligibility for 
immunotherapeutic intervention. 
Second, to study the homing capacity of endogenously activated T cells in the context of 
immune escape, we need to address to what extent the tumor microenvironment is capable 
of triggering T-cell infiltration. To study this, pre-therapy tumor biopsies can be taken from 
patients included in immunotherapy trials and predictive gene-expression signatures 
established that correlate with ongoing or subsequent T-cell infiltration or with clinical 
benefit63. 
The third and final step that needs to be analyzed is the ability of T cells to release their 
effector functions at the site where it is needed. Several feedback mechanisms are at play 
here. Importantly though a hierarchy has not yet been determined, and such a hierarchy 1). 
Is likely to differ between tumor types; 2). Is within tumor types likely to differ depending on 
the specific genetic alterations; 3). May for a given tumor conceivably even vary depending 
on the site of metastasis. Recent work has emphasized the role of PD-L1 expression as an 
important regulator of local T-cell effector function. Using PD-L1 expression as a biomarker 
grouped responding patients in an anti-PD-1 phase I clinical study, although absence of 
expression did not exclude a response to therapy64. These data underscore the value of 
biomarker discovery not only for the early phases of the endogenous immune response 
(e.g. local inflammation) but also for the later effector phase. Notably though, patients with 
colorectal cancer only infrequently show responses to PD-1 blockade, even though these 
tumors have high mutational loads and T-cell infiltrates within these tumors has been shown 
to form a prognostic factor superior to the standard TNM classification65,66. These data are 
consistent with the hypothesis that within these tumors, another inhibitory pathway could 
be dominant.
Strategies to overcome resistance
The efficacy of many immunotherapeutic strategies is dependent on the strength of 
the endogenous T-cell response, including the level of tolerance towards the antigens 
recognized. Therefore, patients with an impaired capacity to mount immune responses, 
or who carry tumors that express few strong T-cell antigens may gain most clinical benefit 
from strategies that create the missing tumor-reactive T-cell pool. This may be achieved by 
the adoptive transfer of T cells genetically modified to express an exogenous CAR or TCR 
capable of effective target killing67,68 69-71. In patients with a weak T-cell response against 
tumor antigens, low-frequency tumor-specific T-cell populations may be enriched from 
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tumor-associated epitopes and thereby augment the anti-tumor response. Alternatively, 
expression of co-stimulatory and co-inhibitory markers in fresh tumor digest has been 
shown to define the tumor-reactive T-cell subset in melanoma lesions, offering a potential 
means to create TIL products that are enriched for tumor reactivity without the need for 
prior knowledge on antigen-specificity72,73. 
In patients that have the capacity to mount a systemic T-cell response but where tumors 
do not permit the infiltration of immune cells or prevent the initiation of a local endogenous 
immune response, are unlikely to benefit from treatment regimens that rely on such local 
immune responses. Such patients might benefit more from pre-conditioning regimens that 
promote an immune supportive tumor microenvironment by providing ‘danger signals’ 
and the establishment of an inflammatory signature74. This may conceivably be achieved 
through the induction of immunogenic cell death either by chemotherapy, radiotherapy or 
even local injection of Toll-like receptor (TLR) agonists75. For cancer types with a relatively 
low mutational load, such as ovarian, breast or pancreatic cancer, the use of DNA damaging 
agents could lead to an increase in the mutation frequency and as such broaden (albeit in a 
non-clonal manner) the epitope landscape76,77. 
Patients that do exhibit an endogenous anti-tumor immune response in all the relative 
compartments discussed before are eligible for at least several immunotherapeutic 
interventions such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). As with many 
classical cytotoxic agents, combination therapy could be of importance here in preventing 
escape from immune pressure. In this context, the nodes in the tumor-immune interaction 
that are targeted should be as little overlapping as possible and preferably complementary 
in nature. The combination of ipilimumab (thought to be involved in the early priming phase 
of T-cell activation) and nivolumab (thought to be involved in the later effector phase of 
T-cell activation) has already shown higher response rates than either treatment modality 
alone78. Presently, little is known about optimal timing or sequencing of available therapies 
but there is increasing evidence that patients failing one type of immunotherapy can respond 
to another, indicating independently operating resistance mechanisms than can be targeted 
accordingly. As an example, patients that have not benefitted from ipilimumab treatment 
still can have a meaningful objective response to anti-PD-1 treatment22 and vice versa64. 
Patients failing ipilimumab treatment can likewise develop a durable complete remission 
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CONCLUSION
In cancer immunotherapy, future rational treatment decision-making should be based on 
the specific node that is affected in the tumor-immune system interaction: 1.) Are antigen-
specific T cells efficiently activated in the treatment-naïve host? 2.) Is there infiltration of 
those T cells into the tumor? and 3.) Are the tumor-infiltrating T cells able to exert their 
function at that site? To achieve this, efforts should be focused on the discovery and 
implementation of simple biomarkers at each stage in the immune response that can 
predict whether a patient is likely to respond to a specific type of immunotherapy or not. 
Considering the variation in response rates of immunotherapy within one tumor entity and 
between tumor types, immunotherapy finds itself at the point where a patient-specific 
approach is required in order to achieve durable tumor control in a larger group of patients. 
ACKNOWLEDGEMENTS
This work was supported by Dutch Cancer Society grant KWF 2012-5463 to T.N.M.S., and by 








































Acquired and intrinsic resistance in cancer immunotherapy  |  67
5
REFERENCES
1. Clemente, C.G., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth 
phase of primary cutaneous melanoma. Cancer 77, 1303-1310 (1996).
2. Erdag, G., et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune 
cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72, 1070-1080 
(2012).
3. Galon, J., et al. Type, density, and location of immune cells within human colorectal tumors 
predict clinical outcome. Science 313, 1960-1964 (2006).
4. Zhang, L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl 
J Med 348, 203-213 (2003).
5. Hwang, W.T., et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-
analysis. Gynecol Oncol 124, 192-198 (2012).
6. Nakano, O., et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic 
factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. 
Cancer Res 61, 5132-5136 (2001).
7. Alexe, G., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast 
cancers correlates with lower recurrence rates. Cancer Res 67, 10669-10676 (2007).
8. Mahmoud, S.M., et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in 
human breast cancer. Breast Cancer Res Treat 127, 99-108 (2011).
9. Coulie, P.G., et al. A new gene coding for a differentiation antigen recognized by autologous 
cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180, 35-42 (1994).
10. Kawakami, Y., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating 
lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 91, 6458-6462 
(1994).
11. Dudley, M.E., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation 
of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26, 5233-5239 
(2008).
12. Dudley, M.E., et al. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate 
regression of metastatic melanoma. Clin Cancer Res 16, 6122-6131 (2010).
13. Besser, M.J., et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic 
melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin 
Cancer Res 19, 4792-4800 (2013).
14. Radvanyi, L.G., et al. Specific lymphocyte subsets predict response to adoptive cell therapy 
using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. 
Clin Cancer Res 18, 6758-6770 (2012).
15. Dudley, M.E., et al. Randomized selection design trial evaluating CD8+-enriched versus 
unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. 
J Clin Oncol 31, 2152-2159 (2013).
16. Tran, E., et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with 
Epithelial Cancer. Science 344, 641-645 (2014).
17. Hunder, N.N., et al. Treatment of metastatic melanoma with autologous CD4+ T cells against 
NY-ESO-1. N Engl J Med 358, 2698-2703 (2008).
18. Hodi, F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N 
Engl J Med 363, 711-723 (2010).
19. Robert, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N 








































68  |  Chapter 5
20. Prieto, P.A., et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with 
metastatic melanoma. Clin Cancer Res 18, 2039-2047 (2012).
21. Topalian, S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N 
Engl J Med 366, 2443-2454 (2012).
22. Hamid, O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N 
Engl J Med 369, 134-144 (2013).
23. Brahmer, J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. 
N Engl J Med 366, 2455-2465 (2012).
24. Harlin, H., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell 
recruitment. Cancer Res 69, 3077-3085 (2009).
25. Butel, J.S. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human 
disease. Carcinogenesis 21, 405-426 (2000).
26. Khan, N., et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the 
response to a coresident EBV infection. J Immunol 173, 7481-7489 (2004).
27. Akbar, A.N. & Fletcher, J.M. Memory T cell homeostasis and senescence during aging. Curr Opin 
Immunol 17, 480-485 (2005).
28. Messaoudi, I., et al. Age-related CD8 T cell clonal expansions constrict CD8 T cell repertoire and 
have the potential to impair immune defense. J Exp Med 200, 1347-1358 (2004).
29. Feng, H., et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 
319, 1096-1100 (2008).
30. Kvistborg, P., et al. Human cancer regression antigens. Curr Opin Immunol 25, 284-290 (2013).
31. van Rooij, N., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an 
ipilimumab-responsive melanoma. J Clin Oncol 31, e439-442 (2013).
32. Robbins, P.F., et al. Mining exomic sequencing data to identify mutated antigens recognized by 
adoptively transferred tumor-reactive T cells. Nat Med 19, 747-752 (2013).
33. Heemskerk, B., et al. The cancer antigenome. EMBO J 32, 194-203 (2013).
34. Champiat, S., et al. Exomics and immunogenics: Bridging mutational load and immune 
checkpoints efficacy. Oncoimmunology 3, e27817 (2014).
35. Brown, S.D., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with 
increased patient survival. Genome Res 24, 743-750 (2014).
36. Alexandrov, L.B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-
421 (2013).
37. Vogelstein, B., et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
38. Gajewski, T.F., et al. Gene signature in melanoma associated with clinical activity: a potential 
clue to unlock cancer immunotherapy. Cancer J 16, 399-403 (2010).
39. Taube, J.M., et al. Colocalization of inflammatory response with B7-h1 expression in human 
melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl 
Med 4, 127ra137 (2012).
40. Parsa, A.T., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and 
immunoresistance in glioma. Nat Med 13, 84-88 (2007).
41. Geissmann, F., et al. TGF-beta 1 prevents the noncognate maturation of human dendritic 
Langerhans cells. J Immunol 162, 4567-4575 (1999).
42. Pickup, M., et al. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 13, 
788-799 (2013).
43. Steinbrink, K., et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-









































Acquired and intrinsic resistance in cancer immunotherapy  |  69
5
44. Braun, D., et al. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during 
dendritic-cell maturation. Blood 106, 2375-2381 (2005).
45. Lutz, M.B. & Schuler, G. Immature, semi-mature and fully mature dendritic cells: which signals 
induce tolerance or immunity? Trends Immunol 23, 445-449 (2002).
46. Vukmanovic-Stejic, M., et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid 
turnover of memory populations in vivo. J Clin Invest 116, 2423-2433 (2006).
47. Gabrilovich, D.I., et al. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12, 
253-268 (2012).
48. Strauss, L., et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and 
transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin 
Cancer Res 13, 4345-4354 (2007).
49. Prahallad, A., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through 
feedback activation of EGFR. Nature 483, 100-103 (2012).
50. Sun, C., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 
508, 118-122 (2014).
51. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 
12, 252-264 (2012).
52. Khong, H.T., et al. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes 
from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 
27, 184-190 (2004).
53. del Campo, A.B., et al. Immune escape of cancer cells with beta2-microglobulin loss over the 
course of metastatic melanoma. Int J Cancer 134, 102-113 (2014).
54. Restifo, N.P., et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five 
patients receiving immunotherapy. J Natl Cancer Inst 88, 100-108 (1996).
55. Matsushita, H., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer 
immunoediting. Nature 482, 400-404 (2012).
56. Dunn, G.P., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat 
Immunol 3, 991-998 (2002).
57. Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of “tumor 
escape” phenotypes. Nat Immunol 3, 999-1005 (2002).
58. Zhang, B., et al. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants 
in established mouse cancers. J Clin Invest 118, 1398-1404 (2008).
59. Chapman, P.B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E 
mutation. N Engl J Med 364, 2507-2516 (2011).
60. Rosenberg, S.A., et al. Durable complete responses in heavily pretreated patients with metastatic 
melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17, 4550-4557 (2011).
61. Di Giacomo, A.M., et al. Long-term survival and immunological parameters in metastatic 
melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access 
programme. Cancer Immunol Immunother 62, 1021-1028 (2013).
62. Bendall, S.C., et al. Single-cell mass cytometry of differential immune and drug responses across 
a human hematopoietic continuum. Science 332, 687-696 (2011).
63. Ji, R.R., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. 
Cancer Immunol Immunother 61, 1019-1031 (2012).
64. Weber, J.S., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-
refractory or -naive melanoma. J Clin Oncol 31, 4311-4318 (2013).
65. Pages, F., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage 








































70  |  Chapter 5
66. Galon, J., et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant 
tumours. J Pathol 232, 199-209 (2014).
67. Morgan, R.A., et al. Cancer regression in patients after transfer of genetically engineered 
lymphocytes. Science 314, 126-129 (2006).
68. Robbins, P.F., et al. Tumor regression in patients with metastatic synovial cell sarcoma and 
melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29, 
917-924 (2011).
69. Grupp, S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N 
Engl J Med 368, 1509-1518 (2013).
70. Kalos, M., et al. T cells with chimeric antigen receptors have potent antitumor effects and can 
establish memory in patients with advanced leukemia. Sci Transl Med 3, 95ra73 (2011).
71. Porter, D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N 
Engl J Med 365, 725-733 (2011).
72. Gros, A., et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating 
human tumors. J Clin Invest 124, 2246-2259 (2014).
73. Ye, Q., et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T 
cells in tumor. Clin Cancer Res 20, 44-55 (2014).
74. Gajewski, T.F. Cancer immunotherapy. Mol Oncol 6, 242-250 (2012).
75. Kroemer, G., et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol 31, 51-72 
(2013).
76. Segal, N.H., et al. Epitope landscape in breast and colorectal cancer. Cancer Res 68, 889-892 
(2008).
77. Zhang, G.N., et al. TP53 K351N mutation-associated platinum resistance after neoadjuvant 
chemotherapy in patients with advanced ovarian cancer. Gynecol Oncol 132, 752-757 (2014).
78. Wolchok, J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369, 122-
133 (2013).
Chapter 6  
Tumor antigens in human cancer control
Sander Kelderman1, Pia Kvistborg1
1The Netherlands Cancer Institute NKI-AVL, Amsterdam, The Netherlands








































72  |  Chapter 6
ABSTRACT
The body of evidence that is supporting the role of T cells in human tumor control is 
substantial and it is now beyond doubt that T cells can be crucial in the clinical response 
to cancer immunotherapies such as adoptive T cell therapy and checkpoint blockade. This 
has been proven in particular for melanoma and non-small cell lung cancer. Strikingly, while 
clinical experience with these therapies is extensive, what these T cells detect on the tumors 
remains largely unknown. An extensive effort has been put into the characterization of 
tumor antigens and based on the recent successes of immunotherapies Cancer/Germline, 
mutated and viral antigens appear rather promising targets for tumor control. Furthermore, 
it is becoming evident that the most potent antigen in tumor control is highly dependent on 
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WHY T CELLS ARE RELEVANT
It is now beyond doubt that the endogenous T cell based immune system can recognize 
cancer cells and in some situations control the disease. Pre-clinical data from numerous 
mouse models have demonstrated the importance of T cells in tumor control by depleting 
either the adaptive immune response or T cells alone resulting in abrogation of tumor 
rejection to various degrees. The importance of T cells in the human setting is supported by 
the correlation of tumor infiltrating T cells with good prognosis in a substantial number of 
different cancers1-4. In particular, it is well described that the location and activation status 
of T cells in colorectal cancer is of high prognostic value. Galon and colleagues have shown 
that quantifying the infiltration of antigen experienced CD8+ T cells in the tumor invasive 
margin and the center of the tumor as a prognostic tool is equally strong (or potentially 
even better) as the currently used staging system5,6. Furthermore, work from Ribas and 
colleagues has shown that tumor infiltration and location of CD8+ positive cells in human 
melanoma can function as a predictive biomarker for clinical outcome to anti-PD-1 therapy7. 
Nevertheless, the mere infiltration of T cells into cancer and the correlation with prognosis 
or clinical outcome is not providing direct evidence for T cells being an active contributor to 
the control of human cancer. 
As a direct proof for the tumoricidal potential of patient autologous T cells, Rosenberg 
and colleagues have shown that infusion of autologous ex vivo expanded tumor infiltrating 
lymphocytes (TIL) can induce objective clinical responses in melanoma patients8,9. Similar 
response rates are achieved when infusing TIL products enriched for CD8+ T cells providing 
direct evidence for the tumor killing capacity of these cells10-12. Within the last few years, 
the evidence for the activity of T cells in tumor control has extended beyond melanoma to 
a number of other human malignancies. This has in particular been demonstrated in clinical 
trials showing responses to anti-PD-1 therapy in a number of cancers including non-small 
cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma and Hodgkin’s lymphoma13-16. 
Furthermore, it was shown in a recent case report that TIL therapy in a patient with 
metastatic cholangiocarcinoma was able to mediate tumor regression17. 
The main point that can be inferred from these clinical trial data is that a proportion of 
tumor cells must express antigens that allow endogenous T cells to specifically recognize 
and kill them. Having established that T cells can play a pivotal role in human cancer control, 









































74  |  Chapter 6
WHICH ANTIGENS ARE DETECTED
T cells can recognize antigens that are presented on the surface of tumor cells in the context 
of HLA class I and II molecules and thereby mediate tumor cell destruction. These stretches 
of antigen bound to HLA molecules, epitopes, are a result of protein degradation in the 
cytosol. The fragmented antigens are transported into the ER lumen where they can be 
loaded onto an HLA molecule that will be translocated to the surface of the cell. Therefore, 
the epitopes bound to the HLA molecule forms a representation of cellular content. The first 
appreciation of such antigens recognized by autologous T cells came from van der Bruggen 
and colleagues in 1991 with the identification of MAGE-A118. Since this first discovery a 
huge number of T cell epitopes have been characterized from proteins with an aberrant 
expression in tumor cells (Fig. 1). 
The characterized T cell epitopes were identified through either the use of patient-
derived T cell populations or by the ‘reverse immunology’ approach. Using the approach of 
dissecting what tumor reactive T cell clones from cancer patients recognize directly provides 
evidence for the immunogenicity of the identified epitopes. The reverse immunology 
strategy does not provide a similar validation and it is therefor central to demonstrate that T 
cell epitopes identified with such a strategy can be recognized by T cells from cancer patients 
directly ex vivo, and very importantly that these T cells recognize the autologous tumor. 
Tumor antigens can be divided into two main classes. The first being the tumor associated 
antigens (TAA), which includes proteins that are shared between tumor and healthy tissue 
and to which tolerance is incomplete. These antigens can be further divided into categories 
based on their expression pattern in healthy tissues. One category is the over-expressed 
antigens19,20. These are proteins expressed by various healthy tissues and tumor cells and 
differ at the expression level of the proteins. A second category is the cell lineage-specific 
group of proteins including the melanocyte differentiation antigens that are expressed by 
the vast majority of melanomas21,22. A third category is the Cancer/Germline (C/G) antigens. 
These proteins are encoded by genes mainly expressed in germline cells and can be re-
expressed in tumor due to dysregulation of demethylation in tumor cells23. 
The second class of antigens is formed by the tumor specific antigens (TSAs) also referred 
to as neo-antigens. These antigens include mutated antigens that arise as a consequence of 
tumor specific DNA damage as well as antigens resulting from the expression of oncogenic 
viral proteins. 
This review will mainly focus on C/G and neo-antigens and discuss the promising 
















































































































Figure 1 S. Kelderman, P. Kvistborg
Figure 1. Time frame of antigen discovery. Over the course of 25 years, a multitude of tumor antigens 
have been discovered using various technologies such as cDNA library cloning, SEREX, reverse-
immunology and, more recently, whole tumor-exome sequencing. The colored parts contain a non-
exhaustive list of tumor antigens for which T-cell responses have been detected, in yellow for shared 
antigens and in blue for private antigens, with a more dominant focus on the latter antigen class 
in recent years. Data was retrieved from the Cancer Immunity Peptide Database74. T cell responses 
detected against the neo-antigens ATR, CSNK1A1 and, KIF2C and POLA2 were retrieved from 40, 41 and 
42, respectively. Asterisk indicates that multiple neo-antigen specific T-cell responses were detected 
but only one here is shown. 
Cancer/Germline antigens
Proteins are stratified to the group of C/G antigens based on their expression in both germ 
line cells and cancers. The C/G proteins are widely expressed during fetal development but 
become silenced for a substantial part by methylation of the genes in adult tissue, except 
for in germ cells. These genes are often re-expressed in cancers likely caused by changes 
in genomic methylation23. The first C/G antigen described was MAGE1 (now known as 
MAGEA1, Fig. 1). This antigen was identified using patient-derived tumor-reactive T cell 
clones isolated from a melanoma patient with an unusual favorable clinical course18. In the 
following decades >200 antigens belonging to this family have been identified. This discovery 
was in particular fast-tracked with the development of the SEREX technology (serological 
analysis of cDNA expression libraries). 
The expression of C/G antigens varies greatly between different malignancies. As 
an example, NY-ESO-1 is expressed in NSCLC, ovarian carcinoma, breast carcinoma and 
melanoma with varying frequency24. Furthermore, within each tumor lesion the expression 
of a certain C/G antigen can be highly heterogeneous. Hence, the expression of C/G antigens 
appears to be somewhat tumor ‘private’ even though it is a shared antigen. 
The reason for the heterogeneous expression pattern of C/G antigens has not yet been 
established but might reflect an ongoing Darwinian pressure together with redundant 
functionality. For some C/G antigens it has been demonstrated that the expression can be 
beneficial for tumor cells. As an example, proteins of the MAGE family have been found 
to modulate cell survival by suppressing the function of p5325 and linked to acquired drug 
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antigens there is no clear function known and thus their expression may be a stochastic 
event caused by tumor related changes in chromosomal stability. Regardless of their 
function that may or may not be linked to survival benefit, these antigens still form a useful 
group of targets.
The restricted expression profile of C/G antigens in healthy tissue and their aberrant 
expression in various tumors has made this group of antigens theoretically highly attractive 
targets for anti-cancer immune interventions. This is reflected by the high number of early 
clinical trials that have used members of this protein family as targets. The vast majority of 
these trials was based on vaccination strategies and did not result in notable toxicities nor 
did they result in sufficient clinical efficacy to be further developed. Despite the conceptually 
attractive characteristics of these antigens there are three crucial points to consider before 
developing therapies that will steer potent immune responses towards them. 
First, more recent studies mapping the expression pattern of these proteins revealed 
that a good number are expressed at varying levels on healthy tissues accessible to the 
immune system. Examples are MAGE-A9 expressed on brain tissue and MAGE-A11 on lung 
tissue28. Based on these data a proportion of antigens that have previously been regarded as 
tumor-restricted targets might potentially cause severe toxicities when targeted with potent 
immune interventions. As a matter of fact, such toxicities have been encountered in clinical 
trials making use of T cell receptor (TCR) gene-engineered T cells for adoptive cell therapy. 
Severe safety issues were observed in a clinical trial in which melanoma patients were 
treated with a MAGE-A3 specific TCR29. This TCR cross-reacted with an epitope derived from 
MAGE-A12, which is expressed at low levels in the gray matter of the brain. This resulted in 
severe brain toxicity in 1/3 of the treated patients. More encouragingly, an NY-ESO-1 specific 
TCR was used in a clinical trial without toxicity issues in melanoma patients and synovial 
cell sarcoma patients achieving high objective response rates30. Taken together, these data 
illustrate that members of this antigen family can be potent tumor regression antigens. 
However, it is important not to view this antigen group as uniform concerning expression 
pattern but rather thoroughly investigate the expression of each protein in healthy tissue 
before targeting them. A second issue to consider is that, as previously mentioned, the 
expression of these antigens within the same tumor can be rather heterogeneous31. Patients 
included in the NY-ESO-1 TCR trial were selected for high homogeneous NY-ESO-1 expression 
and this may well be an important factor that determined the clinical success of this trial, as 
it is not known if sustained tumor control can be achieved when targeting heterogeneously 
expressed antigens. Finally, there is evidence that at least a part of C/G antigens can be 
expressed by thymic epithelial cells indicating that also for those C/G antigens that are truly 
restricted to immune privileged healthy tissue and tumor cells there may exist some level 
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Neo-antigens
All tumor specific antigens that are truly foreign to the immune system belong to the class of 
neo-antigens. These are antigens that either arise as a consequence of tumor specific DNA 
damage or are derived from viral proteins expressed in virus-induced cancers. Because of 
their foreign nature central tolerance towards these antigens is expected to be absent, which 
is in contrast with the self-antigens discussed earlier. Conceptually, this class of antigens is 
highly attractive as they are truly foreign to the immune system, because they are strictly 
restricted to tumor tissue, and no central tolerance should exist32. 
Cancer is, in essence, a genetic disease characterized by an accumulation of mutations 
over time. In general, human cancers are caused by mutations in proto-oncogenes either as 
a single event or in combination with loss of tumor suppressor genes. In most malignancies, 
as described in the hallmarks of cancer, hits in multiple genes are required for the malignant 
process to fully develop33. The genes involved in the malignant transformation comprise only 
a small fraction of the exome with additional mutations occurring at random locations. This 
chance driven process means that an accumulation of mutations in passengers or essential 
passenger genes will occur during tumor formation (reviewed in34). Therefore, the vast 
majority of mutations in each tumor will be in non-essential targets and tumor specific. Non-
synonymous or miss-sense mutations result in an amino acid change in protein sequences. 
When translated, such mutated protein sequences can produce a mutated antigen that can 
be recognized by the immune system. However, the fact that a miss-sense mutation can 
result in an epitope that can successfully bind to one of the patient specific HLA alleles 
and thereby be presented to the T cell based immune system does not necessarily make 
it an immunogenic antigen. Whether the endogenous T cell pool is reactive against these 
antigens is again a chance-driven process due to the random nature of TCR alpha and beta 
chain rearrangements that will not automatically result in a cognate T cell receptor for every 
expressed neo-antigen. 
This class of antigens has long been regarded highly attractive candidates for tumor 
rejection antigens and a landmark study Wölfel et al. was the first to describe a T cell clone 
in a melanoma patient that recognized a mutated antigen within the CDK4 gene (Fig. 1)35. At 
that point in time though, technical limitations prevented a systematic approach to query 
large datasets for the presence of patient-specific putative neo-antigens. In recent years, 
our understanding of the mutational landscapes of human tumors, both at the genomic and 
protein-encoding level, has immensely increased with the development of next-generation 
sequencing technologies that have by now become a mainstream application in tumor 
biology. These advances, together with the development of computational algorithms to 
predict peptide binding chances for large numbers of both human and mouse HLA alleles, 
have allowed immunologists to study the interaction of the consequences of DNA damages 
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Seminal work from Schreiber and colleagues nicely demonstrates how next-generation 
sequencing of the tumor exome can lead to identification of immunogenic neo-antigens in 
a mouse sarcoma model. These identified neo-antigens were found to be involved in tumor 
control in immune competent mice either alone or after checkpoint blockade37,38. As a side 
note, these two studies also show that there is a hierarchy within neo-antigens recognized 
by T cells within a tumor. Some epitopes have the capacity to be a tumor rejection antigen 
alone, and these are more prone to be lost in e.g. clonal selection, whereas others need 
help in form of e.g. checkpoint blocking or vaccine strategies to confer tumor control. 
Other studies have shown that a multi-epitope vaccination strategy utilizing neo-epitopes 
derived from the B16F10 melanoma cell line can elicit protective immune responses in a 
therapeutic setting of a mouse model39. Following these initial preclinical findings, we and 
others have demonstrated that both CD4+ and CD8+ T cells interact with the consequences 
of DNA damage in particular in melanoma but also NSCLC, ovarian cancer and gastro-
intestinal cancers17,40-45. Furthermore, it has been shown that immunotherapy can induce 
and enhance such T cell responses40,43. However, the fact that T cells can recognize these 
neo-antigens does not necessarily imply a role in human tumor control. Even though direct 
evidence of neo-antigens as tumor rejection antigens is lacking from the human setting it 
has been shown that patients with NSCLC with high mutational load have significantly higher 
likelihood of clinical benefit from anti-PD-1 therapy43. A similar correlation, nevertheless not 
as strong, was seen for melanoma patients treated with anti-CTLA-4 therapy46. In line with 
these findings, PD-1 blockade was shown to be clinically effective in metastatic colorectal 
cancer patients with mismatch-repair deficiency. This group had a more than 20-fold higher 
mutational load on average compared to patients that were mismatch-repair proficient and 
in whom no objective clinical responses were observed47. These findings, together with 
the evidence of T cell responses towards neo-antigens, strongly suggest that neo-antigens 
are an important component in the clinical activity of immunotherapy in some human 
malignancies. 
A second group of neo-antigens is the viral antigens. These are as foreign to the immune 
system as mutated antigens, and perhaps even more so, since there is no expected overlap 
between viral epitopes and non-mutated self-epitopes. Viral epitopes are created when a 
part of the viral genome becomes integrated in the host genome upon infection. This is 
often the case in HPV-related cancers such as head and neck cancer and cancers of the 
male and female urogenital region . To date, several immunotherapeutic strategies are in 
development to combat these tumors including DNA or synthetic long peptide vaccines that 
encode immunogenic epitopes of the most oncogenic virus types or the adoptive transfer 
of autologous TIL48-50. One example of such an effective strategy is the administration of a 
synthetic long-peptide vaccine targeting the HPV-16 oncogene E6 and E7 in women with 
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a correlation was found with the induction of HPV-16 specific immunity. Furthermore, for 
tumors with a known viral origin it is possible to develop prophylactic interventions as 
was done for HPV-based cancers for which a vaccine is now incorporated into the children 
vaccine program in multiple countries. 
Human endogenous retroviruses
We have now described two families of antigens, the C/G and the neo-antigens, which have 
been linked to clinical benefit either directly (NY-ESO-1) or indirectly (neo-antigens). In 
addition to the better-characterized groups of antigens there may well be additional types 
that could be potent tumor rejection antigens for some malignancies. 
One such type of antigens could be the human endogenous retroviruses (HERVs). 
Extensive studies have shown that all vertebrate genomes analyzed thus far contain 
exogenous elements closely related to retroviruses51. These sequences are referred to as 
endogenous retroviruses after they infected and integrated into host germ line cells and are 
passed on to offspring in a Mendelian fashion. The presence of ERV elements in humans 
was first discovered in the early 1980s and there is evidence for expression of HERVs or 
HERV elements in many different types of human malignancies52,53. This expression may 
either suggest a functional role for elements of HERVs or is simply reflecting deregulation by 
hypomethylation in tumor cells in general (reviewed in54). 
A very attractive trait of HEVRs is their viral origin as retroviral infections can be sensed 
by the innate immune system and it can be speculated that HERV elements expressed in 
cancers may even serve as adjuvant or ‘danger signal’ inducing or enhancing anti-tumor 
immunity.  
In addition to potentially providing ‘danger signals’ epitopes derived from expressed 
HERV proteins can also function as targets for T cell recognition of the tumor. It is not 
known to what level these proteins are expressed in the thymus (if they are expressed 
at all), however, it is known that part of the HERV elements can be expressed to various 
levels in healthy tissue indicating that tolerance can exist. In a recent study, it was shown 
that the expression of HERVs correlated with a cytolytic signature in a number of human 
malignancies including kidney cancer and ovarian cancer55, although these data do not 
elucidate if the T cells are specific for HERV derived epitopes. However, other studies have 
provided evidence for the presence of a T cell repertoire specifically recognizing HERVs56-58. 
The first study to describe such a T cell response came from Coulie and colleagues in 2002 
showing CD8+ T cells isolated from a melanoma patient were specific for an epitope from 
HERV-K-mel restricted to HLA-A2, and these T cell clones could recognize the autologous 
tumor as well58. Furthermore, we have shown the presence of T cell populations specific for 
HERV-K-mel within TILs56. At this point in time only a few T cell epitopes derived from HERVs 
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the expression of T cell epitopes from HERVs are in human malignancies and if they can play 
a role in tumor control. 
Importantly for these antigens, the uncertainties regarding tumor restriction warrant 
for caution when considering them as potential targets for immunotherapies much like the 
situation for the C/G antigens as a whole. 
Bacterial components
As a more speculative side note; several studies support a role of gut bacteria in playing a 
part in the development of colorectal cancer59,60. Taken together with the evidence that the 
integrity of the mucosal barrier has been compromised it may be speculated that bacterial 
antigens can be part of the cancer antigenome of these cancers. As these antigens are 
truly foreign to the immune system that would make them as conceptually attractive as 
the previously described neo-antigens and perhaps even more so as they can also serve 
as danger signal to the immune system, thus combining two attractive components. 
Nevertheless, this is at a rather speculative state and it needs to be established if T cell 
responses towards these bacterial antigens indeed exist and can cause tumor regression 
while at the same time not cause severe toxicity. 
WHICH ANTIGENS TO TARGET
When considering which antigens are the most successful targets to obtain tumor control, 
it is noteworthy that the most successful immunotherapies to date are those that do not 
target specific antigens but rather systemically activate the endogenous T cell pool. These 
therapies include the checkpoint targeting therapies and the reinvigoration of tumor 
infiltrating T cells ex vivo in TIL therapy11,61. In contrast, the strategies specifically targeting 
molecular defined tumor antigens have for the vast majority lacked clinical success thus far. 
This was already eluded to in a review by Neller et al. from 2008 in which response rates were 
compared between cancer vaccines based on a set of molecular defined antigens or bulk 
tumor cells as antigen source62. This study revealed that the response rate for melanoma 
patients treated with whole tumor cell as antigen source was approximately 2-fold higher 
compared to the molecular defined antigens, albeit still rather low. Taken together, these 
observations warrant re-visiting which antigens are selected as targets. 
As outlined in the above sections, there are clinical data supporting a potential role in 
tumor control for antigens belonging to the two main groups described (neo-antigens and 
C/G antigens). Even though these two groups of antigens have not been compared for their 
quality as tumor rejection antigens in a systematic way, there are data that provide hints 
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different human malignancies showed a correlation between mutational load and intra-
tumoral cytolytic activity in multiple cancer types including lung cancer, colorectal cancer 
and cervical cancer55. Interestingly, this correlation was not found when performing the 
same analysis for the expression of C/G genes. Nevertheless, a correlation between cytolytic 
activity and a few individual C/G antigens were observed in some types of malignancies 
e.g. melanoma, lung, head and neck, stomach, and ovarian cancer. Similar findings were 
made in a large set of colorectal cancer specimens in a study using T cell effector markers 
as a read-out for T cell function63. Furthermore, as described in the section of neo-antigens, 
mutational load has been found to correlate with clinical outcome to checkpoint blocking 
therapies in multiple malignancies. In addition to these data, we have shown in one 
melanoma case that neo-antigen specific TCRs can be superior compared to C/G specific 
TCRs in tumor control when tested in a patient derived xenograft model (Kelderman et 
al., unpublished). Collectively, these data suggest a strong role for neo-antigens in disease 
control in a number of malignancies with a certain level of mutational load. Based on the 
outlined evidence and the previously discussed characteristics of neo-antigens, these are 
highly attractive tumor antigens to target. Nevertheless, there are malignancies with a low 
mutational load that are less likely to yield an immunogenic neo-antigen repertoire but that 
still contain a high level of immune infiltrates. This at least indicates the presence of an 
ongoing immune dialogue, although it is most likely not based on the recognition of neo-
antigens. For these malignancies other classes of antigens including the C/G antigens and 
the HERVs may play a more important role in tumor control. Furthermore, even within the 
malignancies generally characterized by a high mutational load, there is a large spread in 
the number of mutations (Fig. 2)64,65, suggesting that modulating T-cell responses against 
mutated antigens might not be an effective strategy in all cases. Regardless of which antigen 
is selected to target, the most important criteria include tumor restriction for safety and 
lack of pre-existing tolerance. In addition, it is beneficial if the target is crucial for tumor 
cell survival to diminish the risk of clonal escape variants, however, by targeting multiple 
antigens simultaneously this may be of less importance. 
Some 20 years ago, the field set out to design vaccines that could be used to treat 
many patients with the same malignancy. Currently, we know that the optimal targets 
for immunotherapy can differ greatly between patients due to the diversity in mutational 
load as well as the simultaneous expression of several antigen classes within the same 
group of malignancies. Encouragingly, with the current advances in deep-sequencing 
technologies and high-throughput processing of bioinformatics data, it is conceivable that 
a more personalized approach is soon within reach. One possible scenario that we envision 
(Fig. 3) is the mapping of each patient’s individual antigenome using tumor-specific RNA 
sequence data in combination with analyses on the tumor-immune interaction in the tumor-
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characteristics e.g. level of expression and their potential to bind to the patient’s specific 
HLA alleles with high affinity. As a side note, it has been shown by Sahin and colleagues that 
the strength of predicted binding is an important factor for immunogenicity66. In case of 
the C/G antigens, it will be important to understand the expression pattern of each protein 
and likewise for the HERVs. Regarding the mutated antigens we still need to acquire an 
understanding of which mutated antigens are most immunogenic. At this point in time, 
we know that only a minor percentage of mutated epitopes are recognized by T cells in 
melanoma, and we do not know how to specifically select those, or if other mutated epitopes 
can function as better tumor rejection antigens despite the lack of preexisting immune 
recognition. To address this, it is extremely important to verify that therapy-induced neo-
antigen specific T cell responses indeed can recognize autologous tumor. Based on such 
knowledge, the field can gain insight in how to select mutated epitopes for e.g. vaccines. 
An additional ranking can be made by using information from the TME e.g. whether there 
is an active or rather suppressed immune dialogue and to which degree the level of T cell 
infiltration e.g. by measuring clonality of TIL is predictive for a pre-existing anti-tumor 
immune response. Finally, a treatment plan can be devised that incorporates potential pre-
conditioning regimens to boost the endogenous immune response or epitope vaccinations 
in combination with checkpoint blockade to induce new T cell responses. 
Another consideration to take into account in this final step is whether it is preferable 
to target antigens for which a T cell response already exists. The benefit when targeting 
antigens by boosting pre-existing immunity is that the antigen is indeed immunogenic, i.e. it 
is presented by the tumor to a sufficient level for T cell detection and a T cell repertoire exists 
that can recognize the antigen. The advantage of targeting antigens not already targeted by 
the immune system is mainly a lowered risk for clonal selection to have taken place against 
those tumor cell clones expressing the antigen. 
In summary, since the discovery of the first tumor antigen, now more than two decades 
ago, the field has made immense progress in identifying, characterizing and classifying vast 
numbers of antigens. Together with high-throughput deep-sequencing approaches that 
are becoming readily available personalized therapies are a reality. Venturing into patient-
specific strategies utilizing these new therapeutic tools in a systematic approach will be 
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Antigen-independent factors that determine outcome to cancer immunotherapy
Provided the relevant antigens are abundantly presented, many factors can subsequently 
short circuit the so-called cancer-immunity cycle leading to failed or incomplete anti-
tumor immunity. This process can be divided in seven distinct steps as proposed by 
Chen and Mellman and these will be briefly discussed here67. First, the nature of antigen 
release in the tumor microenvironment must be immunogenic rather than tolerogenic. 
More specifically, pro-inflammatory cytokines such as TNF-α, IFN-α and IL1 will stimulate, 
whereas IL-10, IL-4 and IL-13 will hamper DC maturation. Second, should immunogenic 
cell death occur, this will then result in the maturation of DCs and their subsequent 
migration to peripheral lymph nodes where they present antigens in the context of MHC 
class I and II molecules. Third, the nature of costimulatory signals provided in this priming 
and activation phase will determine the fate of naïve T cells. For example, CD28:B7.1 
and CD27:CD70 ligation will stimulate whereas CTLA4:B7.1 interaction will inhibit T cell 
activation. Fourth and fifth, activated T cells depend on complex chemokine gradients 
to migrate to the effector site and extravasate through the endothelial barrier into the 
tumor. Sixth, effector cells require engagement of the TCR with their cognate peptide 
in order to kill cancer cells. This crucial step might be hampered by loss of MHC class I 
expression due to mutations in beta-2-microglobulin, which is likely to play a major role 
in tumor immune-escape68-70. This might be particularly expected in those tumors with a 
hypermutated phenotype71,72. Additionally, in several cancer types, including colorectal 
and kidney clear cell cancer, it was demonstrated that the number of predicted neo-
epitopes was much lower than what was expected based on the silent mutation rate55. 
Taken together with a strong body of evidence in experimental mouse models (reviewed 
in73), this is highly suggestive of cancer immunoediting in which the ongoing immune 
response can shape the antigenome through selection of non-immunogenic epitopes 
or tumor cells that fail to express MHC class I molecules altogether. Finally, expression 
of inhibitory ligands such as PD-L1 on the tumor cell surface can prevent the release of 
T cell granule content thereby escaping immune-mediated destruction in the last phase 
of the cancer-immunity cycle.
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ABSTRACT
Tumor infiltrating lymphocyte (TIL) therapy has shown objective clinical response rates of 
50% in stage IV melanoma patients in a number of clinical trials. Nevertheless, the majority 
of patients progress either directly upon therapy or after an initial period of tumor control. 
Recent data have shown that most TIL products that are used for therapy contain only low 
frequencies of T cells reactive against known melanoma-associated epitopes. Because of 
this, the development of technology to create T-cell products that are enriched for reactivity 
against defined melanoma-associated antigens would seem valuable, both to evaluate the 
tumoricidal potential of T cells directed against different antigen classes and to potentially 
increase response rates. Here, we developed and validated a conditional MHC streptamer-
based platform for the creation of TIL products with defined antigen reactivities. We have 
used this platform to successfully enrich both high frequency (≥1%) and low frequency (<1%) 
tumor-specific CD8+ T-cell populations, and thereby create T-cell products with enhanced 
tumor recognition potential. Collectively, these data demonstrate that selection of antigen-
specific T-cell populations can be used to create defined T-cell products for clinical use. This 
strategy thus forms a highly flexible platform for the development of antigen-specific cell 
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INTRODUCTION
In recent years, many oncological disciplines have moved towards cancer therapies that take 
tumor-specific characteristics into account. Within melanoma, BRAF mutation status is used 
to guide treatment with BRAF inhibitors1, in lung cancer, ALK and EGFR mutation status is 
amongst others used to guide treatment choice2, and a randomized phase II trial in breast 
cancer patients suggests the value of targeted therapy that is matched to the molecular 
profile of the tumor3. 
In cancer immunotherapy, the administration of ex vivo expanded autologous T cells can 
be considered the most patient-specific approach that has been developed to date. This 
treatment modality either comprises the adoptive transfer of tumor infiltrating lymphocytes 
(TIL) that have been expanded from a resected lesion, or the infusion of genetically 
modified PBMCs that express a newly introduced TCR (reviewed in Rosenberg & Restifo, 
20154). To date, the clinical activity of TIL therapy has been particularly promising, with an 
approximately 50% response rate observed in trials at different clinical centers. The clinical 
activity of TIL therapy correlates with the number of CD8+ T cells that are infused and the 
infusion of CD8+ enriched TIL has also been shown to lead to clinical responses5-9. As such, 
it is likely that the clinical activity of TIL therapy is in large part mediated by CD8+ T cells. 
Strikingly though, the antigen reactivities of the CD8+ T cells present within the infusion 
product is not controlled. Furthermore, as different antigen-specific T-cell pools are likely to 
vary significantly in their tumoricidal potential (see below), the generation of TIL products 
of a more defined composition would appear attractive.
Conceptually, two major classes of tumor antigens can be distinguished. First, human 
melanomas commonly express a series of non-mutated self-antigens, such as the cancer/ 
germline (C/G) antigens and the melanocyte differentiation (MD) antigens, which are 
both expressed in a restricted set of healthy tissues10. Second, because of the significant 
amount of UV-induced DNA damage in melanomas11, these tumors can be expected to also 
frequently express neo-antigens that arise as a consequence of tumor-specific mutations 
(reviewed in12). Indeed, recent work that has utilized exome-based analysis to uncover 
the patient-specific neo-antigen directed T-cell repertoire has shown that T-cell responses 
against mutated antigens are common in melanoma13-15. The clinical benefits of targeting 
these two different antigen classes are presently unclear. Specifically, while it is likely that 
the affinity of T-cell responses against some of the shared antigens is affected by central 
T-cell tolerance, it is unclear whether this applies to all shared antigens10. 
In order to directly reveal the relative value of T-cell responses against neo-antigens 
and specific self-antigens, it would be valuable to generate TIL products with a defined 
composition. Furthermore, in most TIL products, the frequency of CD8+ T cells that target 
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efficacy of TIL therapy could be further improved by enhancing the reactivity towards (a set 
of) defined tumor antigens. 
To enable the development of antigen-specific T-cell products, we here created a flexible 
platform that allows the selection of T cells directed against defined tumor-specific antigens 
from bulk TIL cultures. Importantly, the high degree of flexibility of this technique should 
facilitate clinical implementation of antigen-specific TIL therapy for both shared antigens 
and patient-specific neo-antigens.
RESULTS
Enrichment of high and low frequency antigen specific T-cell populations from TIL by UV-
exchange MHC streptamers
As described previously, MHC streptamers that are generated through the use of MHC 
molecules tagged with an epitope that displays a moderate affinity for streptavidin can 
bind antigen-specific T-cell populations in a reversible manner17,18, and can be used to 
create virus-specific T-cell products for therapy. In order to provide this platform with the 
required flexibility to create antigen-enriched T-cell products for a variety of T-cell antigens, 
we generated HLA-A*02:01 streptamers loaded with a UV-sensitive ligand19,20. Validation 
experiments demonstrated that the resulting ‘conditional MHC streptamers’ could be 
loaded with peptides of interest in one-hour UV exchange reactions (data not shown). 
To determine whether the resulting MHC streptamers could successfully be used to 
generate antigen-specific T-cell populations from bulk TIL cultures, we enriched a total 
of five T-cell specificities in eleven independent experiments from donors NKIRTIL006, 
NKIRTIL012 and NKIRTIL025. The majority of enrichments were done for T cells reactive with 
the MART-1ELA and gp100KTW epitopes (Fig. 1A). In addition, enrichments were performed 
for T-cell populations reactive with the MAGE-C2LLF, MAGE-C2VIW, MAGE-C2ALK, MAGE-A10GLY 
and Meloe-1TLN epitopes. Single antigen-specific T-cell populations with a frequency of 1% 
or higher in the bulk TIL could be enriched with a 29-fold median increase in frequency, to 
an average purity of 73%. Furthermore, enrichment of T-cell populations that were present 
at a very low frequency (<1%) within the TIL population was effective in two out of three 
cases, resulting in a purity of >50% (Fig. 1B). Simultaneous enrichment of multiple high and 
low frequency antigen-specific T-cell populations was also feasible, and increased the mean 
purity of the T-cell product from 3.8% pre-enrichment to 74.7% post-enrichment (Fig. 1C). 
Median recovery of the target T-cell populations for high and low frequency antigen-specific 
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To evaluate whether subsequent expansion of the enriched TIL product substantially 
influenced its composition, a total of eight enriched cell cultures containing 25 enriched 
antigen-specific T-cell populations were expanded according to the rapid expansion protocol 
(REP) that is used to create TIL products for therapy. Following expansion, there was on 
average a modest drop in the frequency of enriched antigen-specific T-cell populations (mean 
42% pre-REP versus 36.2% post-REP, Fig. 1E). This was however unlikely to be explained by 
negative effects of the enrichment procedure, as the frequency of these antigen-specific 
cells in control non-enriched bulk TIL cultures likewise decreased upon expansion (mean 
1.6% pre-REP versus 0.9% post-REP, Supplementary Fig. 1A). Notably, the magnitude of 
T-cell expansion was not affected by T-cell enrichment, with a 1087-fold mean expansion for 
antigen-enriched TIL, as compared to a 937-fold mean expansion for non-enriched bulk TIL 
(Supplementary Fig. 1B).
Phenotypic analysis of antigen-enriched TIL cultures
Next, we measured the effect of antigen-specific T-cell selection on the phenotypic 
characteristics of the T cells that were obtained. For this, we performed phenotypic analyses 
of both enriched and non-enriched antigen-specific TILs from patient NKIRTIL025. A total of 
five antigen-specific T-cell populations (three independent enrichment experiments) were 
analyzed for the expression of CCR7, CD27, CD127, CD95, CD45RA, CD45RO and CD62L. No 
significant difference in expression of CCR7, CD95, CD127, CD45RA, CD45RO and CD62L, was 
observed within the antigen-specific T-cell populations after enrichment and subsequent 
expansion (Fig. 2A). Expression of CD27 on antigen-specific cells was increased following 
enrichment and subsequent expansion compared to non-enriched antigen-specific cells (P 
< 0.05, Fig. 2A and 2B), resulting in a cell product with a more favorable phenotype. 
 
Functional reactivity of antigen-enriched TIL cultures
Having demonstrated the feasibility of antigen-specific T-cell selection, we aimed to 
determine whether enriched TIL cultures were more reactive than non-enriched bulk TIL 
against autologous and partially HLA-matched tumor lines. To this purpose, we generated 
three TIL cultures from donor NKIRTIL012 that were enriched for MART-1- and gp100-
specific T cells, either separately or in combination. We then compared the functional 
activity of the enriched cell products with the non-enriched cell product by measurement 
of T-cell degranulation upon coculture with four melanoma lines (Fig. 2C). As a first test, we 
compared reactivity of the enriched and non-enriched TIL products against the autologous 
tumor line. In this setting, the effect of enrichment of the intended antigen-specific T-cell 
populations is seen, but also the effect of the concomitant depletion of other CD8+ T-cell 
populations that are reactive with the autologous tumor. Analysis of CD8+ T-cell reactivity 
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non-enriched CD8+ T cells were reactive against the autologous tumor cell line. Notably, 
reactivity of TIL cultures that had been enriched for T cells specific for the gp100 antigen, 
MART-1 antigen, or both antigens combined was higher (32%, 46% and 46%, respectively). 
Second, we assessed recognition of bulk TIL and enriched TIL against the HLA-A*02:01 
matched cell line mel526 to directly test the effect of T-cell enrichment on reactivity towards 
shared HLA-A*02:01-restricted epitopes. This analysis demonstrated that enrichment of 
T cells specific for the gp100KTW antigen, MART-1ELA antigen, or both antigens combined 
resulted in an approximately 10-fold increased reactivity against these antigens. 
Figure 1. Enrichment and expansion of high and low frequency antigen-specific T-cell populations 
from bulk melanoma TIL cultures. (a) Examples of two representative enrichments (total N = 11) of 
a high frequency MART-1ELA specific T-cell population (upper panel) and a low frequency gp100KTW 
specific T-cell population (lower panel) are depicted. Enrichment was performed using antigen-
specific streptamers loaded with the peptide of interest and a subsequent MACS column pull-
down. Antigen-specific T-cell populations are visualized by flow cytometry using pMHC complexes 
generated with a UV-induced ligand exchange and fluorochrome conjugation. Pre indicates pre-
enrichment, post indicates post-enrichment. Numbers reflect the percentage of pMHC multimer+ 
CD8+ cells of total CD8+ cells. Gating strategy is shown in Supplementary Fig. 2B.  (b) Overview of 
enrichments of 13 antigen-specific T-cell populations in a singular fashion is depicted. Squares indicate 
pre-existing frequencies of less than 1%, whereas triangles indicate pre-existing frequencies of 1% 
or higher. Purity is determined as the frequency of pMHC multimer+ CD8+ cells of total CD8+ cells; 
fold enrichment is calculated by dividing the post-enrichment frequency over the pre-enrichment 
frequency. (c) Results of five independent enrichments are depicted, in which several high and low 
frequency antigen-specific T-cell populations were purified simultaneously. A cumulative bar shows 
the percentage purity of each antigen-specific T-cell population. Colored bars represent TIL that 
recognize the defined shared antigens that collectively formed the targeted T-cell population; the 
white bar represents the remaining TIL that were not targeted. (d) Recovery of antigen-specific T cells 
upon enrichment is shown in squares for high (≥1%, N=16) and low (<1%, N=17) frequency antigen-
specific T-cell populations. Recovery was calculated as the fraction of antigen-specific T cells that was 
obtained after enrichment from the total antigen-specific T cells present in the bulk TIL culture prior 
to enrichment. Black squares indicate T-cell populations that were enriched in a singular manner; 
red squares indicate T-cell populations that were enriched simultaneous with one or up to four other 
antigen-specific T-cell populations. Horizontal line indicates mean recovery of antigen-specific cells 
from all enrichment procedures ± standard deviation. (e) Percentage of the targeted antigen-specific 
T-cell populations directly after enrichment and following a subsequent 14-day expansion (N=25, 8 
independent experiments). Note that in most cases the percentage of antigen-specific T cells is not 
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Clinical-scale enrichment of antigen-enriched TIL products 
Having established that enrichment of antigen-specific T-cell populations present within 
TIL is feasible and can be used to steer the antigen reactivity of TIL products, we aimed 
to determine the feasibility of clinical-scale antigen-specific T-cell enrichment in a closed 
system. To this purpose, three antigen-specific T-cell populations, specific for MART-1ELA, 
MAGE-C2LLF and gp100KTW, were enriched from a pre-REP TIL culture of 1x10
8 cells from 
patient NKIRTIL025 using the CliniMACS system. The total purity of the obtained cell product 
was 94% directly after enrichment, and 87% after a subsequent 924-fold expansion (Fig. 
3A). Overall recovery of the target T-cell populations was 22% (Fig. 3B). Reactivity against 
the autologous tumor cell line was increased from 7% in the non-enriched TIL product, to 
48% in the enriched TIL product (Fig. 3C). Furthermore, reactivity against the HLA-A*02:01 
matched cell line mel526 increased from 4% to 79% after antigen-specific T-cell enrichment, 
corresponding with the frequency of antigen-reactive T cells in the final cell product. 
Figure 2. Functional analyses of antigen-enriched TIL cultures. (a) Phenotypic analysis of antigen-
specific cells after enrichment and expansion, comparing non-enriched and enriched TIL cultures. Five 
antigen-specific T-cell populations of donor NKIRTIL025 enriched in three independent experiments 
were assessed by flow cytometry using pMHC-multimers in combination with a panel of phenotypic 
markers indicated in the graph. Black bars indicate expression of phenotypic markers on antigen-
specific T cells in non-enriched control cultures; grey bars indicate expression of markers on antigen-
specific T cells in enriched cultures. Expression of CD27 was significantly higher, indicated by asterisk, 
on antigen-specific cells following enrichment and subsequent expansion, as compared to CD27 
expression on the same antigen-specific T-cell population in the non-enriched TIL culture (P<0.005, 
paired Student’s t test). (b) Two representative examples showing expression of CD27 in expanded 
T-cell products that were enriched for the indicated antigen-specific T-cell populations. Top panels 
show results for a low frequency MAGE-C2
LLF specific T-cell population, bottom panels show results for 
a high frequency MART-1ELA specific T-cell population. Left panels show efficacy of enrichment, right 
panels show CD27 expression on the antigen-specific T-cell population. Percentages indicate positive 
population within the gates. (c) Expression of CD107a of a non-enriched TIL culture (black bar) and 
three independently enriched TIL cultures (red bar indicates gp100KTW specific T cell enrichment; blue 
bar indicates MART-1ELA specific T cell enrichment; green bar indicates combined gp100KTW/MART-1ELA 
specific T cell enrichment) from donor NKIRTIL012 upon a 5-hour co-culture with autologous tumor 
(NKIRmel012), an HLA-A mismatched tumor cell line (NKIRmel084), and a tumor cell line (mel526) 
matched for the HLA*A02:01 allele that presents the gp100KTW/MART-1ELA antigens.  Non-stimulated T 
cells are shown as a control. Gating strategy for CD107a expression is shown in Supplementary Fig. 2A. 
The percentage of CD107a positive cells was significantly higher in all three enriched TIL cultures, as 
compared to the non-enriched TIL culture (indicated by asterisks). Mean values of technical triplicates 
plus standard deviation are depicted. Results are representative of two independent experiments. 
Samples were compared using a two-tailed paired Student’s t test. A p-value < 0.05 was considered 
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Figure 3. Generation of clinical grade enriched TIL products. (a) Simultaneous enrichment of three 
antigen-specific T-cell populations from a bulk TIL culture from patient NKIRTIL025 using the CliniMACS. 
Samples were processed in a similar fashion as described above, but enriched in a closed system 
instead of on MACS columns to assess feasibility of GMP-grade enriched TIL production. Composition 
of the cell product pre-enrichment, post-enrichment and post-expansion (REP) is shown. Antigen-
specific T-cell populations are depicted as colored stacked bars; white bar depicts non-targeted 
T-cell populations of unknown specificity. Purity was determined by pMHC multimer staining. Data 
are representative of two independent CliniMACS runs. (b) Cell numbers pre- en post-enrichment of 
MART-1ELA, gp100KTW and MAGE-C2LLF antigen specific T-cell populations are shown. Average recovery 
was 22%, calculated as the ratio of antigen-specific T cells before and after the enrichment procedure. 
(c) Expression of CD107a in non-enriched and enriched TIL cultures from donor NKIRTIL025 upon 
coculture with autologous tumor (NKIRmel025) and a tumor cell line (mel526) matched for the 
HLA*A02:01 allele that presents the gp100KTW/MART-1ELA antigens. Non-stimulated T cells are shown as 
a control. Black bar depicts mean percentages with standard deviations of non-enriched TIL cultures, 
grey bar depicts enriched TIL cultures. The percentage CD107a positive cells was significantly higher 
for the enriched TIL product (P<0.001, indicated by asterisks). Mean values of triplicates plus standard 
deviation are depicted. Samples were compared using a two-tailed paired Student’s t test. A p-value < 
0.05 was considered statistically significant. 
Enrichment of neo-antigen reactive T-cell populations
The effectiveness of cancer immunotherapy is positively correlated with mutational burden, 
likely due to T-cell recognition of the neo-antigens that arise as a consequence of tumor-
specific mutations12. As neo-antigens are entirely tumor-specific, and as the affinity of neo-
antigen specific T cells is not capped by thymic tolerance, the steering of immune reactivity 
towards this particular class of antigens may be particularly attractive. To assess the feasibility 
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aimed to enrich neo-antigen reactive T-cell populations from a bulk melanoma TIL culture. 
For patient NKIRTIL027, we performed exome and RNA sequencing of the autologous tumor 
cell line which was overlaid with exome sequence data of healthy reference TIL to identify 
tumor-specific mutations. In this way, we identified 909 non-synonymous mutations, of 
which 582 were present within expressed genes. Using our epitope prediction pipeline 13, 
we predicted 318 putative neo epitopes for the HLA-A*01:01 allele for which streptamer 
reagents were available. Subsequently, a bulk TIL culture was screened for the presence of 
neo-antigen reactive T cells, resulting in the identification of two T-cell responses, directed 
against the mutated gene products of ENTPD4(P85L) (0.23% of CD8
+ T cells), and TTC37(A692V) 
(0.45% of CD8+ T cells) (Fig. 4A). Utilizing HLA-A*01:01 streptamers, we could enrich 
ENTPD4(P85L) and TTC37(A692V) specific T-cell responses by 55- and 45-fold, respectively, to a 
combined frequency of 29.4% (Fig. 4B). During the subsequent rapid expansion culture, 
TTC37(A692V) specific T cells expanded further, whereas the frequency of ENTPD4(P85L) specific 
T cells slightly dropped, resulting in a combined purity of neo-antigen specific T cells of 
60%. In line with this enrichment, we demonstrated a 29-fold increase in recognition of 
autologous tumor cells (Fig. 4B). These data demonstrate that the production of enriched 
antigen-specific TIL cultures is not limited to T cells reactive against shared antigens but can 











































































































































Figure 4. Enrichment of neo-antigen specific T-cell population. (a) Exome sequencing and neo-epitope 
predictions were performed for NKIRTIL027. A subsequent neo-antigen specific T cell screen utilizing 
pMHC multimer combinatorial encoding technology revealed two distinct HLA-A*01:01 restricted T-cell 
responses with a combined frequency of 2.96% of total CD8+ T cells. Reactivity was directed towards 
the mutated gene products of ENTPD4 with a proline to leucine substitution at position 85 (P85L) and 
TTC37 with an alanine to valine substitution at position 692 (A692V). The total purity of neo-antigen 
reactive T cells was 29.4% directly after enrichment and 60.1% following a 14-day rapid expansion 
culture. Grey population in lower left corner depicts pMHC negative T cells; green population in upper 
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Negative populations are unevenly distributed across FACS plots because different combinations of 
pMHC multimers were used in enrichment and expansion experiments. Combined purity is shown 
below flow cytometry plots. (b) Following REP, both the enriched TIL culture (grey bar) as well as a 
control non-enriched TIL culture (black bar) was tested for reactivity against the autologous tumor 
cell line NKIRmel027. Following a 5-hour incubation, cells were fixed, permeabilized, and stained for 
intracellular IFN-γ expression. Data are depicted as mean percentages of technical triplicates plus 
standard deviations for cytokine positive cells in total CD8+ T cells. Unstimulated TIL were used as 
controls. Enriched TIL showed significantly higher recognition of autologous tumor cells compared 
to non-enriched TIL (P<0.05, Student’s t test). Representative data from two experiments are shown. 
DISCUSSION
In this study, we demonstrate the feasibility of enriching antigen-specific T-cell populations 
from bulk melanoma TIL cultures. Both high frequency and low frequency T-cell populations 
can successfully be enriched, resulting in clinical-grade cell products with a high degree 
of purity and enhanced anti-tumor activity. Because of its flexible nature, this approach is 
feasible for the isolation of T cells reactive against non-mutated self-antigens and patient-
specific mutated antigens, making it feasible to directly compare the relative value of T-cell 
responses against both antigen classes (Kelderman et al., ms submitted).
The clinical value of T-cell products enriched for defined antigen-specific T-cell populations 
has already been demonstrated in patients suffering from recurrent CMV infections after 
allogeneic stem-cell transplantations21-23. Furthermore, studies from Lang and colleagues 
have demonstrated the enrichment of T-cell populations reactive to melanoma antigens 
by an MHC-based platform24,25. The current work builds on these efforts by developing 
an ‘open’ system for MHC-based T-cell purification, in which purification reagents can be 
charged with any epitope of interest, including patient-specific antigens.  
Phenotypic analysis of antigen-specific T cells from enriched and non-enriched TIL 
cultures revealed that overall phenotypic characteristics were unaltered after selection and 
expansion. Following enrichment, there was a moderate increase in the fraction of CD27-
positive antigen-specific cells. Prolonged TCR-MHC interaction has been shown to correlate 
with a decrease rather than an increase in CD27 expression26, which makes the possibility of 
a persistent interaction between remaining multimer reagents and antigen-specific cells an 
unlikely explanation, also since multimer reagents are dissociated directly after enrichment. 
Potentially, the short-duration TCR-MHC interaction leads to the preferential outgrowth of 
the CD27+ subset, which could be beneficial for clinical purposes as the number of CD8+CD27+ 
TILs infused in melanoma patients has been shown to correlate with clinical response27.
Following enrichment and expansion, we observed that enriched TIL cultures are more 
reactive towards autologous and a partially HLA-matched melanoma cell line than non-
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are two-fold. First, total tumor reactivity of the TIL product can increase, which is especially 
beneficial in cases of low-level reactivity against autologous tumor. Second, the reactivity 
of the obtained TIL products will be focused towards those epitopes for which selection is 
performed, at the expense of any others. As an example, enrichment of TIL products that 
already have a very high reactivity is unlikely to increase total reactivity substantially. In 
such cases, enrichment will only be attractive when it focuses the resulting cell product on 
T-cell reactivities with above average tumoricidal potential. At present, our understanding 
of the relative tumoricidal potential of different tumor antigen specific T-cell populations 
is still limited. However, the platform described here makes it feasible to generate TIL 
products steered towards a wide variety of antigen classes, and thereby test the potential 
of different antigen classes in preclinical models. In this regard, CD8+ T-cell reactivity against 
patient-specific mutated antigens, which appears common in human melanoma13-15 is of 
particular interest. Clinical data suggest the potential relevance of such neo-antigens in 
cancer immunotherapy. However, the evidence is thus far only correlative28,29. Utilizing 
the UV-exchange streptamer technology described here, we have directly compared the 
ability of a neo-antigen directed TIL product and ‘standard’ unselected TIL product to 
control autologous tumor in a preclinical model of human melanoma (S. Kelderman et al. 
ms submitted). These experiments revealed superior tumor control by neo-antigen directed 
TIL for this patient, thereby providing a strong rationale to target neo-antigens in a clinical 
setting. Other work has demonstrated that TIL may also be enriched based on the expression 
of one or several co-stimulatory and co-inhibitory receptors such as CD137 and PD-130,31. 
While this approach has the advantage of maintaining the diversity of the tumor antigen-
specific T-cell response32, it does not allow one to specifically focus reactivity towards T-cell 
responses that are considered most valuable. As such, side by side (pre-)clinical evaluation 
of both approaches appears most attractive. 
The approach developed here relies on already established clinical protocols and can 
be performed under Good Manufacturing Practice conditions, and clinical implementation 
should therefore be relatively straightforward. Taking into account the rapid advances in 
tumor exome sequencing and immunomonitoring, the production of antigen-specific TIL by 
MHC-based enrichment does appear feasible when dedicated equipment and appropriate 
infrastructure are in place33, in particular when targeted therapies such as BRAF-inhibitors 
with a median progression-free survival of 5.6 months are utilized as a bridging treatment34, 
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MATERIALS AND METHODS
Patient material and cell cultures. TIL cultures NKIRTIL006, NKIRTIL012, NKIRTIL025, 
NKIRTIL027, NKIRTIL084 and corresponding melanoma lines were established from patient 
material obtained in-house following informed consent and in accordance with local 
guidelines. Cell line mel526 was a kind gift of Dr. S. Rosenberg (Surgery Branch, NIH). Tumor 
lines were cultured in RPMI1640 supplemented with 10% FCS and penicillin (100 IU/ml) 
and streptomycin (100 µg/ml). T cells were cultured in complete medium (CM; RPMI-1640 
supplemented with human AB serum (10%), IL-2 (6000 IU/ml, Novartis), penicillin (100 IU/
ml, Roche), streptomycin (100 µg/ml, Roche) and glutamax (200mM, Life Technologies). 
Expansion of TIL cultures was performed according to the standardized Rapid Expansion 
Protocol (REP) that is also used for clinical applications9. Cells were cryopreserved in FCS 
with 10% DMSO and stored in liquid nitrogen.
Deep sequencing and epitope predictions. Screens to identify neo-antigen reactive 
T-cell populations were performed as described previously13. In short, genomic DNA was 
extracted from NKIRmel027 using a DNeasy kit (Qiagen) and processed for deep-sequencing 
on an Illumina HiSeq DNA Analyzer (75bp paired-end reads). Resulting reads were aligned 
to a human reference genome. Subsequently, epitope predictions were performed for 
the patient’s corresponding HLA alleles (A*01:01, A*26:01, B*08:01 and B*44:02) using 
NetChop c-term 3.0 and NetMHCpan2.835-37.
MHC-multimer reagents and T-cell staining. Peptides were synthesized in-house and stored 
in 100% DMSO at -20°C. MHC multimer-reagents were generated in-house as described 
previously 38. In brief, HLA-A*02:01 or HLA-*01:01 monomers containing a UV-conditional 
ligand (100µg/ml) were exposed to UV-irradiation (360nm, Camag) for 1 hr in the presence 
of a rescue peptide (200µM). The resultant peptide-MHC (pMHC) complex was conjugated 
to streptavidin-conjugated fluorochromes (Life Technologies). After 30 min of incubation, 
NaN3 (0.02% wt/vol) was added, and an excess of D-biotin (26.4 mM, Sigma) was added 
to block residual binding sites. T cells were stained with titrated amounts of fluorochrome 
conjugated pMHC complexes and 2 µl anti-CD8 FITC (BD Biosciences, clone SK1) in a total 
volume of 135 µl. Cells were incubated at 37 °C for 15 minutes. Cells were washed two 
times with FACS buffer and stained with DAPI (5 µl) in standard enrichment experiments or 
LIVE⁄DEAD® Fixable Violet Dead Cell Stain Kit (0.5 μl) in neo-antigen specific T-cell screens. 
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Streptamer-based T-cell enrichment. Streptagged HLA-A*02:01 and HLA-A*01:01 reagents 
were loaded with peptides of interest by UV-induced exchange reactions, as described 
above. Subsequently, the resultant MHC monomers were conjugated to Strep-Tactin-loaded 
nanobead-particles (IBA) according to the manufacturer’s protocol. Cryopreserved TIL 
were thawed 1 hr prior to antigen-specific T-cell enrichment, incubated for 20 mins with 
benzonase (25 IU/ml), and washed with IS buffer (IBA). MHC/bead complexes (1µg MHC / 
1x107 cells) were loaded on a pre-washed LS MACS column (Miltenyi) to remove unbound 
MHC molecules. The conjugated MHC/beads mixture was eluted with IS buffer from the 
column and mixed with the cells in suspension. The resultant mixture was incubated at 4°C 
for 45 min on a roller. Cells were washed twice with IS buffer to remove unbound MHC/bead 
complexes and subsequently loaded on a pre-washed LS column with pre-filter. The column 
was washed twice with IS buffer and cells were subsequently eluted and washed twice with 
IS buffer containing D-biotin (100mM, IBA) to dissociate MHC multimer reagents. Recovery 
was defined as the number of the targeted antigen-specific cells obtained after purification, 
relative to the number of the targeted antigen-specific cells within the starting material. 
Clinical-scale enrichments were performed on a CliniMACS (Miltenyi), using a Tubing Set 150 
and the selection program “Enrichment 1.1.” Eluted cells were expanded using the Rapid 
Expansion Protocol (REP) that is used for TIL production for adoptive cell therapy, in 50/50 
medium (50% CM / 50% AIM-V, Life Technologies), in the presence of irradiated autologous 
feeder cells (200 fold excess), IL-2 (3000IU/ml), and anti-CD3 (30ng/ml OKT3, Janssen-Cilag).
T-cell functionality assays. Enriched and non-enriched TIL cultures were stained for 
expression of a panel of phenotypic markers, using 1 µl anti-CD8 V500 (BD Biosciences, 
clone RPA-T8), 2 µl anti-CD27 APC (BD Biosciences, clone M-T271) or 2 µl anti-CD27 BV-421 
(BD Biosciences, clone M-T271), 2 µl anti-CD127 PE (BD Biosciences clone hIL-7R-M21), 5 
µl anti CD95 FITC (BD Biosciences clone DX2) or 2 µl anti-CD62L FITC (BD Biosciences, clone 
DREG-56), 0.25 µl anti-CD45RA PE-Cy5.5 (Life Technologies, clone MEM-56), 0.5 µl anti-
CD45RO PE-CF594 (BD Biosciences, clone UCHL1), 1 µl anti-CCR7 PE-Cy7 (BD Biosciences, 
clone 3D12), 5 µl DAPI or 0.5 µl of LIVE⁄DEAD Fixable IR Dead Cell Stain Kit (Invitrogen, 
L10119) and 1 µl PE-pMHC or 3 µl Q605-pMHC and 2 µl Q655-pMHC. Cells were incubated 
for 20 min at 4°C in a total staining volume of 50 µl. 
T-cell reactivity assays were set-up by co-culturing 2x105 T cells and the indicated tumor 
cells in a 1:1 ratio, in 96-well plates for 5 hrs at 37°C in the presence of anti-CD107a PE 
antibody (BD Biosciences, clone H4A3). After one hour, Monensin and Brefeldin A (BD 
Biosciences) were added. Following incubation, cells were washed and stained with 1 µl anti-
CD3 FITC (BD Biosciences, clone SK7) and 1 µl anti-CD8 PerCP Cy5.5 (BD Biosciences, clone 
SK1), and subsequently fixed and permeabilized according to the manufacturer’s protocol 
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with 0.5 µl anti-IFN-γ APC (BD Biosciences, clone B27) in permeabilization buffer. Cells were 
washed twice prior to data acquisition. 
Flow-cytometry. Data acquisition was performed on an LSRFortessa or LSR-II flow cytometer 
(Becton Dickinson) with FacsDiva software. The following instrument settings on the 
LSRFortessa were used: Blue laser (488nm): FITC, 505LP, 530/30. Violet laser (405nm): DAPI, 
450/50; V500, 505LP, 525/50. Red laser (640nm): APC, 670/14. Yellow-green laser (561nm): 
PE, 586/15; PE-CF594, 600lP, 610/20; PE-Cy5.5, 685LP, 710/50; PE-Cy7, 750LP, 870/60. 
The following gating strategy for T cells in standard enrichment experiments was applied: 
selection of live single-cell lymphocytes (FSC-W/H low, SSC-W/H low, FSC/SSC-A), followed 
by selection of CD8+ cells (Supplementary Fig. 2A). Data was analyzed using FlowJo software 
(Treestar Inc.). Instrument settings on the LSR-II flow-cytometer in neo-antigen screens have 
been described previously39.
Statistical analyses. Data are expressed as means plus standard deviations. A paired 
Student’s t-test was performed to compare pre and post variables, and a p-value of <0.05 
was considered statistically significant.  
Accession codes. DNA and RNA sequencing data for melanoma specimen NKIRTL027 
have been deposited in the European Genome-Phenome Archive with accession codes 
EGAD00001000243 and EGAD00001000325. 
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Supporting Information Figure 1: Expansion of TIL cultures. A) Effect of T-cell expansion 
on the frequency of defined antigen-specific T-cell populations in non-enriched TIL cultures 
(1,087-fold mean expansion for the antigen-enriched TIL versus 937-fold mean expansion for 
non-enriched bulk TIL). B) Fold expansion of 16 paired non-enriched and enriched TIL 
cultures. Bars represent mean values plus standard deviation. Samples were compared using a 
two-tailed paired Student’s t test. No significant difference in fold expansion between non-
enriched and enriched TIL cultures was observed (p = 0.26, Student’s t test). 
Supplementary Figure 1. Expansion of TIL cultures. (a) Effect of T-cell expansion on the frequency of 
defined antigen-specific T-cell populations in non-enriched TIL cultures (1,087-fold mean expansion 
for the antigen-enriched TIL versus 937-fold mean expansion for non-enriched bulk TIL). (b) Fold 
expansion of 16 paired non-enriched and enriched TIL cultures. Bars represent mean values plus 
standard deviation. Samples were compared using a two-tailed paired Student’s t test. No significant 
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Supporting Information Figure 2: Gating strategy. General gating strategy applied in all flow 
cytometry experiments, as described in Methods section. A) First, a lymphocyte gate was set, followed 
by a duplicate exclusion. For reactivity assays, gates were set to identify CD3+ and CD8+ T cells, 
B) In pMHC multimer screens, as 
well as T-cell enrichment experiments, gates were set on single live CD8+ T cells, positive for either one 
(shown here) or two (not shown) fluorochrome-conjugated pMHC complexes.
Supplementary Figure 2. Gating strategy. General gating strategy applied in all flow cytometry 
experiments, as described in Methods section. (a) First, a lymphocyte gate was set, followed by a 
duplicate exclusion. For reactivity assays, gates were set to identify CD3+ and CD8+ T cells, followed by 
CD107a and IFN-γ gates set on unstimulated control cells. (b) In pMHC multimer screens, as well as 
T-cell enrichment experiments, gates were set on single live CD8+ T cells, positive for either one (shown 
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INTRODUCTION
In cancers with a high mutational load, such as melanoma, lung and colorectal cancer1,2, 
large numbers of mutated peptides (hereafter referred to as neo-antigens) are potentially 
presented by MHC class I and II molecules on the surface of tumor cells3-5. Furthermore, 
recent reports have demonstrated that neo-antigen-specific T-cell reactivity is frequently 
observed in melanoma5-9. However, the contribution of neo-antigen specific T-cell reactivity 
to tumor control is only partially understood. In this report, we explore the potential clinical 
relevance of neo-antigens that are recognized by CD8+ T cells. We first demonstrate how 
treatment with a clinically effective TIL product can lead to the marked dominance of a neo-
antigen specific T-cell response in a patient with melanoma. We then provide direct evidence 
in a patient-derived xenograft model of human melanoma that T-cell responses against neo-
antigens can mediate superior tumor regression as compared to bulk TIL. Finally, we show 
that within this patient, the anti-tumor potential of neo-antigen specific T-cell receptors is 
greater than that of T-cell receptors directed against the Cancer/Germline antigen family. 
Collectively, these data provide support for the selective targeting of neo-antigens in cancer 
immunotherapy.
RESULTS
For this study, we obtained tumor tissue from a 46-year old female patient (MDACCTIL2379) 
suffering from metastatic melanoma who underwent treatment with 100x109 autologous 
TIL according to a previously described clinical protocol10. Radiologic evaluation six weeks 
post TIL infusion showed a rapid clinical response, with a more than 50% decrease of 
baseline tumor burden. Seven months post-therapy, the patient was in complete remission, 
and continues to be so at two years of follow-up (Supplementary Fig. 1A). Based on the fact 
that T-cell responses against neo-antigens are not hampered by central T-cell tolerance, an 
important role of such T-cell reactivities in anti-tumor immune responses has previously 
been postulated6,11-13. Furthermore, through the development of cancer exome sequencing 
approaches and high-throughput immunomonitoring technology, it is now possible to 
evaluate T-cell reactivity against neo-antigens within individual patients. By this method, 
T-cell responses against neo-antigens have been observed in T-cell products successfully 
used for therapy, including one case in which infusion of a CD4+ T-cell population with high 
reactivity towards a neo-antigen was shown to lead to a reduction in tumor burden14. To 
address the potential involvement of neo-antigen directed T-cell reactivity in the tumor 
response of patient MDACCTIL2379, we performed whole-exome sequencing on a primary 
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A total of 960 non-synonymous mutations were found, (953 substitution and 7 insertions/
deletions, FDR 0.07). As expected, substitutions were predominantly C>T/G>A transitions 
enriched at dipyrimidine sequences indicative of a UV-induced mutational signature1 
(Supplementary Fig. 1B, left). Next, mutations present within expressed genes were identified 
using RNAseq data, and 39 amino-acid stretches encompassing these mutations were used 
for the prediction of potential neo-antigens (Fig. 1A). Using a low cut-off to avoid false 
negatives, this resulted in 1,008 potential CD8 T-cell epitopes for HLA-A*01:01, HLA-A*23:01 
and HLA-B*55:01. Subsequently, the autologous TIL culture of this patient was analyzed for 
the presence of neo-antigen reactive T-cell populations against any of these peptides, by 
combinatorial coding with a library of peptide-MHC (pMHC) complexes generated through 
UV-induced peptide exchange15-17. This screen revealed the presence of two neo-antigen 
reactive T-cell populations within the TIL infusion product: one low-level response (0.17% of 
CD8+ T cells), specific for a mutation in the RASSF1 (RAS association domain family member 
1) gene product, and one very dominant response (23% of CD8+ T cells within the infusion 
product), specific for a mutation in the DHX33 (DEAH box polypeptide 33) gene product (Fig. 
1B). 
To reveal whether T-cell reactivity against these neo-antigens was substantially influenced 
by TIL therapy, pre- and post-therapy PBMC samples were analyzed by staining with MHC 
multimers loaded with the RASSF1R244C and DHX33R186W neo-epitopes. Within pre-therapy 
PBMC, total T-cell responses against the two neo-antigens were barely detectable (0.011% 
of CD8+ T cells). However, at day 7 post-infusion, approximately 50% of peripheral blood T 
cells were directed against the single neo-antigen within DHX33, and this T-cell response 
expanded further in the subsequent weeks to approximately 62%, a more than 6,800-fold 
increase relative to pre-therapy levels (Fig. 1C and Supplementary Fig. 1C).
Prior data have shown the common occurrence of neo-antigen specific CD8+ T-cell 
responses in TIL products8,9,18, and the above data demonstrate that T-cell responses against 
a mutated antigen can subsequently dominate the T-cell compartment at the time of clinical 
response. Nevertheless, this type of clinical data can only provide correlative evidence for 
the importance of neo-antigen reactive T cells. To evaluate the relevance of neo-antigen 
specific T-cell reactivity in a more direct manner, we aimed to develop a system in which 
the activity of different T-cell populations against autologous tumor could be analyzed in 
parallel. For this purpose, we studied tumor tissue and TIL obtained from a 61-year old 
female patient with metastatic melanoma (NKIRTIL006) who had undergone a palliative 
metastasectomy in 2005 and never received any form of immunotherapeutic intervention. 
From the tumor digest, TIL and tumor cell line cultures were established in parallel and 
tumor tissue was used for both whole exome sequencing and to generate a PDX model in 
NOD-SCID-IL2R gamma-chain deficient (NSG) mice. Within the tumor of this patient, a total 
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our epitope prediction pipeline, 252 potential neo-antigens were predicted. Subsequent 
screening of autologous TIL with an MHC multimer library containing these epitopes led 
to the identification of three neo-antigen reactive T-cell populations within this patient: (1) 
a T-cell response (1.604% of CD8+ T cells) directed against an R24L mutation in the CDK4 
(cyclin-dependent kinase 4) gene product; (2) a T-cell response (0.407% of CD8+ T cells) 
directed against a mutation in the GCN1L1 (general control of amino-acid synthesis 1-like 1) 
gene product; (3) a low-magnitude (0.003%) T-cell response directed against a mutation in 
the DNAH17 (dynein axonemal heavy chain 17) gene product (Fig. 1D). 
In order to compare the relative activity of neo-antigen specific T cells versus that of 
standard TIL, we developed a T-cell enrichment procedure that uses HLA-A*0201 UV-
exchange streptamers to purify T-cell populations of interest and utilized this to enrich for 
the GCN1L1L2330P and CDK4R24L -specific HLA-A*02:01 restricted T-cell responses
19. Both the 
enriched cell culture (92.4% total GCN1L1L2330P and CDK4R24L reactivity) and the standard bulk 
culture (2.78% total GCN1L1L2330P and CDK4R24L reactivity) were expanded according to a rapid 
expansion protocol (REP)10 that is used to create TIL products for treatment (Supplementary 
Fig. 1D). High functional activity of the enriched T-cell product towards the two mutant 
epitopes was established by analysis of intracellular cytokine secretion upon coculture of 
T cells with HLA-A*02:01 restricted target cells loaded with either the mutant epitope or 
the wild type counterpart (Fig. 1E). Notably, a subsequent coculture of the standard TIL and 
the enriched TIL with the autologous tumor cell line revealed a more modest increase in 
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Figure 1. Neo-antigen reactive T-cell populations in human melanoma TIL cultures. (a) Overview 
of methods used to identify neo-antigen reactive CD8+ T cells in bulk melanoma tumor-infiltrating 
lymphocytes (TIL) cultures. Brown cells: tumor cells; blue cells: TIL; red stars: tumor-specific mutations. 
(b) Flow cytometric analysis of neo-antigen reactive T-cell populations in TIL of MDACCTIL2379. Top: 
neo-antigen reactive T-cell populations specific for mutant RASSF1 (left) and DHX33 (right). Percentages 
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MHC-restriction and MHC-binding affinities for wild type (WT) and mutant (MT) peptides, as well as 
RNA expression levels in Fragments Per Kilobase of exon per Million fragments mapped (FPKM). (c) Flow 
cytometric analysis of mutant DHX33-specific T cells present in peripheral blood pre-therapy (left) and 
seven days post-therapy (right). Percentages of pMHC double-positive cells within total CD8+ cells are 
indicated. (d) Flow cytometric analysis of neo-antigen reactive T-cell populations in TIL of NKIRTIL006. 
Top: neo-antigen reactive T-cell populations specific for mutant CDK4 (left), mutant GCN1L1 (middle), 
and mutant DNAH17 (right). Percentages of pMHC double-positive cells within total CD8+ cells are 
indicated. Bottom: epitope characteristics as in Fig. 1B. (e) Functional activity of enriched TIL, analyzed 
by intracellular IFN-γ cytokine staining upon coculture with wild type and mutant peptide-loaded T2 
cells. Data are presented as percentages of IFN-γ producing CD8+ T cells. Bars represent means of 
triplicates plus standard deviation. (f) Functional activity of standard TIL and enriched TIL, analyzed 
by intracellular IFN-γ cytokine staining upon coculture with autologous (NKIRTIL006) melanoma, and 
two allogeneic HLA-A*02:01 matched (mel526, which is known to express the previously described 
CDK4R24C mutation) and mismatched (mel938) melanoma cell lines. Data are presented as percentages 
of IFN-γ producing CD8+ T cells. Bars represent means of triplicates plus standard deviation. Data are 
representative of two independent experiments. Samples were compared using an unpaired two-
sided Student’s t -test (*** P < 0.001; NS, not significant).
To evaluate the potency of neo-antigen specific T cells in an in vivo setting, NSG mice 
were injected with tumor cells of patient NKIRTIL006, and either the autologous standard 
TIL product or the autologous enriched TIL product was administered once when tumors 
were palpable (Fig. 2A). Engraftment of CD8+ T cells in peripheral blood of mice treated 
with standard TIL and enriched TIL was comparable, with a peak in T-cell frequencies at day 
5 and a subsequent rapid decline (Fig. 2B). Importantly, the composition of the engrafted 
T-cell compartment was significantly different, with dominance of GCN1L1L2330P and CDK4R24L 
-specific T cells only seen in mice treated with enriched TIL (2% versus 85% mean combined 
GCN1L1L2330P and CDK4R24L reactivity at day 5, Fig. 2B). Strikingly, while a slight decrease in 
tumor growth was initially seen in both treatment groups, prolonged tumor control and 
survival was only observed in mice treated with enriched TIL (Fig. 2C and 2D). This superior 
activity of neo-antigen selective TIL is directly due to the higher number of these cells, 
rather than the removal of potentially inhibitory T-cell subsets, as shown by analysis of 
tumor growth of mice treated with the fraction of neo-antigen reactive cells present within 
the bulk TIL product (Fig. 2E). Interestingly, while in vivo retreatment had no effect on tumor 
outgrowth in two out of three mice previously treated with enriched TIL (Supplementary 
Fig. 2A), all recurring tumors still expressed MHC class I (Supplementary Fig. 2B) and were 
recognized efficiently in vitro (Supplementary Fig. 2C), suggesting that escape of antigen-








































118  |  Chapter 8
Figure 2. Neo-antigen reactive TIL mediate superior tumor control over standard ‘bulk’ TIL in a 
mouse model of human melanoma. (a) In vivo set-up to compare tumor control upon treatment with 
standard TIL and TIL enriched for neo-antigen reactivity. Brown cells: tumor cells; blue cells: bulk TIL; 
red cells: neo-antigen specific TIL. (b) Flow cytometric analysis of tail vein-derived blood taken from 
mice treated with standard (n = 5, blue square) or enriched TIL (n = 5, red triangle), or from untreated 
control mice (n = 4, green circle) at the indicated time points post-TIL infusion (16 x 106 total cells per 
mouse administered i.v.). All mice received high-dose IL-2 (7.2 x 105 IU) twice daily for three days after 
TIL infusion. Left: percentage of human CD8+ T cells of total live lymphocytes; middle: percentage of 
mutant CDK4R24L -specific T cells within the total CD8
+ T-cell population; right: percentage of mutant 
GCN1L1L2330P -specific T cells within the total CD8
+ T-cell population. Data are presented as mean ± 
s.d. There was no statistically significant difference between engraftment of total CD8+ T cells from 
standard TIL and enriched TIL. Frequencies of neo-antigen specific cells were significantly higher in 
recipients of enriched TIL as compared to recipients of standard TIL at all time points (P < 0.001). 
(c) Tumor growth in mice treated with standard TIL or enriched TIL, or in untreated control mice. 
Data are presented as mean ± s.d. (d) Survival analysis of mice treated with standard TIL or enriched 
TIL, or of untreated control mice. Survival distribution was analyzed by log-rank test (standard vs. 
enriched P < 0.005). (e) Tumor growth in non-treated mice (n = 4, green circles), and in mice treated 
with standard TIL (n = 4, 10 x 106 cells per mouse, blue squares), neo-antigen enriched TIL (n = 5, 10 x 
106 cells per mouse, red triangles), or an equivalent number of neo-antigen reactive TIL as present in 
the bulk TIL (n = 5, 2.72 x 105 cells per mouse, yellow triangles). In this setup, the standard TIL group 
and fraction TIL group received equal numbers (1.95 x 105) of neo-antigen reactive T cells. All mice 
received high-dose IL-2 (7.2 x 105 IU) twice daily for three days after TIL infusion. Data are presented 
as mean ± s.d. There was a statistically significant difference in tumor control from day 17 onward for 
neo-antigen enriched TIL vs. standard TIL (P < 0.005) and neo-antigen enriched TIL vs. fraction TIL (P 
< 0.005). At day 17, mice treated with standard TIL had significantly lower tumor burden compared 
to mice treated with fraction TIL (P = 0.02). Samples were compared using an unpaired two-sided 
Student’s t -test. (f) Tumor growth in untreated control mice (n = 7, green circles), or in mice treated 
with standard TIL (n = 6, blue squares), neo-antigen enriched TIL (n = 5, red triangles), or C/G-antigen 
enriched TIL (n = 6, yellow triangles). All treated mice received 20 x 106 total cells i.v. Contribution of 
the aimed for antigen-specific T-cell population, as assessed by MHC multimer staining, was 37.5% 
for both recipients of C/G-antigen and neo-antigen enriched TIL. All mice received high-dose IL-2 (7.2 
x 105 IU) twice daily for three days after infusion. Previously expanded TIL cultures were used, which 
were re-expanded (REP2) after enrichment to generate the TIL infusion products. Data are presented 
as mean ± s.d. There was a statistically significant difference in tumor control at day 14 for neo-antigen 
enriched TIL vs. standard TIL (P = 0.02) and neo-antigen enriched TIL vs. C/G-antigen enriched TIL (P = 
0.02), but not for standard TIL vs. C/G-antigen enriched TIL (P = 0.98). Samples were compared using 
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Next, we aimed to address whether TIL products enriched for reactivity against other 
classes of potentially relevant tumor rejection antigens could achieve a similar anti-tumor 
effect as TIL enriched for neo-antigen reactivity. Analysis of NKIRTIL006 by staining with 
a panel of HLA-A*02:01 multimers containing shared melanoma antigens had revealed 
the presence of T-cell reactivity against the Cancer/Germline (C/G) antigens MAGE-A10GLY, 
MAGE-C2LLF, MAGE-C2VIW and MACE-C2ALK (3.16%, 0.09%, 0.59% and 0.89% of CD8
+ T cells, 
respectively)20. To analyze the potential value of these C/G-antigen reactive T-cell responses, 
we independently enriched TIL cultures for either neo-antigen (CDK4R24L and GCN1L1L2330P) 
reactivity or C/G-antigen (MAGE-A10 and MAGE-C2) reactivity (Supplementary Fig. 3A). 
For both groups, the TIL cultures were again expanded after enrichment (necessary to 
obtain sufficient numbers of MAGE-A10/ MAGE-C2 enriched T cells from the low number 
of starting cells). Subsequently, frequencies of MHC multimer positive cells were adjusted 
to the same level for both groups (resulting in a combined frequency of either neo-
antigen or C/G-antigen reactive T cells of 37.5%) and the C/G and neo-antigen specific T 
cell-enriched TIL products were used for treatment of NSG mice carrying established 
autologous melanoma. Following infusion, a similar engraftment of TIL was observed across 
all treatment groups (Supplementary Fig. 3B). While overall anti-tumor activity was lower 
than in experiments using TIL expanded only a single time, also in this setting a significant 
difference in tumor outgrowth between mice treated with standard TIL and neo-antigen 
enriched TIL was observed (P < 0.05).  In contrast, infusion of C/G-antigen enriched TIL was 
not superior over treatment with standard TIL (P = 0.98, Fig. 2F). Furthermore, we observed 
a significant difference in tumor outgrowth between mice treated with neo-antigen 
enriched TIL as compared to mice treated with C/G-antigen enriched TIL (P = 0.02, Fig. 2F), 
indicative of a qualitative difference between epitope classes targeted by TIL therapy in 
this patient. However, the relative fitness of the enriched cell populations could be a major 
confounder for their tumoricidal potential. To enable a full qualitative comparison between 
TCR specificities, we sequenced the genes of each respective TCR alpha/beta chain, cloned 
them into a retroviral vector for expression on peripheral blood mononuclear cells (PBMCs) 
(Supplementary Fig. 4A) and confirmed their reactivity against the autologous tumor cell line 
(Supplementary Fig. 4B). We then treated tumor-bearing NSG mice with either a mixture of 
the two neo-antigen reactive TCR transduced PBMCs or a mixture of the four C/G antigen 
reactive TCR transduced PBCMs or with non transduced PBMCs as a control (Supplementary 
Fig. 4C). Upon infusion, all mice treated with neo-antigen reactive TCRs experienced 
complete tumor control (Fig. 3A), without late recurrence as was initially observed in the 
TIL treatment setting. Mice treated with C/G antigen reactive TCRs experienced some initial 
tumor control but eventually all mice were sacrificed because of tumor recurrence (Fig. 
3B). To dissect differences with respect to tumor clearance within the group of neo-antigen 
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PBMCs. To our surprise, only mice treated with the CDK4 TCR transduced PBCMs completely 
rejected the tumor (Fig. 3C). This may be a TCR intrinsic feature, as a subsequent koff-rate 
assay21 showed a significant difference in binding affinity of the CDK4 TCR in comparison 
with the GCN1L1 TCR and two of the four MAGE TCRs that we were able to test (Fig. 3D). 
These data indicate that within the group of neo-antigen reactive T cells there still may be 
heterogeneity in, although this is certainly not limited to, the quality of the T-cell response. 
Validation of TCR binding affinity may thus provide important information on tumor-control 
efficacy of reconstructed autologous TCRs for adoptive cell therapy approaches. 
This report provides both indirect and direct support for the (pre-) clinical relevance of 
neo-antigen reactive T-cell populations in two melanoma patients. It is, however, important 
to point out that neo-antigen specific CD8+ T-cell reactivity will not be a dominant factor in 
all patients that respond to immunotherapy. For instance, in tumors with a more modest 
mutational load, T-cell reactivity against non-mutant antigens could be a more critical 
factor, for the simple reason that the available repertoire of mutant antigens is limited. The 
observation that the clinical activity of recently developed immunotherapeutics is particularly 
pronounced in tumors with high mutational loads suggests that at least for these tumors 
an increased focus on patient-specific mutated antigens is warranted22-25. Clinical studies 
performed by Rosenberg and colleagues have already demonstrated that neo-antigen 
reactive T-cell populations enriched from clinical TIL products can exert profound clinical 
effects and that such a procedure is feasible at a clinical-grade level. Unfortunately, data 
from such trials will only provide correlative evidence for the involvement of T cells targeting 
neo-antigens, whereas the combination of our in vivo model system and T-cell receptor 
affinity assessment makes it possible to compare the quality of distinct T-cell responses 
targeting putative tumor-rejection antigens in a direct manner. As mentioned earlier, the 
differences we observed in tumor-clearance efficacy are likely not limited to TCR affinity 
alone but can also be related to whether a driver or a passenger mutation is being targeted 
or to differences in antigen expression levels. Furthermore, analyses on additional patients 
are required to gain insights in the tumoricidal fraction of the total neo-antigen reactive 
T-cell pool. Ultimately, mouse model systems might still be required as a learning strategy 
for the effects of hierarchical targeting of neo-antigens26 before we will be able to discern 
which form the more superior targets in obtaining tumor control in each individual patient.
In summary, ongoing developments in next-generation sequencing platforms and in silico 
prediction algorithms have made it feasible to identify patient-specific mutant epitopes 
within individual patients, and should make it feasible to enhance T-cell responses against 
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Figure 3. (a) Tumor growth in mice treated with control non transduced T cells (left), C/G TCR 
transduced T cells (middle) or neo TCR transduced T cells (right). Graphs show tumor growth of each 
individual mouse (grey line) and the average of the group (black line). Dotted line indicates time-point 
of T-cell infusion. Number of complete responders per group is indicated between brackets. Mice 
received 1e6 total CD8+TCR+ T cells. (b) Survival analysis per group is shown. (c) Tumor growth in mice 
treated with either CD8+CDK4+ T cells or CD8+GCN1L1+ T cells. (d) koff-rate assay was performed at 4 °C 
or room temperature (RT) for 4 out of 6 TCRs. TCR staining with streptamers was not detectable for 
MAGE-C2ALK and MAGE-A10GLY TCRs.
METHODS
Patient material and cell cultures. Material was obtained from patients (NKITRIL006 and 
MDACCTIL2379) with progressive stage IV melanoma after informed consent had been 
signed and with approval of the local medical ethical authorities. MDACCTIL2369 was 
treated in a phase II clinical trial study of TIL therapy (NCT00338377) at the MD Anderson 
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according to standard RECIST criteria as well as irRC27. TIL and tumor cell line cultures from 
both institutes were established from resection material according to identical protocols. 
Expansion of TIL cultures was performed according to a Rapid Expansion Protocol10. Cells 
were cryopreserved in 10 % DMSO and stored in liquid N2. 
Exome sequencing and detection of somatic mutations. Genomic DNA was extracted 
from cell pellets using the QIAGEN DNeasy purification kit. Libraries of genomic DNA were 
prepared using the Illumina Paired-End Sample Prep kit following the manufacturer’s 
guidelines. Resulting gDNA libraries were enriched for exonic sequences as described 
previously using the Agilent Sure Select Human All Exon 50Mb target enrichment system28. 
Sequencing was performed on an Illumina HiSeq DNA Analyzer (75bp paired-end reads), 
according to the manufacturer’s instructions. Reads were aligned to the human reference 
genome (NCBI Build 37) using the Burrows-Wheeler Aligner algorithm29. Unmapped reads, 
read mapping outside the targeted region and PCR-derived duplicates were excluded from 
further analyses.
To call substitutions and indels, the CAVEMAN and PINDEL algorithms were used, 
respectively, as implemented by the Cancer Genome Project30. The precision of substitution 
calling was determined by re-sequencing DNA from one sample (NKIRTIL006) at the NKI 
Genomics Core Facility, using the same sequencing platform but calling substitutions using 
Somatic SNIPER31. Indels were validated by manual inspection.
RNA sequencing and gene expression. RNA was isolated using the QIAGEN RNeasy 
purification kit. Poly-A selected RNA libraries were then prepared, using the TruSeq RNA 
library protocol (Illumina, San Diego, CA, USA), and the resulting libraries were sequenced 
on an Illumina HiSeq2000 using 75bp paired-end reads. Reads were aligned using Tophat 
(version 1.3.3)32. Expression values were calculated as FPKM using Cufflinks (version 1.0.2)33. 
Epitope Predictions. Amino acid stretches of 39 aa with the mutated amino acid at position 
20 were used to perform predictions of proteasomal cleavage (NetChop34,) and MHC class I 
binding (NetMHC3.2 and NetMHCpan2.435,36). For those mutations located within 20 amino 
acids from the N- or C-terminus of the protein, shorter fragments were used. The following 
peptides were selected; 1) those epitopes that contain the mutated amino acid; and 2) 
derived from genes with FPKM values > 0 (as there is little known about the importance of 
RNA expression levels, this low threshold was chosen); and 3) with a predicted C terminal 
cleavage probability of > 0.5; and 4) with predicted binding affinities of: < 8,500nM for the 
HLA-A*01:01 allele, <3,100 nM for the HLA-A*23:01 allele, <13,000 nM for the HLA-B*55:01 
allele, < 1,000nM for the HLA-A*02:01 allele, and <600 nM for the HLA-B*15:01 allele. The 
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sum of 9-, 10- and 11-mers) are included in the screen for each allele, a number based on 
predictions using a model set of mutations. 
Generation of pMHC multimers. Panels of pMHC multimers were generated by coupling 
each pMHC complex to a defined combination of two out of eight different fluorescent 
streptavidin (SA) conjugates (Invitrogen, Carlsbad, CA, USA). For each 10 μl of pMHC 
monomer (100 μg ml-1), the following amount of SA-conjugates were utilized: 1.5 μl SA-
QD605, 1.0 μl SA-QD625, 1.5 μl SA-QD655, 1.5 μl SA-QD705, 1.0 μl SA-QD800, 0.9 μl SA-PE 
(1 mg ml-1) and 0.6 μl SA-APC (1 mg ml-1). Mixtures were incubated on ice for 30 min. NaN3 
(0.02% wt/vol) and an excess of D-biotin (26.4 mM, Sigma-Aldrich, St. Louis, MO, USA) were 
added, the latter to block residual binding sites.
T-cell staining with pMHC multimers. Thawed cells were incubated with 25 U/ml benzonase 
(Novagen, EMD Millipore, Billerica, MA, USA) for 1 hr at 37 °C. For T-cell staining, the 
following amounts of fluorescently labeled pMHC complexes were pooled together for 
combinatorial coding: 1 μl for each PE-labeled pMHC complex, 2 μl for each APC-labeled 
pMHC complex, 3 μl for each QD605-labeled pMHC complex, 2 μl for each QD625-labeled 
pMHC complex, 2 μl for each QD655-labeled pMHC complex, 4 μl for each QD705-labeled 
pMHC complex, 4 μl for each QD800-labeled pMHC complex, and 3 μl for each PE-Cy7-
labeled pMHC complex. Cells were incubated in a total volume of 135 μl at 37 °C for 15 
min. 2 μl anti-CD8-FITC (clone SK1, BD Bioscience, San Diego, CA, USA), 1 μl anti-CD4-AF700 
(clone S3.5, Invitrogen, Carlsbad, CA, USA) and 0.5 μl LIVE⁄DEAD® Fixable Violet Dead Cell 
Stain Kit (Invitrogen, Carlsbad, CA, USA) was subsequently added, and cells were incubated 
on ice for 30 min. Prior to flow cytometric analysis, cells were washed twice in 200 μl FACS 
buffer, 1500 RPM, 3 minutes.
Flow cytometry. Data acquisition of T-cell screens was performed on an LSR-II flow cytometer 
(BD Bioscience, San Diego, CA, USA) with FacsDiva software, utilizing the following eleven 
color instrument setting: UV laser (355 nm): QD605, 595LP, 605/12; QD705, 685LP, 710/50; 
QD800, 750LP, 780/60. Violet laser (405 nm): QD625, 610LP, 625/20; QD655, 635LP, 
655/8. Blue laser (488 nm): FITC, 505LP, 525/50. Yellow-green laser (561 nm): PE, 585/15; 
PE-Cy7, 750LP, 780/60. Red laser (640 nm): APC, 670/14; AF700, 685LP, 710/50; IR-Dye, 
750LP, 780/60. To identify antigen-specific T cells, the following gating strategy was used. 1) 
Selection of live (IR-dye negative) single cell lymphocytes (FSC-W/H low, SSC-W/H low, FSC/
SSC-A). 2) Selection of anti-CD8-FITC+ and ‘dump’ (anti-CD4) negative cells. 3) Selection of 
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T-cell enrichment. Enrichments were performed using MHC-exchange molecules equipped 
with a strep-tag III19. Complexes were exposed to 366 nm UV light (CAMAG, The Netherlands) 
at 4 °C in the presence of a rescue peptide. MHC streptamers were generated by conjugating 
the resulting exchange reaction to magnetic microbeads, according to the manufacturer’s 
protocol (IBA, Göttingen, Germany).  T cells were labeled using 1 μg of MHC streptamer per 
1x107 cells. Antigen-specific cells were positively selected using LS columns (Miltenyi Biotec, 
Bergisch Gladbach, Germany). After enrichment, cells were incubated with 10 mM D-biotin 
(IBA, Göttingen, Germany) to dissociate MHC reagents. 
TCR gene expression on PBMCs. TCR genes from single-cell sorted T-cell clones were 
determined by high-throughput deep-sequencing using a previously published method 
and subsequently cloned into a retroviral vector construct37. Transduction efficiency was 
determined by pMHC multimer and murine constant domain staining (anti-mouse-beta-
chain-PE, clone H57-597, BD Pharmingen, San Diego, CA, USA). 
Koff-rate assay. TCR binding affinity was assessed in a koff-rate assay as previously described
21. 
In short, transduced T cells were stained with pMHC Alexa488 and Strep-Tactin APC beads 
(Superflow, 50 % suspension, IBA). The decay of fluorescence signal was measured after 
the addition of D-biotin using real-time fluorescence microscopy, followed by the decay of 
fluorescence signal reflecting the dissociation of monomeric MHC molecules. koff-rate and 
half-life time (t½) values were calculated using MetaMorph Offline image analysis software 
(Molecular Devices).
Functional analyses. To determine antigen reactivity (analyses performed in triplicate), 
indicated effector cells were cultured at a 1:1 ratio with target cells for 5 hr at 37 °C and 
5% CO2 (BD Pharmingen, San Diego, CA, USA). Target cell lines were either autologous 
(NKIRTIL006), HLA-A*02:01 matched (mel526), HLA-A*02:01 mismatched (mel938) or 
peptide-loaded T2 cells. Peptide loading was performed for 1 hr at 37 °C and 5% CO2 and 
cells were washed twice after incubation. After a 5 hr coculture, cells were stained with anti-
CD8 PerCP-Cy5.5 (clone SK-1, BD Pharmingen, San Diego, CA, USA) and anti-CD3 FITC (clone 
SK7, BD Pharmingen, San Diego, CA, USA), fixed with Cytofix/Cytoperm according to the 
manufacturer’s guidelines (BD Bioscience, San Diego, CA, USA), and stained for intracellular 
IFN-γ expression using anti-IFN-γ APC (clone B27, BD Pharmingen, San Diego, CA, USA). 
Samples were measured on a Fortessa flow cytometer (BD Bioscience, San Diego, CA, USA) 
with FacsDiva software and analyzed using FlowJo software version (version 9.4, Treestar 
Inc., San Carlos, CA, USA).
Chromium release assays were performed by labeling target cells for 1 hr at 37 °C with 
100 mCi (3.7 MBq) 51Cr (Amersham, Ghent, Belgium). Labeled target cells were washed three 
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cells at the indicated ratios for 4 hr at 37 °C and 5% CO2 in 200 μL medium. Maximal and 
spontaneous release was determined by the addition of 1 % Triton X-100 (Sigma-Aldrich, 
St. Louis, MO, USA) or addition of medium alone, respectively. 51Cr release was determined 
by transfer of 50 μl of supernatant to a Lumaplate (Perkin-Elmer, Waltham, MA, USA) and 
measurement in an automatic counter (Topcount, Perkin-Elmer). The percentage of specific 
release was calculated as: ((cpm experimental release – cpm spontaneous)/(cpm maximal 
– cpm spontaneous)) x 100.
In vivo model. NSG mice (The Jackson Laboratory, Bar Harbor, ME, USA) were housed in 
the Experimental Animal Department of The Netherlands Cancer Institute. All mouse 
experiments were performed in accordance with institutional and national guidelines and 
were approved by the Experimental Animal Committee (DEC) of The Netherlands Cancer 
Institute.
Female mice of at least 8 weeks old were challenged by subcutaneous injection of 1 
x 106 tumor cells embedded in matrigel (BD Bioscience, San Diego, CA, USA) in the flank. 
When tumors were palpable, mice were ranked by tumor size and randomized to ensure 
equal average tumor size per group with at least four mice per experimental group (no 
power calculations were performed). Subsequently, the indicated numbers of autologous 
T cells were injected intravenously, immediately followed by high-dose (7.2 x 105 IU) IL-2 
(Proleukin, Novartis) intraperitoneally twice daily for three consecutive days. Control mice 
received no T cells or non transduced PBMCs. Tumors were measured twice per week by 
a researcher blinded to the experimental condition, using a digital caliper. Animals were 
sacrificed when tumors exceeded 15 mm in any dimension or when the average of two 
dimensions was higher than 12 mm. Blood samples were taken from the tail vein twice 
weekly. Recurring tumors were enzymatically digested and stained with anti-HLA-ABC-PE 
(clone G46-2.6, BD Pharmingen, San Diego, CA, USA). Immune monitoring was performed 
on a Fortessa flow-cytometer (BD Bioscience, San Diego, CA, USA).
Statistical analysis. Samples were compared using an unpaired, two-sided Student’s t-test, 
unless specified otherwise. P-values <0.05 were considered statistically significant.
Data deposition. DNA and RNA sequencing data are deposited: EGAD00001000243
(https://www.ebi.ac.uk/ega/studies/EGAS00001000216) and EGAD00001000325
(https://www.ebi.ac.uk/ega/studies/EGAS00001000251). Data on MDACCTIL2379 can be 
found under PD13414a, PD13414b and PR13414a. Data on NKIRTIL006 can be found under 
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Supplementary Figure 1. Enrichment and functional analysis of neo-antigen reactive T cells in bulk 
melanoma TIL culture. (a) Change in tumor burden of patient MDACCTIL2379 relative to that at 
start of TIL therapy (1 x 1011 cells plus high-dose IL-2) is depicted. Measurements were performed 
on a target lesion in the right long using computed-tomography (CT) scanning images and reported 
according to immune-related response criteria (irRC) and RECIST. (b) Mutational profiles of patient 
MDACCTIL2379 (left) and NKIRTIL006 (right). Total number of somatic mutations is indicated. (c) 
Engraftment of mutant DHX33-specific T cells in peripheral blood of patient MDACCTIL2379 upon TIL 
therapy, as measured by MHC multimer combinatorial coding. (d) MHC multimer-based enrichment of 
neo-antigen reactive TIL from bulk melanoma TIL culture of patient NKIRTIL006. Left: pre-enrichment; 
Middle: post-enrichment; Right: post-REP. Data depict the percentage of pMHC double-positive cells 
within the total CD8+ T-cell population. Combined purity of TIL product (in percentages) is depicted 
below. (e) Chromium-release assay to measure cytolytic activity against autologous tumor cells of 
either standard TIL or neo-antigen enriched TIL at the indicated effector to target (E:T) ratios. Data 
are presented as means of triplicates ± s.d. Samples were compared using an unpaired two-sided 
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Supplementary Figure 2. Disease recurrence in the absence of immune editing. (a) Tumor growth 
in individual untreated control mice (n = 4, green), or in mice treated (first dotted vertical line) with 
standard TIL (n = 4, blue), neo-antigen enriched TIL (n = 5, red), or fraction TIL (n = 5, yellow). Three 
recipients of neo-antigen enriched TIL group were retreated (TIL x2, second dotted vertical line) with 
neo-antigen enriched TIL (10 x 106 total cells per mouse) and high-dose IL-2 (7.2 x 105 IU) twice daily for 
three days at the time of tumor recurrence (day 51). The remaining two mice received no additional 
infusion of TIL but did receive high-dose IL-2 (7.2 x 105 IU) twice daily for three days at the time of 
tumor recurrence (day 85). (b) Recurring tumors were analyzed for expression of MHC class I by flow 
cytometry. Overlays of histograms are shown, grey filled area are unstained control cells. MFI denotes 
median fluorescence intensity. TIL x1 denotes mice that were treated with a single TIL infusion and 
had complete tumor regression until day 80; TIL x2 (R) denotes the mouse that, after initial tumor 
control received a second TIL infusion at day 51 and experienced complete regression until day 80; TIL 
x2 (NR) denotes mice that, after initial tumor control, received a second TIL infusion at day 51 to which 
they did not respond. (c) Analysis of (neo-) antigen presentation by recurring tumors, as measured by 
intracellular IFN-γ cytokine staining of standard TIL and enriched TIL upon coculture with tumors from 
control mice, or mice treated with standard TIL or neo-antigen enriched TIL. Data are presented as 
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 Monitor tumor growth and  
 T-cell persistence  
Supplementary Figure 3. Comparison of neo-antigen enriched T-cell product with C/G antigen 
enriched T-cell product. (a) In vivo set-up to compare tumor control upon treatment with standard TIL, 
neo-antigen enriched TIL and C/G-antigen enriched TIL. Brown cells: tumor cells; blue cells: bulk TIL; 
red cells: neo-antigen specific TIL; yellow cells: C/G-antigen specific TIL. For this experiment, previously 
expanded TIL cultures were enriched and re-expanded (REP2) to generate the TIL infusion products. 
(b) Flow cytometric analysis of tail vein-derived blood taken from untreated control mice (n = 7, green 
circles), or mice treated with standard TIL (n = 6, blue squares), neo-antigen enriched TIL (n = 5, red 
triangles), or C/G-antigen enriched TIL (n = 6, yellow triangles).  All treated mice received 20 x 106 total 
cells i.v. plus high-dose IL-2 (7.2 x 105 IU) twice daily for three days. Numbers depict the percentage 
human CD8+ T cells of total live lymphocytes. There was no statistically significant difference between 
engraftment of total CD8+ T cells between all treatment groups. Data are presented as mean ± s.d. 
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Supplementary Figure 4. Comparative analysis of isolated TCRs. (a) Transduction efficiency of each 
indicated TCR is shown by pMHC multimer staining (upper panel) or Murine constant domain staining 
(lower panel). (b) Reactivity of transduced T-cell cultures was determined by measuring intracellular 
IFN- γ cytokine staining upon coculture with the autologous tumor cell line. (c) Flow cytometric 
analysis of tail vein-derived blood from mice treated with non transduced (green circles), neo TCR 
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ABSTRACT
The presence of cytotoxic T lymphocytes is strongly correlated with a favorable prognosis 
in a number of cancer types. However, whether such infiltrates primarily consist of tumor-
specific T cells or of bystander T cells has not been established. Furthermore, as intratumoral 
T cells are frequently characterized by an exhausted phenotype, it is challenging to address 
this question by classical assay systems that rely on in vitro expansion or testing of the 
tumor-resident T-cell pool. 
To allow an unbiased functional assessment of the intrinsic tumor recognition capacity 
of cytotoxic T lymphocytes (CTLs) present in human solid tumors, we have developed and 
exploited a high-throughput screening platform that combines next-generation sequencing 
of T cell receptors (TCRs) from single intratumoral CTLs with in silico reconstruction of full-
length TCRα/β heterodimers. Using this approach, we reconstructed a collection of TCRs 
isolated from colorectal and ovarian cancer samples. Functional analysis of a collection of 
isolated TCRs by TCR gene transfer experiments uncovered the presence of tumor-reactive 
CTLs, but also substantial tumor infiltration by T cells without detectable tumor recognition 
potential. Thus, the strategy presented here provides a powerful tool to query tumor-
resident T-cell populations for their intrinsic tumor-reactive potential in an unbiased manner, 
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INTRODUCTION
Over the past five years, immunotherapy has become a new pillar in the treatment of human 
cancer1,2. Initially, clinical benefit of cancer immunotherapy was predominantly observed in 
metastatic melanoma, but subsequent clinical studies, evaluating the potential of blockade 
of the PD-1 – PD-L1 axis, have demonstrated activity in other common solid and non-solid 
tumor types3-6. To date, response rates in colorectal cancer (CRC) and ovarian cancer (OVC) 
have however been low, in spite of the previously reported strong association between 
patient survival and the presence of intratumoral cytotoxic T lymphocytes (CTLs)7,8. In CRC, 
anti-PD-1 therapy has shown effectiveness in a molecular subset that is characterized by 
deficiencies in the DNA mismatch repair machinery9, and it is hypothesized that the high 
levels of neo-antigens resulting from this deficiency enhance the visibility of these tumors 
to the immune system10. In contrast, patients with OVC and mismatch repair-proficient 
CRC derive hardly any clinical benefit from the currently available immunotherapeutic 
interventions. One potential reason for this poor clinical efficacy may be a scarcity of true 
tumor-specific T cells among the infiltrating lymphocytes,. As an alternative possibility, the 
tumor-resident T-cell pool may be intrinsically tumor-reactive but rendered inactive by 
signals from the tumor micro-environment. 
In-depth sequence analysis of the tumor-resident T-cell receptor (TCR) repertoire in 
combination with functional validation of these TCRs would therefore be highly relevant in 
these malignancies, as such an effort could be used to assess the intrinsic tumor-reactive 
nature of bulk tumor infiltrating CTLs. Currently, a number of technologies exist that could 
address this matter, but these generally depend on the use of large collections of V-gene 
specific primers or require extensively cultured cells of clonal origin, which unavoidably 
bias the resulting data11. Additionally, the full-length sequence of endogenously paired 
chains at the single cell level is required to reconstruct functional TCRα/β heterodimers, 
thereby hampering a bulk approach. Here, we develop a novel PCR-based next-generation 
sequencing (NGS) platform that allows the identification of TCR genes at single-cell resolution 
in an unbiased manner. Using this technology, we were able to successfully identify 106 TCR 
pairs (of which 66 were unique) from 189 single intratumoral T cells from patients with 
primary OVC and CRC, of which 35 were tested functionally. Interestingly, although reactivity 
against autologous tumor material was observed with TCRs isolated from both patients, the 
majority of TCRs in the two samples analyzed were not tumor-reactive, suggesting that the 
endogenous immune response in these tumors is largely composed of T cells that have no 
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RESULTS
High throughput single-cell TCR sequencing technology
The functional reconstruction of endogenous TCRα/β heterodimers from a mixed CTL 
population is complicated by the requirement to correctly pair the two unique chains of 
single cells. To address this, we adapted a previously established single-cell PCR (scPCR) 
methodology12 to incorporate targeted amplification of TCRα/β chains from single cell-sorted 
TIL (Fig. 1A). In this set-up, single alpha and beta chain sequences are identified per sample, 
thus automatically constituting the endogenous receptor of the original T cell. To determine 
whether we could correctly identify TCRα/β sequences with this approach, we employed 
flow cytometry based single-cell sorting of CMV pp65-specific and minor histocompatibility 
antigen HA2 specific T-cell clones expressing a known CDR3 sequence13. Real-time Taqman 
PCR assays on reverse-transcribed and PCR-amplified samples demonstrated successful 
cDNA generation and PCR amplification in 83% (126/153) of single cell samples (pooled data 
from 18 independent experiments) (Fig. 1B). Subsequently, for ten CMV single-cell sorted 
samples we tested whether cDNA yield was sufficient to reliably detect TCR sequences using 
next-generation sequencing (NGS). Average read counts for the TCR alpha and beta chains 
were 1.9x105 and 3.3x104, respectively, sufficient to identify both CDR3 sequences in each 
individual sample (Fig. 1C). Finally, we assessed whether we could correctly call endogenous 
TCR pairs from four previously sequenced melanoma derived T-cell clones that were mixed 
in a 1:1:1:1 ratio and subsequently single-cell sorted14. Pairing of the endogenous alpha and 
beta chain was correct in 88% of cases (79/90 sorted single cells) (Fig. 1D), with an overall 
efficiency of TCR sequence detection from single lymphocytes of 73%.
Figure 1. Establishment and validation of single-cell derived T-cell receptor deep-sequencing 
technology. (a) Single CD8+ T cells are sorted from thawed single cell tumor digest in PCR lysis buffer 
(top left) containing four TCRα/β constant domain specific primers. After lysis, first-strand cDNA 
synthesis is performed (top middle) followed by a polyguanylation step of the reverse transcribed 
strand (top right). Next, a template switch and second strand cDNA synthesis is performed using a 
poly-(C) primer containing anchor sequences to be used in subsequent PCR steps (centre right). Finally, 
two rounds of nested PCRs are performed to further amplify the obtained PCR product that can be 
processed for NGS (centre middle and left). Schematic overview of the used primer sets is shown 
(bottom). (b) CMV or HA2 specific single T cells were used to assess the feasibility of single-cell cDNA 
generation using real-time PCR as a read-out. A threshold cycle value (Ct) of 35 was used as a cut-off 
for successful cDNA generation. Data are taken from 18 independent experiments representing a total 
of 153 single cells. (c) Ten CMV sorted single cells were processed according to the scPCR protocol and 
processed for NGS. Read count indicates the number of reads per sample for the CMV-specific CDR3 
sequences of the alpha and beta chains. (d) A mixture of four tumor-antigen specific T-cell clones 
was sorted as single cells (N=90) and processed by scPCR for NGS. Upon analysis, 88% of the samples 
contained the correct alpha/beta TCR combination (left), input ratio of the 4 clones was recapitulated 
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Reconstruction of TCRs from primary CRC
Having established this technology, our next aim was to assess whether we could identify 
TCR sequences of tumor infiltrating CD8+ T cells. For this purpose, we collected material 
from a patient with primary CRC who had not received any prior treatment. We sorted CD8+ 
single cells from frozen, uncultured tumor digest, performed scPCR and processed 94 of the 
resulting PCR products for Illumina NGS. Subsequently, sequence data were analyzed by 
the MiTCR algorithm to detect CDR3 regions15 and filtered for high read counts. Resulting 
TCRα/β pairs were cross compared to a database containing all CDR3 amino-acid sequences 
identified in prior sequence runs allowing for the identification of potential contaminations. 
Finally, we analyzed non-recurring sequences with the TCRprimer algorithm (developed in-
house) to determine a full-length consensus sequence. By this approach, we were able to call 
TCR pairs of 68% of total single cells from patient sample CRC11 (Fig. 2A). Interestingly, 75% 
of the TCR sequences identified within TIL of this patient were encountered more than once, 
including two dominant TCR pairs present in 39% and 11% of all called samples (Fig. 2B). 
To assess tumor-specificity of isolated TCRs, we randomly selected 20 TCR sequences (with 
the inclusion of the 2 recurring TCR pairs) and expressed these in donor PBLs (Fig. 2C). Thus 
far, we have assessed functionality of 16 transduced T-cell cultures and observed reactivity 
against autologous 3D-cultured tumor cells in five (31%) (Fig. 2D and 2E). Interestingly, one 
of the two dominant clones contained a TCR pair that was reactive with autologous tumor, 
indicating that the initiation of an endogenous immune response in this CRC patient led to 
clonal outgrowth of tumor-specific T cells. 
Reconstructing TCRs from primary OVC
Next, we employed the same approach to an OVC sample obtained from a patient undergoing 
primary abdominal surgery in the absence of prior therapy. Analysis of deep sequencing 
data resulted in 44% of single cell samples being called (Fig. 3A). Upon crosscheck with our 
database we discovered that 7% of identified OVC21 samples consisted of contaminating 
CMV pp65 and HA2 sequences, and these were excluded from further analysis. In the set 
of called samples, only a single recurring TCR sequence was identified (combined 5% of 
total called sequences) indicating a highly heterogeneous intratumoral T-cell population in 
this particular patient (Fig. 3B). To assess tumor-specificity of the identified TCR pairs, we 
randomly selected 20 TCR pairs (with the inclusion of the duplicate sequence) and expressed 
these in donor PBLs (Fig. 3C). For one TCR (OVC21-9), no substantial TCR expression was 
observed. Upon functional validation of the remaining TCRs, one out of 19 TCRs showed 
production of IFN-γ above background upon exposure to uncultured autologous tumor 
digest (Fig. 3D and 3E). Thus, in this highly heterogeneous OVC-derived endogenous T-cell 
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Figure 2. Reconstruction and functional testing of TCR sequences from a colorectal cancer patient. 
(a) From patient CRC 11, 180 single cells were processed by scPCR of which 94 were sequenced. Pie 
chart denotes analysis of all sequenced samples, resulting in 68% of samples being called. Remaining 
samples were not called due to low read counts (30%) or inconsistent pairing of TCRα/β chains (2%). 
No contaminating sequences were found. (b) Within the group of called samples, two dominant clones 
(CRC11-1 and CRC11-4a/b) were identified, constituting half of all TCR pairs, as well as a number of 
less frequent clones (25% of total called samples). An equal number of TCR pairs occurred only once 
(in red). (c) A selection of reconstructed TCR sequences was cloned into the pMP71 retroviral vector 
and expressed on healthy donor PBLs. A representative example of twenty independent transduction 
experiments is shown. (d) A total of 16 TCR constructs was tested for functional reactivity against 
autologous 3D cultured tumor cells in an overnight stimulation assay (black bars). Unstimulated 
transduced T-cell cultures and one non-transduced T-cell culture served as background controls 
(grey bars). Five T-cell cultures recognized autologous tumor cells. Reactivity has been corrected for 
transduction efficiency. (e) Flow cytometric analysis of CRC11-1 transduced T cells upon coculture with 
autologous tumor cells. Upper panel shows unstimulated T cells, lower panel shows T cells stimulated 
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Figure 3. Reconstruction and functional testing of TCR sequences from an ovarian cancer patient. 
(a) From patient OVC21, 180 single cells were processed by scPCR of which 95 were sequenced. 
The pie chart denotes analysis of all sequenced samples, resulting in 44% of samples being called. 
Remaining samples were not called due to low read counts (43%), inconsistent pairing of TCRα/β 
chains (5%), or presence of contaminating sequences (7%). (b) Of the called samples, one TCR pair 
(OVC21-15, blue) occurred twice, whereas all others (red) occurred only once. (c) A selection of 
reconstructed TCR sequences was cloned into the pMP71 retroviral vector and expressed on healthy 
donor PBLs. A representative example of twenty independent transductions is shown. (d) A total of 
19 TCR constructs was tested for functional reactivity against autologous uncultured tumor cells in 
an overnight stimulation assay (black bars). Unstimulated transduced T-cell cultures and one non-
transduced T-cell culture served as background controls (grey bars). Sample OVC21-34 recognized 
autologous tumor cells. Reactivity has been corrected for transduction efficiency. (e) Flow cytometric 
analysis of OVC21-34 transduced T cells upon coculture with autologous tumor cells. Upper panel 
shows unstimulated T cells, lower panel shows stimulated T cells. Plots are gated on CD3+CD8+ single 
live lymphocytes. 
DISCUSSION
The presence of tumor infiltrating CTLs in colorectal and ovarian cancer strongly correlates 
with patient survival. Despite this association, immunotherapy has thus far not shown a 
substantial rate of objective clinical responses in these cancer types16-19. The degree to which 
these T cells are truly tumor-reactive has remained an unanswered question in the field, 
although attempts have been made to address it. A recent study investigated the role of 
adaptive immunity in CRC by stimulating purified intratumoral T cells from 26 patients with 
DCs loaded with either lysate of autologous tumor digest or normal colonic mucosa and 
found tumor-reactivity in 44% of patients20. Subsequently, a panel of MHC pentamers for six 
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0.1% to 2.5% of T cells being antigen-specific and tumor-reactive. Although this analysis 
likely underestimates the frequency of total tumor-reactive T cells, as non-shared antigens 
were not included, and as analysis was restricted to a single HLA-A2 allele, antigen-specific 
T cells were observed in the majority of CRC patients. Another study aimed to address this 
matter by assessing tumor-reactivity of CRC derived T-cell cultures, finding reactivity in three 
out of five patients for which autologous tumor material was available21. However, due to 
the extensive culturing of both T-cell clones and autologous tumor cell lines, tumor reactivity 
can be lost over time as was demonstrated in one of the three patients. In OVC, tumor-
reactivity has been particularly observed in the CD137+ fraction of intratumoral CTLs22. 
Even though these studies indicate that tumor-specific T-cell reactivity can be present 
in these tumors, the methodology used cannot be used to accurately determine the tumor 
reactivity of the intratumoral TCR pool, both because of the potential bias in T-cell outgrowth, 
and because of potential exhaustion of intrinsically tumor-reactive T cells. 
Here, we provide the first unbiased analysis of the tumor-reactive fraction of single 
cytotoxic T cells in primary human ovarian and colorectal cancer. In the first patient, we 
observed the presence of two highly abundant T-cell populations (39% and 11%), which is 
indicative of clonal expansion. Indeed, one of these TCRs was reactive against autologous 
tumor cells. Investigation of microsatellite status revealed that CRC11 was of the stable (MSS) 
subtype, indicating that patients with mismatch repair proficient CRC can still be able to elicit 
a numerically strong endogenous tumor-specific T-cell response. Whether such patients are 
sensitive to immune modulation by for example immune checkpoint blockade, as is the case 
for MSI positive CRC, should be investigated further. Samples from a second CRC patient 
are currently being processed for functional testing (data not shown). In the OVC sample, a 
total of 19 TCRs were assessed for reactivity. We found one TCR (5%) to be reactive against 
uncultured autologous tumor cells. A second OVC sample is currently being processed for 
similar analyses (data not shown). Whether the low degree of intrinsic reactivity in OVC is 
a general feature should be determined on larger patient cohorts. Together, the majority 
of tumor-infiltrating T cells in the two samples analyzed thus far is comprised of TCRs that 
are not reactive to tumor-specific antigens present within the tumor cell population. If 
this finding is extended in larger sample collection, this observation should have profound 
implications for the efficacy of immunotherapeutic approaches that aim to reinvigorate the 
tumor-resident endogenous T-cell pool.
Despite the high sensitivity of our assay, several factors should be taken into account 
that could influence our analyses. First, our calling efficiency in these two samples was 
68% and 44% for CRC11 and OVC21 respectively, which is lower than the 83% efficiency 
observed in our HA2/CMV experiments. This is likely a representation of cellular fitness in 
combination with RNA quality and transcript abundance in tumor-resident versus cultured 
T cells. In addition, the differentiated state of antigen-specific T cells may potentially lead to 
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TCRs, 5 (12.5%) repeatedly failed to be expressed on PBLs and were thus excluded from 
functional assessment. It is conceivable that errors occasionally occur along the multi-step 
process of TCR reconstruction, thereby leading to potential false negatives. In order to assess 
the false negative rate of our technology, we aim to reconstruct TCRs from T cells that are 
known upfront to be reactive against autologous tumor cells. The number of TCRs that show 
tumor reactivity when analyzed by the strategy developed here will provide an indication on 
the fraction of tumor-reactivity that is successfully recovered by our experimental process. 
Notwithstanding these limitations, the value of this technology with respect to our 
understanding of the T-cell based immune system in response to the two tumor types 
that we describe here is two-fold. First, it allows us to determine the fraction of tumor-
reactive T cells that is present within a bulk TIL population in any solid tumor. Analyses 
on larger patient cohorts could provide insights whether reactivation of the endogenous 
T-cell pool, using for example immune-checkpoint inhibitors, will primarily be useful in those 
patients that have a high rate of intrinsic anti-tumor reactivity. Second, TCR sequence data 
in combination with matching exome data from the autologous tumor will make it possible 
to identify the cognate antigens that are recognized, a question of clinical relevance since 
it is as yet unknown which antigen class – i.e. shared antigens versus mutated neo-antigens 
– is preferentially recognized on these tumors. For instance, in colorectal tumors that are 
microsatellite instable (MSI), immune-reactivity may preferentially be targeted against 
mutated antigens25, which might not be the case or apply to a lesser degree in MSS CRC. 
Similarly, in ovarian cancer the mutational load is on average much lower than in MSI CRC, 
and targeting of Cancer/Germline (C/G) or overexpressed antigens such as NY-ESO-1 or 
HER2/neu may there play a more significant role26. 
In conclusion, as cancer immunotherapy is continuously improving life expectancy 
of cancer patients, a better understanding is required of the intrinsic tumor recognition 
potential of endogenous tumor-resident T cells in patient groups that do not benefit from 
current cancer immunotherapies. Although the presence of intratumoral T cells in OVC 
and CRC correlates with improved prognosis, our data suggest that bystander infiltration 
may be a prominent feature, which warrants a more personalized approach towards the 
administration of cancer immunotherapy. 
METHODS
Patient material. Tumor material was collected from patients treated at the Antoni van 
Leeuwenhoek Hospital. All patients gave informed consent in accordance with local ethical 
committee guidelines. Included patients did not receive any prior treatment. Collected 
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Primary cell cultures. Organoid cultures were established from primary CRC tumor digest27 
and subsequently injected into immunodeficient NSG mice or stored for further use. Mice 
were sacrificed upon outgrowth of patient-derived xenografts (PDX) and tumors were 
harvested. PDX tumors were passaged until sufficient numbers of target cells were obtained. 
Following each passage, tumor cells were analyzed for expression of MHC class I (HLA-ABC, 
clone G46-2.6, BD Biosciences) and epithelial cell adhesion molecule (EpCAM, clone 9C4. BD 
Biosciences) by flow cytometry or immunohistochemistry. 
Single-cell FACS sorting. Tumor digests from CRC and OVC patients were stained with 
antibodies for a panel of phenotypic markers prior to single-cell sorting. These included 
anti-CD3 AF700 (clone UCHT1, Invitrogen), anti-CD8 FITC (clone SK1, BD Biosciences), anti-
PD-1 PE (clone J105, eBioscience), anti-TIM-3 PE-Cy7 (clone F38-2E2, eBioscience), anti-
LAG-3 APC (R&D Systems), anti-CD137-BV421 (clone 4B4-1, Biolegend), anti-CD103 BV711 
(clone Ber-ACT8, BD Biosciences), anti-CD45RO (clone UCHL1, BD Biosciences). IR-dye (LIVE/
DEAD® FixableNear-IR Dead Cell Stain, Invitrogen) was used to exclude dead cells. Gates 
were set on single live CD3+CD8+ lymphocytes and single cells were sorted into 96-well PCR 
plates using a MoFlo Astrios sorter set at 1.0 sorting stringency. 
PCR methods. The PCR protocol used in this project was modified from Tang et al.12. PCR 
plates containing lysis buffer were prepared under RNAse free conditions. Samples were 
lysed immediately after sorting, followed by RT-PCR using four pairs of TCRα/β constant-
domain specific primers (Supplementary Table 1). Subsequently, free primers were 
degraded and double-stranded DNA was obtained by addition of a poly-G tail to the first 
strand and template switch to synthesize the second strand. Finally, two rounds of nested 
PCR amplification were performed using additional constant domain primers and adaptor 
primers annealing to an anchor sequence introduced in the poly-G domain. Libraries were 
made using the Kappa Illumina kit and subsequently sequenced on an Illumina MiSeq. 
Reconstruction of TCR chains. Sequence data were analysed using the MiTCR script that 
extracts CDR3 regions and identifies TCR V, D and J segments14. Called CDR3 sequences were 
subsequently ranked by read count and discarded if below 100 reads. Remaining sequences 
were considered true (called) when they comprised more than 75% of total reads for that 
chain in a given sample and when this TCR sequence was not observed in combination with 
any other chain in other samples. When there were multiple in-frame α-chains in a single 
sample the combined frequency of the reads had to exceed 75%, in which case multiple 
TCRα/β pairs per sample were generated and tested (e.g. CRC11-4a and CRC11-4b). Full-
length TCR chains were reconstructed using an in-house developed script, TCRprimer, which 
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sequence by cross-linking the input sequence data to a database containing all human TCR 
variable domains. Output was manually verified for each sample using IMGT/V-Quest28. 
Generation of retroviral vectors and TCR expression in PBLs. The resulting consensus 
sequences were codon-optimized, synthesized and subcloned into the retroviral vector 
pMP71 (Life Technologies). In this vector, human TCRα and β constant domains are replaced 
by their murine counterparts to reduce mispairing with endogenous TCR chains, and to allow 
expression analysis by flow cytometry with anti-murine TCRβ constant domain antibody. Viral 
packaging cells (FLYRD18) were transfected with 10µg of plasmid DNA using Extremegene 
transfection reagent. Virus-containing supernatant was spinoculated onto anti-CD3/CD28 
bead-activated T cells from healthy blood donors (Sanquin, The Netherlands). Transduction 
efficiency was measured four days later by flow cytometry using an antibody directed 
against the murine TCRβ constant domain (clone H57-597, BD Biosciences). T-cell cultures 
with at least 20% transduction efficiency were expanded in the presence of IL-2 (100 U/ml, 
Proleukin®, Novartis) and IL-15 (5ng/ml, Peprotech) for 14 days prior to functional validation. 
Validation of TCR functionality. Tumor-reactivity of TCR transduced T-cell cultures was 
determined by intracellular cytokine staining. TCR-transduced T cells were cocultured with 
patient autologous tumor cells in a multi-well format. For CRC11, a 3D-cultured target cell line 
was established27, whereas for OVC21 primary uncultured tumor cells were used as target 
cells. After 1 hr of stimulation, brefeldin A and monensin were added to allow intracellular 
cytokine accumulation. Following overnight incubation, cells were fixed, permeabilized, and 
stained with anti-IFN-γ-APC (clone B27, BD Biosciences). Samples were analysed on an LSR 
Fortessa or LSRII (BD Biosciences). Reactivity was corrected for transduction efficiency. 
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Supplementary Table 1. Primer sequences utilized to amplify single-cell derived TCR-specific mRNA.
















TRAC: T-cell receptor alpha constant domain, TRBC: T-cell receptor beta constant domain, N denotes 
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ABSTRACT
The positive prognostic value of intratumoral T cells in primary epithelial ovarian cancer 
(EOC) suggests that these patients may benefit from cancer immunotherapy. However, to 
date, these therapies have demonstrated little clinical effectiveness. One approach that 
should be revisited in view of our increased understanding of T-cell differentiation is the 
adoptive transfer of ex vivo expanded autologous tumor infiltrating lymphocytes (TIL). To 
investigate the potential of such a strategy, we utilized material from six primary ovarian 
tumors to establish preclinical TIL cultures according to standardized protocols used for TIL 
therapy of melanoma. We show that expansion of ovarian cancer TIL is comparable to that 
seen for melanoma TIL. Furthermore, we observed both MHC-I and MHC-II restricted T-cell 
reactivity in vitro in response to autologous tumor cells. Based on these data, we propose to 
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INTRODUCTION
Epithelial ovarian cancer (EOC) has a poor prognosis upon disease recurrence and 
development of resistance to platinum and taxane-based chemotherapy. The median 
overall survival in patients with stage III-IV disease ranges from 29 to 38 months depending 
on the recurrence and platinum-free interval1, with a 5-year relative overall survival rate 
between 17% and 36%2. Attempts to improve overall survival by means of chemotherapy 
has for decades met with only limited clinical success3. Therefore, alternative approaches 
such as immunotherapy are currently being explored. An incentive to study EOC in the 
context of cancer immunotherapy is derived from a landmark study conducted by Zhang et 
al. in which the presence of intratumoral T cells positively correlated with overall survival4. 
These findings have been confirmed in subsequent independent studies as well as a meta-
analysis5-7. Recently, T-cell checkpoint blockade with anti-PD-1/PD-L1 antibodies was shown 
to be able to induce clinical responses in 10-20% of heavily pretreated women with EOC, 
indicating that mobilization of the endogenous T-cell pool by immunotherapy has potential 
in this disease8-10.
Another form of immunotherapy that may be utilized for the treatment of EOC is TIL 
therapy - a strategy in which patients receive large numbers of autologous ex vivo cultured 
tumor-infiltrating lymphocytes (TIL). Already in the early ‘90s, clinical responses were 
observed in several EOC patients treated with TIL therapy, although no follow-up trial 
data have been published11,12. Importantly, patients in these trials underwent treatment 
with extensively cultured T cells in the absence of prior lymphodepleting chemotherapy. 
In recent years, the body of knowledge regarding TIL therapy has increased considerably 
and so has our understanding of the requirements for a clinically effective autologous T-cell 
product. In particular, clinical trial data in melanoma patients treated with TIL therapy have 
shown reproducible response rates of 50% with long-term cures in 10-20%13. The increase in 
effectiveness of this form of T-cell therapy that was obtained in the past decade is thought 
to be largely dependent on two factors: 1) a relatively short-term in vitro culture period 
to generate less differentiated T cells; 2) systemic non-myeloablative lymphodepletion to 
enhance engraftment of the transferred T cells14,15. Taking into account that the EOC studies 
conducted in the ‘90s lacked both of these conditions, a renewed look at TIL therapy for EOC 
patients appears justified. To enable the development of such a study, we obtained material 
from six patients with primary EOC and established T-cell cultures according to currently 
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RESULTS
Expansion of EOC TIL cultures
Tumor tissue was collected from six patients with newly diagnosed EOC for which they 
underwent primary debulking surgery. The growth rate of these six EOC TIL cultures was 
comparable to that observed for eight control malignant melanoma (MM) preclinical 
TIL cultures, with a median fold expansion of 984 and 1311 (P = 0.30), respectively (Fig. 
1A). Characterization of all TIL cultures revealed a 95-100% pure CD3+ T-cell product with 
preferential outgrowth of CD4+ T cells over CD8+ T cells in EOC, 56% and 39% respectively, 
whereas in MM this was 29% and 63%, respectively (non-significant difference, Fig. 1B).
Reactivity of EOC TIL cultures against autologous tumor
Next, we assessed whether these EOC TIL cultures were able to recognize autologous tumor 
cells in standardized coculture assays. In the first set of three patients that we analyzed 
we observed that 12.7%, 0.64% and13.4% of CD4+ T cells expressed IFN- γ in response 
to autologous tumor cells (Fig. 1C). In the same cultures, reactivity in the CD8+ T-cell 
compartment was 4.6%, 22.2% and 18.3%, respectively (Fig. 1D). Overall, we observed 
reactivity in 5/6 EOC TIL cultures with a majority of cultures showing tumor reactivity 
within the CD4+ T-cell compartment, whereas reactivity in the CD8+ T-cell compartment was 
observed in half of the cultures (Fig. 1E). Flow cytometric analysis of the target cells showed 
expression of MHC class II (HLA-DR, DP and DQ) molecules (data not shown). Eight cultures 
established under a clinical protocol for melanoma TIL production revealed a similar degree 
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Figure 1. Analysis of EOC TIL cultures. (a) Fold expansion of eight MM TIL (circles) cultures is shown 
in comparison with six EOC TIL cultures (squares). Black bars indicate mean fold expansion. A 2-sided 
unpaired t-test showed no significant difference in expansion rates. (b) Phenotypic analysis of MM and 
EOC TIL by flow cytometry. Horizontal bars indicate mean frequencies of CD3+, CD4+, and CD8+ cells 
of total live lymphocytes. (c) Intracellular IFN-γ staining of CD4+ T cells upon coculture of established 
TIL cultures with autologous tumor cells is shown for three EOC patients. Tumor digests containing 
a mixture of tumor cells and lymphocytes were used as target cells. Unstimulated T cells and T cells 
stimulated with PMA/ionomycin served as negative and positive control samples, respectively. (d) 
Intracellular cytokine staining of CD8+ T cells upon coculture of established TIL cultures with autologous 
tumor cells is shown for the same three EOC patients as in Figure 1C. (e) Percentage of cells with 
detectable intracellular IFN-γ expression are shown for all six EOC TIL cultures for both the CD4+ and 
CD8+ T-cell compartment. Horizontal bars indicate mean levels of cytokine expression. (f) Reactivity of 
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DISCUSSION
Metastatic EOC has a poor prognosis and few systemic treatment options exist for patients 
with chemotherapy refractory disease. Cancer immunotherapy might provide a new 
lead for treatment, as in primary EOC the presence of TIL has been positively correlated 
with survival7. Several studies have reported responsiveness of EOC patients to different 
forms of immunotherapy such as DC based vaccination strategies and immune checkpoint 
blockade8,16. However, the majority of patients still succumb to progressive disease after 
immunomodulation. Early TIL trials in the ‘90s demonstrated a potential clinical benefit in 
a therapeutic and prophylactic setting but treatment protocols have changed significantly 
since then, which justifies a renewed analysis of the potential of TIL therapy for EOC. Here, 
we show in six preclinical laboratory-scale expanded TIL cultures that tumor-reactivity is 
present in CD4+ and CD8+ T-cell compartments. In several TIL trials, the presence of CD8+ T 
cells was found to be a predictive marker for response to therapy, and in this respect the 
bias towards CD4+ T cells observed in EOC TIL cultures may form some concern17,18. However, 
recent data suggest a relevant role for CD4+ tumor-reactive T cells as well. In particular, one 
case study demonstrated a clinical response in a cholangiocarcinoma patient treated with a 
TIL product that was highly enriched (>95%) for CD4+ T-cells reactive against an MHC class II 
restricted neo-antigen19. In addition, a study from our group indicated that reactivity against 
neo-antigens is commonly observed in the CD4+ T-cell compartment in melanoma patients, 
including patients that respond to TIL therapy20. Thus, the high frequency of CD4+ T cells in 
our EOC TIL cultures could be of clinical relevance. 
Our current approach has two caveats that need to be taken into account when planning 
to conduct a clinical trial. First, TIL expansions in the current setting have been performed at 
a laboratory-scale in which we did not reach cell numbers usually obtained in clinical-scale 
protocols. However, experience with melanoma-derived TIL showed that these small-scale 
expansions are a good predictor for expansion at clinical scale18,21. Second, we observed 
tumor-reactivity in TIL cultures derived from untreated patients with newly diagnosed EOC. 
Whether these findings can be extrapolated to the metastatic setting in which patients have 
been heavily pretreated still needs to be assessed. 
Nonetheless, the current data are encouraging with respect to the feasibility of 
establishing tumor-reactive TIL cultures in EOC. Therefore, we plan to perform a phase I/II 
trial in ten patients with stage III/IV EOC that have failed at least two lines of therapy. These 
patients are expected to progress rapidly and have few treatment options left. Primary 
endpoints will be feasibility and safety as well as clinical efficacy. To our knowledge, two 
other centers are currently conducting a similar trial (NCT01883297 and NCT02482090), 
with slightly different protocols. The combined data of these studies will hopefully act 








































TIL therapy in epithelial ovarian cancer  |  159
10
METHODS
Patient material. EOC samples were obtained from six patients undergoing primary surgery 
for suspected ovarian cancer. MM samples were obtained from eight patients undergoing 
a palliative metastasectomy and eight additional patients that were treated with clinical-
grade TIL. Informed consent had been given prior to the surgical procedure and the study 
protocols (N12-INT for EOC TIL, N03-LAM for preclinical MM TIL and N10-TIL for clinical 
MM TIL) were approved by the local medical ethical committee. Tumor samples were 
enzymatically digested to obtain single-cell suspensions, containing both lymphocytes and 
tumor cells.
Cell culture. TIL cultures were initiated from both frozen and fresh single cell digests. Cells 
were seeded at 1x106 cells/ well in a 24-well plate in complete medium (RPMI, 10% human 
AB serum), supplemented with IL-2 (6000IU/ml, Novartis). TIL density was maintained at 
0.5e5-075x105 cells/ ml of medium over the following weeks. After 10-14 days, TIL cultures 
were analyzed by flow cytometry for the expression of T-cell markers, using anti-CD3 FITC 
(clone SK7, BD Biosciences), anti-CD4 PE (clone SK3, BD Biosciences) and anti-CD8 APC (clone 
SK1, BD Biosciences) antibodies. Finally, each TIL culture was subjected to a 14-day rapid 
expansion protocol (REP) in the presence of allogeneic irradiated feeder cells (Sanquin, The 
Netherlands), anti-CD3 and IL-218.
Tumor reactivity assay. Upon completion of the REP, T-cell cultures were exposed to 
autologous tumor cells at a 1:1 ratio in a multi-well format. Brefeldin A and Monensin were 
added to allow intracellular cytokine accumulation. After overnight coculture, samples were 
fixed and permeabilized, and stained for IFN-γ (clone B27, BD Biosciences). Unstimulated T 
cells and T cells stimulated with PMA and ionomycin (Sigma-Aldrich) were used as negative 
and positive controls for T-cell activation, respectively. Samples were analyzed on a BD 
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In recent years, cancer immunotherapy has proven itself as a valuable addition to the 
therapeutic arsenal of medical oncologists. The current stage of cancer immunotherapy 
development, as discussed in Chapter 1, is characterized by numerous phase III trials 
showcasing significant improvements in overall survival that have led to the approval of 
immune checkpoint inhibitors as therapy for metastatic melanoma, renal cell cancer, 
and NSCLC. Encouragingly, melanoma patients that respond to therapy appear to benefit 
long-term, as 3-year survival rates of ipilimumab treated patients plateaus at 22%, which 
is a doubling in overall survival for stage IV melanoma1. This stands in stark contrast with 
targeted therapies, to which the majority of patients respond but of whom few seem to 
benefit long-term2,3. This potentially “deep” responsiveness is likely a characteristic of 
immunotherapeutic intervention as a similar effect is witnessed in melanoma patients 
treated with autologous tumor infiltrating lymphocytes (TIL). One study demonstrated 
3- and 5-year survival rates of 36% and 29%, respectively, in a group of 93 TIL patients of 
which 19 (20%) were free of disease 10 years after treatment4. It is tempting to speculate 
that activation of the endogenous T-cell pool by immunotherapy causes the formation of 
immunological memory against tumor-associated antigens, thereby conferring long-lasting 
protection (discussed in Chapter 5), which is unique in the treatment of cancer.
Now that survival rates for metastatic melanoma have doubled and the promise of 
immunotherapy seems to hold true for other cancer types as well, does this mean that we 
have reached the zenith of cancer immunotherapy development? All clinical successes aside, 
there are still many challenges ahead and, based on the findings in this thesis, I highlight 
the top three that in my opinion deserve most attention in the coming years. These are: 
1) overcoming resistance to cancer immunotherapy, 2) identifying biomarkers for clinical 
responsiveness and, 3) designing patient-specific therapies.
Overcoming resistance
As mentioned earlier, cancer immunotherapy can be quite effective in some patients but 
certainly does not benefit all patients with the same type of malignancy (Chapter 2 and 
3). Therefore, one important question that is emerging from our growing experience with 
cancer immunotherapy is how to deal with such therapy resistance. In Chapter 5, three 
levels of resistance to immune attack are described: 1) intrinsic resistance, 2) naturally 
acquired resistance and 3) therapy-induced acquired resistance, with an increasing focus 
on the latter in recent years. In cancer immunotherapy, disease benefit is often defined as 
stable disease (SD) >24 weeks, partial response (PR) or complete response (CR), with the 
majority of patients experiencing SD and PR. The latter group is more at risk of subsequent 
disease progression than the group of CR patients. Apparently, the immune system can only 
keep a temporary check on tumors in these patients before they eventually grow out. While 
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limited, a number of observations can be made.  First, sequential treatment with different 
forms of immunotherapy (e.g. immune checkpoint blockade and TIL therapy) appears to be 
feasible, with patients failing one regime sometimes responding to the next5-7, indicating 
that the mechanism of resistance can be therapy line-specific. Second, cytotoxic T cells are 
regarded as an important (if not the main) mediator of anti-tumor immunity and therefore 
the extent to which these immunotherapeutic interventions alter the function and behavior 
of antigen specific T cells is of more than academic interest. Transcriptome analysis of neo-
antigen specific T cells in a mouse sarcoma model treated with anti-CTLA-4 or anti-PD-1 
antibodies have revealed profound differences in gene-expression profiles8. How these 
findings relate to the human situation is presently unknown but could be determined by 
mining RNA sequence data from (neo-) antigen reactive T-cell populations before and after 
the administration of cancer immunotherapy. Such datasets will improve our understanding 
on how immunotherapy shapes the anti-tumor immune response and may conceivably also 
reveal T-cell based mechanisms of therapy resistance. Finally, the other side of therapy-
induced acquired resistance is the effect of immune pressure on the tumor cells themselves 
and the mechanisms they employ to evade T-cell mediated killing. Obvious candidates for 
immune escape are loss of molecules involved in the antigen-presentation machinery (e.g. 
beta-2-microglobulin), or the selection of epitope negative variants9-11. Development of in 
vitro or in vivo screening platforms, using for example short-hairpin or CRISPR/Cas9 guiding 
RNA libraries, could reveal additional mechanisms of immune escape unrelated to antigen 
presentation and thereby provide novel targets for treatment refractory tumors. 
The two other forms of resistance (intrinsic and naturally acquired resistance) discussed 
in Chapter 5 are also of significant importance; as many patients do not derive benefit 
whatsoever from immunotherapeutic intervention. In some disease histologies, such as 
ovarian and colorectal cancer, this is particularly surprising as there is a strong correlation 
between immune infiltration and clinical prognosis. Tools to determine the degree of tumor 
reactivity of the intratumoral T cells directly ex vivo, as developed in Chapter 9, will provide 
important information on the usefulness of stimulating the endogenous T-cell repertoire in 
these malignancies. 
Biomarker assessment
As the number of immunotherapies available for clinical use is rapidly increasing, so does 
our need for biomarkers that can predict responsiveness towards them. The importance of 
biomarker development can be viewed from a number of perspectives.
First, physicians prefer to treat patients within a given tumor type that are most likely 
to respond, in order to avoid unnecessary side effects and delay other, potentially more 
effective, treatment options. Second, although perhaps an unpopular view from a medical 
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pressure on health care resources, and therefore need to be controlled. A large variety 
of biomarkers in the context of cancer immunotherapy have been identified, mostly in 
melanoma. Importantly, none of these markers is able to provide a black-and-white cut-off 
for responsiveness to immunotherapy12. Arguably, such a perfect biomarker is unlikely to 
exist, as the cancer immunity cycle is a complex process13, which can fail at multiple steps 
and that can therefore not be captured by a single parameter. In Chapter 2, we identify 
lactate dehydrogenase (LDH) and to a lesser extent erythrocyte sedimentation rate (ESR), 
both measurable in patient serum, as correlates of survival upon ipilimumab treatment. 
Whether the observed correlation is of prognostic or predictive nature is unclear as it is 
unknown whether LDH influences lymphocyte function upon CTLA-4 blockade. Notably, LDH 
has recently been shown to also serve as a biomarker for outcome in anti-PD-1 treated 
patients14, suggesting a broader value.
Third, biomarker development can lead to the identification of disease histologies that 
were previously not considered targetable by cancer immunotherapy. While responsiveness 
was in first instance primarily observed in melanoma patients, it is now clear that many 
other cancer types can be responsive as well. Molecular profiling of human cancer in 
combination with high-throughput immunomonitoring has led to the realization that T cells 
specifically targeting mutated gene products that are presented on the cell surface of tumor 
cells in the context of MHC class I or II form an important contributor to the establishment of 
tumor control (Chapter 6 and Chapter 8). Screening technologies aimed at identifying such 
T-cell populations are elaborate and few labs have the resources or material to approach 
this issue in a systematic manner for both responding and non-responding patients. 
Therefore, several groups have assessed mutational load, as an indirect measure of ‘tumor 
foreignness’, in patients treated with immunotherapy and found a positive correlation with 
clinical benefit15-17. By this reasoning, other “non-melanoma” cancer types with a similar 
mutational load could as well be responsive to immune modulatory therapy18-20. Indeed, 
this appears to be the case in particular for PD-1/PD-L1 blockade in patients with tobacco-
induced non-small cell lung cancer (NSCLC) and bladder cancer21-24. 
Supporting evidence that links mutational load to immunotherapy-derived disease 
control comes from a phase II trial in colorectal cancer patients with either mismatch repair 
proficient or deficient tumors in which clinical activity was exclusively observed in the latter 
cohort25. Additionally, clinical responses were observed in a small cohort of mismatch repair 
deficient non-colorectal cancer patients. Although factors unrelated to neo-antigen specific 
T-cell reactivity also remain a possible explanation for the observed correlation (Chapter 4), 
these findings warrant the investigation of immunotherapy effectiveness in other cancers 
with large amounts of DNA damage. Interestingly, a large fraction of patients with Hodgkin’s 
lymphoma, a disease known to have a low mutational burden, is responsive to anti-PD-1 
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interference with reverse signaling through PD-L1 explains the effect of PD1 blockade in 
this malignancy. Alternatively, non-mutant antigens or neo-antigens that are encoded by 
somatically hypermutated immunoglobulin genes or induced by first-line chemotherapy 
may explain the effects of therapy, an area for future study.
In order to identify novel biomarkers, clinical trials in all phases need to be designed 
in such a way that they permit the collection of tumor biopsies and blood at least before 
treatment and upon development of resistance, but preferably also during treatment. 
Analysis of the impact of immunotherapy on the tumor microenvironment will without 
doubt provide important mechanistic insights that will guide the development of future 
(combination) therapies (Chapter 6). It is important to bear in mind though that tissue-
based immunomonitoring has its disadvantages, as only a small fragment of tumor can 
be sampled each time. Due to inter- and intratumor heterogeneity, type II errors can be 
expected to occur regularly, perhaps explaining the clinical responses that are occasionally 
seen in PD-L1 negative tumors in several anti-PD-L1/ anti-PD-1 trials24.
Patient-specific immunotherapy
In the sections above, I have primarily focused on antibody-based cancer immunotherapies. 
At this moment, these therapies certainly form the most advanced branch of cancer 
immunotherapy, a success that, in addition to its clinical potency, is also due to its relative 
ease of generation and uniform clinical application. There are, however, other more patient-
tailored branches that are worth exploring, which may particularly benefit those patients that 
fail standard treatment regimens. Two of the most investigated patient-specific approaches 
to date are adoptive cellular therapy (comprising TIL, TCR and CAR therapy) and therapeutic 
cancer vaccinations. Although intensively studied and potentially highly effective, it is still 
unknown which therapy is best applied in which situation. To answer this question, it will 
be important to better understand the status of the cancer immune response in individual 
patient, and in the following section I sketch how such knowledge could conceivably be 
used to guide treatment choice. A first step to achieve this is to identify the expression of 
potential tumor-rejection antigens by means of next-generation sequencing as they form the 
prime targets in personalized cancer immunotherapy (discussed in Chapter 4). In a second 
step, these data should be combined with multiplexed immunomonitoring assays that allow 
one to assess the presence, number and frequency of antigen-specific T-cell populations 
on a per patient basis27-29. Although perhaps a gross oversimplification of the entire cancer-
immunity cycle, these two steps should provide at least a fundamental understanding of the 
immunogenicity of each tumor. Additional information on the general immunocompetence 
of the cancer-bearing patient or the presence of local immune suppressive mechanisms 
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With such information, one could distinguish four scenarios in which different patient-
specific immunotherapies could be applied: when an endogenous immune response has 
occurred against 1) a tumor with multiple antigens or 2) a tumor with single to a few 
antigens, or when an immune response has not occurred against 3) a tumor with multiple 
antigens, or 4) a tumor with few antigens.
In the first case, a setting where a variety of antigens is expressed (either neo-antigens, 
shared antigens or a combination) to which the immune system has mounted an endogenous 
immune response, TIL therapy is likely a good option. The ex vivo expansion and adoptive 
transfer of autologous TIL has already shown to durably benefit a substantial percentage of 
melanoma patients that underwent treatment7,31,32. 
The second setting, in which only few relevant antigens are expressed or few have elicited 
an immune response, offers even more space for a patient-specific approach. This is the 
case in cancers with a moderate mutational load, such as micro-satellite stable colorectal 
cancer or ovarian cancer (Chapter 9). Low-frequency tumor-specific T-cell populations may 
conceivably be isolated or stimulated from bulk TIL (Chapter 7 and 8) or peripheral blood 
and subsequently reinfused into a lymphodepleted host33. As an example, clinical responses 
have now been observed in HPV-induced cervical cancer (3/9 patients) by selecting TIL 
cultures that showed in vitro reactivity against E6 and E7 loaded target cells34. In gastro-
intestinal tract malignancies, phase I/II trials are currently underway in which TIL cultures 
reactive against autologous mutated epitopes are selected for infusion with notable success 
in at least one published case35. The benefit of such an approach is that a predefined set 
of antigens can be targeted simultaneously, although selection for reactivity against a 
given antigen automatically entails losing other, potentially more relevant, cell populations 
(Chapter 7 and 8).
In the third setting, multiple antigens are expressed but the host fails to induce an 
adequate immune response. In these cases, there is likely a problem in antigen-presentation, 
either at the tumor site or in peripheral lymph nodes where matured professional APCs 
need to prime T-cell responses (discussed in Chapter 5). Cancer epitope vaccinations that 
induce de novo immune responses could overcome this problem. For years, much effort 
has been put in optimizing strategies (e.g. RNA, DNA or peptide-based) resulting in potent 
vaccines with the ability to raise immune responses against several antigens simultaneously 
that are detectable in peripheral blood36. However, aside from anecdotal clinical responses, 
a significant benefit over standard treatment has not yet been observed37. In recent years, 
the focus has shifted from targeting shared antigens towards mutated antigens for which 
there is expected to be only low-level, if any, tolerance and thus an increased likelihood 
of inducing clinically relevant immune responses. Results from immunotherapy trials that 
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In the fourth setting, only a single or few antigens form relevant targets to which the host 
immune system fails to induce a strong immune response. In this case, TCR gene therapy, 
in which immune-reactivity is imposed by genetically transferring T-cell receptor genes into 
healthy naïve PBMCs with ample tumor-killing capacity, would be the preferred clinical 
choice. Treatment with autologous PBMCs redirected to target the NY-ESO-1 epitope has 
shown clinical effectiveness in melanoma, synovial cell sarcoma, and multiple myeloma39,40. 
In cases where the target antigen is not expressed on MHC molecules one may turn to the 
use of CAR therapy. Clinical effectiveness has been observed in leukemia patients using CARs 
that target CD19, an antigen that is expressed exclusively on B cells41,42. 
In summary, as patient-specific immunotherapy is largely driven by the upfront choice of 
potential tumor rejection antigens, there is a need for ongoing characterization of antigenic 
profiles in human cancer and the identification and prioritization of the most relevant 
targets (Chapter 6). Additional components, such as the presence of MDSCs or other non-
checkpoint related inhibitory mechanisms that shape the cancer-immunity cycle would 
obviously need to be taken into account when making a final stratification into the different 
therapeutic branches of personalized cancer immunotherapy.
Concluding remarks
In this thesis, I have shown how cancer immunotherapy has taken up its place in oncological 
practice, have demonstrated several technologies than can broaden its application, and 
have provided insights on how to improve overall anti-tumor efficacy. Furthermore, I have 
discussed how the focus of immunologists and clinicians is shifting, as the field is moving 
towards the management of presently unknown resistance mechanisms and treatment of 
additional cancer types. Currently, immunotherapeutic options are abound, ranging from 
one size fits all antibodies to highly patient-specific cellular therapies that (for now) can only 
be fabricated in specialized centers, and combination (immuno-) therapies are expected 
to diversify the therapeutic arsenal even further. Ongoing research aimed at elucidating 
factors that dictate outcome to specific cancer immunotherapeutics should ultimately help 
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ENGLISH SUMMARY
In recent years, immunotherapy has taken up a place alongside surgery, chemotherapy and 
radiotherapy in the therapeutic arsenal against cancer. The scientific development of cancer 
immunotherapy has gone through three distinct stages, outlined in Chapter 1, which are 
1) discovery and compilation of knowledge on the immune system and cancer, mainly by 
murine modeling, 2) understanding tumor-specific immune response in humans and the 
first translational efforts, 3) the release of clinically effective immunotherapeutic drugs 
on the market. Since the start of the last stage, which began in 2010 with FDA and EMA 
approval of ipilimumab for metastatic melanoma, cancer immunotherapy has developed 
into a stand-alone treatment modality alongside classical approaches such as chemotherapy 
and radiotherapy. A unique characteristic of immunotherapy is that cancer cells are targeted 
indirectly as its primary effect is the (re-) activation of cells of the adaptive immune system. 
Although a growing number of patients are now benefitting from immunotherapy, there are 
still many more that do not or only do so temporarily. 
The scope of this thesis is to identify factors that could predict responsiveness, or 
lack thereof, to cancer immunotherapy, and develop tools for personalized treatment 
approaches. 
From bedside
In Chapter 2 and 3, we retrospectively investigate the efficacy of an anti-CTLA-4 blocking 
antibody, ipilimumab, in patients with metastatic uveal and cutaneous melanoma. While 
we find that for uveal melanoma only few patients benefit, in cutaneous melanoma survival 
rates are much higher and, importantly, that they are comparable to the initial phase III 
trials. In the cohort of cutaneous metastatic melanoma patients we furthermore identified 
elevated baseline levels of serum ESR and LDH to negatively correlate with survival. The 
latter was confirmed in an independent cohort of patients thus suggesting its usefulness as 
a selection marker for treatment initiation. We continue on the topic of immune-checkpoint 
blockade in Chapter 4 by discussing the findings derived from a phase II trial in which an 
anti-PD-1 blocking antibody is used to effectively treat colorectal cancers with defects in 
their DNA-mismatch repair machinery. We hypothesize that other tumor types may be 
targeted as well, depending on their mismatch repair status, rather than their site of origin. 
Although immune-checkpoint blockade is potentially highly effective, as observed in the 
first chapters, not all patients with the same cancer type benefit in a durable manner. In 
Chapter 5, we discuss potential mechanisms of resistance to cancer immunotherapy in 
its entirety and highlight the need for personalized approaches. One such a personalized 
approach would be to target cancers in an antigen-specific manner. In Chapter 6, we discuss 
our current knowledge on the classes of C/G antigens and mutated antigens and elaborate 
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To bench
Personalized treatment approaches are the way forward in tumors that have become 
resistant to immunotherapy. Such an approach is already applied in patients receiving TIL 
therapy. However, TIL infusion products often exhibit only low frequency antigen-specific 
T-cell responses. In Chapter 7, we have developed a technology platform to isolate defined 
T-cell populations of interest, whether they are targeting non-mutated or mutated antigens, 
and show that this can enhance anti-tumor reactivity in in vitro assays. In Chapter 8, we 
show in a mouse model of human melanoma that a TIL product enriched for reactivity 
against mutated antigens is of superior quality than a non-enriched TIL product. We also 
demonstrate that there is likely some degree of hierarchy between T-cell responses targeting 
mutated antigens. 
In Chapter 9, we describe the development of a technology that allows us to isolate 
and reconstruct TCR gene sequences from single T cells without the need for extensive 
culturing. We apply this method to a small set of ovarian and colorectal cancer samples 
and find that the majority of the T cells infiltrating these tumors are non tumor-specific. An 
interesting finding that requires further exploration and should be taken into consideration 
when choosing the treatment strategy for these tumors. 
And back
The presence of intratumoral T cells in ovarian cancer has been linked in many studies 
to prolonged overall survival. In Chapter 10, we demonstrate that TIL cultures can be 
established according to standard clinical protocols and, importantly, that they harbor in 
vitro tumor-reactivity against MHC class I and II molecules. With these preclinical data 
we aim to initiate a phase I/II clinical study for metastatic epithelial ovarian cancer at the 
Netherlands Cancer Institute. 
Finally, we discuss the findings described in this thesis in Chapter 11 and highlight some 
of the future prospects of cancer immunotherapy development. In the coming years the 
field will focus on mechanisms of resistance, development of biomarkers for response and 
the design and implementation of patient-specific approaches. A major challenge for the 
future is that a growing number of immunotherapeutic drugs are now entering the final 
stages of development, and physicians will need to make evidence-based choices on which 
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NEDERLANDSE SAMENVATTING
Immuuntherapie is naast chirurgie, radiotherapie en chemotherapie een nieuwe optie in het 
behandelarsenaal tegen kanker. De wetenschappelijke ontwikkeling van immuuntherapie 
kan worden onderverdeeld in drie verschillende periodes, zoals besproken in Hoofdstuk 
1, te weten 1) het verzamelen van kennis omtrent het immuunsysteem en kanker, veelal 
aan de hand van muismodellen, 2) de analyse van tumor-specifieke immuniteit in mensen 
en enkele eerste translationele toepassingen van deze kennis, 3) het beschikbaar komen 
van medicijnen voor patiënten. Sinds de aanvang van deze laatste periode, die begon in 
2010 toen de FDA en EMA hun goedkeuring gaven voor het gebruik van ipilimumab tegen 
gemetastaseerd melanoom, heeft immuuntherapie zich ontwikkeld tot een op zichzelf 
staande behandelmodaliteit naast de meer klassieke behandelingen zoals chemotherapie 
en radiotherapie. Een uniek kenmerk van immuuntherapie is dat de kankercellen niet 
rechtstreeks worden aangevallen, maar op een indirecte manier via de cellen van het 
adaptieve immuunsysteem die zich op hun beurt weer richten op antigenen die tot expressie 
komen op het oppervlak van de tumorcel. Ondanks dat een groeiende groep patiënten 
baat heeft bij behandeling met immuuntherapie zijn er nog velen die dat niet, of slechts in 
beperkte mate, hebben.
Het doel van dit proefschrift is om factoren te identificeren die kunnen voorspellen welke 
patiënten wel en welke patiënten niet reageren op immuuntherapie. Daarnaast richt dit 
proefschrift zich op de ontwikkeling van technologieën die het mogelijk maken om patiënt-
specifieke therapieën verder te ontwikkelen. 
Van het bed
In Hoofdstuk 2 en 3 onderzoeken we in een retrospectief cohort patiënten met uveaal en 
cutaan melanoom de effectiviteit van ipilimumab, een antilichaam dat de werking van CTLA-
4 tegengaat. In de groep patiënten met uveaal melanoom wordt slechts een enkele respons 
gezien, terwijl de overleving in de groep met cutaan melanoom veel hoger is. Daarnaast werd 
in de laatste groep serum LDH als marker voor overleving geïdentificeerd waarmee deze 
mogelijk kan worden ingezet als selectiecriterium voor behandeling. Voortbordurend op het 
onderwerp van immuun checkpoint blokkering bespreken we in Hoofdstuk 4 de bevindingen 
uit een fase II studie waarin een antilichaam tegen PD-1 wordt ingezet om patiënten met 
colorectaal carcinoom te behandelen. Dit middel blijkt in het bijzonder goed te werken bij 
een subgroep van tumoren die gekenmerkt wordt door defecten in het mechanisme dat 
DNA-schade repareert. Onze hypothese is dat andere tumorsoorten met grote hoeveelheden 
DNA schade mogelijk ook gevoelig kunnen zijn voor deze behandeling, onafhankelijk van 
het celtype waaruit de kanker ooit is ontstaan. Ondanks dat immuuntherapie zeer effectief 
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dezelfde tumorsoort evenveel baat hebben bij behandeling. In Hoofdstuk 5 bespreken we 
de mogelijke mechanismen waarmee kanker zich kan onttrekken aan de invloeden van 
immuuntherapie en bespreken we de noodzaak van de ontwikkeling van patiënt-specifieke 
behandelingen. Zo’n individueel patiëntgerichte aanpak kan bestaan uit een behandeling 
die specifieke T cel populaties activeert om vooraf gedefinieerde (groepen) tumor antigenen 
te bestrijden. Aangezien de antigeendiversiteit groot is, is het belangrijk een onderscheid te 
kunnen maken tussen relevante en minder relevante doelwitten. In Hoofdstuk 6 bespreken 
we de huidige kennis omtrent twee groepen antigenen, namelijk de C/G antigenen en 
de gemuteerde antigenen, en de factoren die bepalend zijn voor hun geschiktheid als 
doelwitten voor antigeen-specifieke immuuntherapie.
Naar de labtafel
Een individuele aanpak biedt waarschijnlijk de beste kansen om tumoren te behandelen die 
resistent zijn geworden tegen immuuntherapie. Een dergelijke individuele aanpak wordt 
reeds toegepast in de behandeling met autologe TIL. In Hoofdstuk 7 laten we een methode 
zien waarmee antigeen-specifieke T cel populaties kunnen worden geïsoleerd, gericht tegen 
zowel niet-gemuteerde als gemuteerde antigenen, en tonen we aan dat doormiddel van 
isolatie van tumor-specifieke T cel populaties de in vitro anti-tumor reactiviteit van TIL 
producten toeneemt. In Hoofdstuk 8 demonstreren we vervolgens dat een TIL product, 
verrijkt voor reactiviteit tegen gemuteerde antigenen, betere tumorcontrole geeft dan een 
niet-verrijkt cel product in een muismodel voor humaan melanoom. Daarnaast laten we 
zien dat er kwalitatieve verschillen bestaan tussen afzonderlijke T cel responsen en de mate 
waarin deze gemuteerde antigen weten uit te schakelen.
Van tumorsoorten als ovarium en colorectaal carcinoom is inmiddels bekend dat de 
aanwezigheid van intratumorale T cellen van prognostische waarde is voor de overleving. 
Echter in welke mate deze T cel populaties gericht zijn tegen tumor specifieke antigen is tot 
op heden onbekend. In Hoofdstuk 9 beschrijven we een technologie die ons in staat stelt om 
TCR genen te isoleren uit afzonderlijke T cellen, zonder dat daar uitvoerige celkweken voor 
hoeven te worden verricht. We hebben deze methode toegepast op een kleine collectie 
materiaal afkomstig van patiënten met ovarium en colorectaal carcinoom, waarbij we zien 
dat de meerderheid van de T cellen die zich in de tumor bevinden niet specifiek gericht zijn 
tegen tumor-specifieke antigenen. Dit is een interessante bevinding waar meer onderzoek 
naar gedaan moet worden en waar rekening mee moet worden gehouden wanneer voor 
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En weer terug
In meerdere studies is de aanwezigheid van intratumorale T cellen in ovarium carcinoom 
positief gecorreleerd aan langere overleving. In Hoofdstuk 10 laten we zien dat TIL kweken 
afkomstig uit ovariumcarcinoom materiaal opgezet kunnen worden volgens de geldende 
klinische protocollen voor TIL productie. Bovendien laten we zien dat deze kweken reactief 
zijn tegen MHC klasse I en II antigenen die tot expressie komen op deze tumoren. Deze 
verkregen preklinische data worden nu gebruikt om een fase I/II klinische trial in het 
Antoni van Leeuwenhoek ziekenhuis op te zetten voor gemetastaseerd epitheliaal ovarium 
carcinoom. 
Tot slot bespreken we in Hoofdstuk 11 de bevindingen uit dit proefschrift en komen 
de toekomstige perspectieven voor de ontwikkeling van kankerimmuuntherapie aan 
bod. De komende jaren zullen gekenmerkt worden door een toenemende aandacht voor 
resistentiemechanismen, de ontwikkeling van voorspellende biomarkers en het ontwerpen 
en implementeren van patiënt-specifieke behandelmethoden. De grote hoeveelheid 
immuuntherapieën die in de komende jaren op de markt zullen verschijnen, vormen een 
grote uitdaging voor artsen die een evidence-based keuze dienen te maken over de vorm 
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DANKWOORD
Het duurt niet lang of de zon komt straks weer op. In het zusterhok naast mij hoor ik een 
baby huilen, maar verder is het nu rustig. Verlicht door de TL buizen op de verloskamers en 
lichtelijk vermoeid na een nachtelijk weekje werken, begin ik uiteindelijk aan het laatste 
onderdeel van mijn proefschrift. Het resultaat daarvan heb je nu in handen, het dankwoord! 
De mensen die hebben bijgedragen aan de totstandkoming van dit proefschrift ben ik 
namelijk heel wat dank verschuldigd. 
Allereerst wil ik mijn promotor en co-promotor, Ton en Christian, bedanken voor hun 
steun en begeleiding de afgelopen jaren. Ton, ik ben je dankbaar dat  je mij een plek hebt 
gegeven binnen je onderzoeksgroep waarin ik me onder jouw supervisie de afgelopen jaren 
heb kunnen ontwikkelen. De uitdagende onderzoekslijnen die je voor mij wist uit te stippelen 
en je vertrouwen dat het uiteindelijk allemaal wel zou gaan werken hebben dit proefschrift 
gemaakt tot wat het is. Christian, met jou heb ik mijn eerste publicaties geschreven en ik 
heb van dichtbij meegemaakt met hoeveel enthousiasme en passie jij kliniek en onderzoek 
combineert. Iets wat niet altijd even makkelijk is en waar ik, nu ik zelf weer in de kliniek zit, 
des te meer bewondering voor heb gekregen.
Ook de overige groepsleiders van de afdeling, Jannie, John en Karin wil ik graag bedanken 
voor hun kritische blik op mijn werk en alle waardevolle discussies die we de afgelopen jaren 
hebben gevoerd. Daarnaast wil ik de leden van mijn promotiecommissie bedanken voor het 
kritisch lezen van dit proefschrift. In het bijzonder bedank ik Gemma, die mij na vier jaar 
onderzoek opnieuw heeft geïntroduceerd bij de gynaecologie. 
Grote dank gaat uit naar mijn twee paranimfen, Pia en Sascha. To start with Minipigtje, 
I admire your passion for science, your fun-loving character, your crazy sense of humor and 
your ability to chit-chat with the high rollers in the field without blinking an eye. So many 
memorable and glorious moments on both scientific and personal level we shared the last 
couple of years. Sascha, hoe cool dat jij straks tijdens mijn verdediging naast mij staat! Niet 
alleen sta je daar als een hele waardevolle vriend waar ik alles mee kan bespreken, je bent 
ook in bredere zin de vertegenwoordiger van een club mensen waar ik stapelgek op ben. 
Dankzij jullie kan ik geregeld even stoom afblazen, alle hectiek in mijn hoofd relativeren en 
beseffen dat het leven niet alleen om werken en presteren draait. 
Mijn lieve (oud-)collega’s uit het NKI die me zo op mijn gemak hebben doen voelen in 
een wereld die aanvankelijk niet de mijne was. Silvia’tje, there are so many things to thank 
you for that I don’t know where to start, and I probably shouldn’t even try because you 
already know all of them. You are one of the most thoughtful, energetic and loyal friends 
that I have and I thank you for passing some of it on to me. Joost, fijne collega, fijne vriend, 
het was heerlijk om een kamer met je te mogen delen. Raquel, de toewijding en passie die 
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samen. Buurtje, zonder jou waren een hoop van mijn projecten nooit gelukt, mooi hoe we 
ons er samen doorheen hebben geslagen. Tomasz, thanks for designing that beautiful cover, 
you already said it before and I see it now, you are truly an artist. Mijn kamergenoten van de 
afgelopen jaren a.k.a. het TIL/TCR team: Bianca, Nienke, Samira, Maaike, Noor, Renate en 
Wouter, bedankt voor al jullie hulp, ondersteuning en gezelligheid. 
Alle overige B3 collega’s van de afgelopen jaren, wat zijn jullie een heerlijke groep om 
mee samen te werken. Zoveel kennis en kunde op één afdeling en tegelijkertijd zoveel 
gezelligheid, wat heb ik er van genoten! Speciale dank ben ik verschuldigd aan Laura en 
Lorenzo, voor al die oneindige muisproeven. En mijn studenten, Lois en Marije, enorm 
bedankt voor al het harde werk en de goeie inzet tijdens jullie stage. 
Alle mede-auteurs op mijn publicaties en collaborators binnen en buiten het NKI, 
bedankt voor jullie steun en de prettige samenwerking de afgelopen jaren. Special thanks 
to Dan Powell and Evros (leventimou!) from UPenn, my internship at your department 
has been a decisive moment in my career and I am forever grateful that you accepted an 
inexperienced med student, who had never held a pipette in his hand before, into your lab.
Mijn fijne vrienden uit Groningen en alles wat daar in de loop van de jaren bij 
is aangehaakt. Ik kan niet vaak genoeg benadrukken hoeveel waarde ik aan onze 
vriendschappen hecht. Jullie hebben mij de afgelopen jaren, vaak zonder dat jullie het door 
hadden, door de lastige momenten heen gesleept en vormen een vertrouwde basis waar 
ik altijd op terug kan vallen en helemaal mezelf kan zijn. Speciale dank aan Thomas (mijn 
zelfbenoemde schaduwparanimf), Jytte en Gemma voor alle ontspannende momenten en 
goeie gesprekken verspreid over de hele stad, gewoon om even stoom af te blazen en elkaar 
waar nodig een hart onder de riem te steken.
Lieve Frieda en Hannah, onze maandelijkse etentjes waren en zijn zo ontzettend 
waardevol voor mij. Frieda, jouw scherpe blik verbaast me elke keer weer en ik kan geen 
genoeg van je indrukwekkende verhalen krijgen. Ik ben ontzettend dankbaar met zo’n 
bijzondere vriendin als jij in mijn leven. Hannah, het ene hoofdstuk gesloten, een nieuw 
hoofdstuk begint. Ik spreek voor twee als ik zeg hoe trots de boys op jou zijn en wat je 
bereikt hebt en dankbaar dat we deel van die reis hebben mogen uitmaken.  
Mijn Haarlemse collega's. Ik weet niet of jullie het gemerkt hebben, maar ik vond het 
nogal een heftige overgang van lab naar kliniek. Jullie hebben er in korte tijd voor gezorgd 
dat ik me helemaal op mijn plek voel. Speciale shout-out naar Lot en Eef: ANIOS for life! 
Gerda, bedankt voor je verhelderende inzichten, dankzij jou durf ik nu met een gerust hart 
de volgende grote stap op mijn carrièrepad te maken. 
Pap en mam, ik heb zoveel van jullie geleerd en ik weet dat jullie altijd voor mij klaar 
zullen staan. Ik kan jullie hier niet vaak genoeg voor bedanken. Lieve zusjes, ik ben er 
ongelofelijk trots op dat ik me jullie grote broer mag noemen. Famylje Veenema, wat bin 
ik bliid mei jimme. Fryslân fielt foar my as thúskommen en ik sjoch út nei noch in hiel soad 
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Tjibbe, met jou is het leven zo leuk! Samen ontdekken we de wereld en alles wat het te 
bieden heeft. Jij weet wanneer ik er doorheen zit, ver voordat ik het zelf in de gaten krijg 
en je hebt inmiddels voldoende trucs bedacht om mij tot rust te krijgen als ik weer eens 
doordraaf. Je geeft me de ruimte die ik nodig heb, maar houdt me tegelijkertijd met de 
benen op de grond. Bedankt voor alles wat we al samen hebben beleefd en voor de mooie 
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